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Co-infection with the human immunodeficiency virus (HIV) negatively impacts the natural 
progression of hepatitis B virus (HBV) infection, including causing rapid progression to liver 
fibrosis and hepatocellular carcinoma (HCC). In sub-Saharan Africa the overlap between high 
HIV and HBV prevalence may increase the incidence of HCC. The aim of this study was to 
investigate the effect of HIV co-infection on presentation of HCC among HBV-infected 
patients. Since HCC is thought to be driven by ongoing severe inflammation, the study also 
evaluated the association between the expression of markers of immune activation/exhaustion 
and liver inflammation in patients with chronic hepatitis B (CHB) to determine if the risk of 
hepatofibrosis is increased by exposure to gut microbial products and compared HIV-infected 
patients with HBV-infected and HIV-HBV co-infected patients. 
Ethical approval was obtained to conduct two sub-studies. The first sub-study (HCC 
Epidemiology Study) involved recruitment of patients diagnosed with HCC at oncology units 
of selected teaching hospitals in South Africa. A total of 107 HCC cases were recruited 
between December 2012 and October 2015. Demographic, laboratory and clinical data 
together with blood specimens were collected. Patients were tested for HBV, hepatitis C virus 
(HCV) and HIV. Molecular characterization of HBV and HCV was also performed. For the 
second sub-study (Liver Fibrosis and Immune Markers Study), 46 HBV/HIV co-infected; 47 
HBV monoinfected; 39 HIV monoinfected and; 39 HIV-/HBV-uninfected controls were 
recruited following informed consent. All HIV-infected patients had been on highly active 
antiretroviral therapy (HAART) for ≥3 months. Liver stiffness measurements were taken 
using the Fibroscan 402. Cell-based immunomarkers of activation/exhaustion were measured 
using flow cytometry of fresh whole blood. Soluble serum/plasma immunomarkers were 
measured using ELISA and Luminex. HIV and HBV viral loads and genotyping of HBV were 
performed. 
Of 107 cases in the HCC Epidemiology study, 83 (78%) were male and 68/106 (64%, 95% 
CI: 59-77) were positive for HBsAg. HIV seropositivity was seen in 22/100 (22%, 95% CI: 
14-30) of all HCC cases. Among HBsAg-positive HCC cases, 19/66 (29%, 95% CI: 18-40) 
were HIV-infected compared to only 3/34 (9%) among those that were HBsAg-negative, 
p=0.04. The proportion of females among the HBV/HIV co-infected HCC cases 6/18 (33%, 
95% CI: 11-55) was significantly higher compared to those that were HBV-mono-infected 
6/47 (13%, 95% CI: 3-23), p=0.005. HIV/HBV co-infected females presented younger, at 
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mean age 36.8 years (95% CI: 32.2-41.5) compared to 50.5 years (95% CI: 30.2-70.8) in 
HBV-mono-infected women, p=0.09. Males continue to be disproportionally affected with 
HCC. There is a trend towards younger age at diagnosis of HCC among HIV-positive 
compared to HIV-negative women.  
The Liver Fibrosis and Immune Markers Study showed a high percentage of CD8+ T 
lymphocytes from co-infected subjects expressing HLA-DR/CD38 and PD-1 (p<0.05). 
Soluble CD14 and IP-10 were also significantly elevated in plasma of co-infected patients. 
Co-infected subjects exhibited delayed immune recovery with lower CD4/CD8 T cell ratio; 
CD4 cell counts and frequent HIV viremia compared to HIV mono-infected participants 
(p<0.05). The HBV mono-infected group had the highest proportion of participants with 
moderate/advanced liver fibrosis measured by Fibroscan, together with highest plasma 
concentrations of most of the cytokines measured. The results showed positive correlation 
between HIV and HBV viral replication and liver fibrosis. The results suggest that there is 
persistent T-lymphocyte dysregulation and delayed immune recovery in ART-experienced 
HBV/HIV co-infected patients. However this does not appear to be associated with severity of 
liver fibrosis in this cohort. HAART used in HIV is also effective against HBV and may 
therefore have led to control of viral replication leading to better fibrosis scores compared to 
the HBV mono-infected patients. Moderate/advanced liver fibrosis in HBV-mono-infection 
may well be an indicator of poor access to HBV screening and treatment. 
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1 Introduction and problem identification 
Chronic infection with hepatitis B virus (HBV) is endemic to sub-Saharan Africa where it is 
the predominant cause of hepatocellular carcinoma (HCC) (Ferlay et al., 2010). HCC is one of 
the leading causes of cancer deaths worldwide and has a very high incidence within Africa, 
second only to Asia (Bosch et al., 2004). Apart from HCC, chronic HBV infection (CHB) is 
also a cause of liver fibrosis which is an abnormality characterized by excessive deposition of 
fibrous extracellular material.  
A safe and effective vaccine to prevent HBV infection has been available for more than 2 
decades. Despite this, 240 million people are chronically infected with CHB, a significant 
proportion of who are at risk of progressing to end-stage liver disease including liver cirrhosis 
and HCC (Ott et al., 2012). Even more people will become infected with HBV if vaccination 
is not administered timeously and if coverage with all recommended doses is not complete. 
This study built on the work from a pilot epidemiological study performed at Tygerberg 
Hospital, South Africa which showed that up to 5.9% of human immunodeficiency virus 
(HIV)-infected pregnant women carried HBV surface antigen (HBsAg) as a marker of active 
hepatitis B infection (Andersson et al., 2012). Also, using a larger sample size, the prevalence 
of HBsAg was found to be 3.4% among HIV-infected and HIV-uninfected pregnant women 
from the Western Cape whose mean age was 26 years (Andersson et al., 2013). In addition, 
HBV/HIV co-infected pregnant women were found to have higher infectivity compared to 
those with HBV-mono-infection as shown by increased carriage of HBV e antigen (HBeAg) 
as a marker of highly active HBV infection and thus have a higher likelihood of transmitting 
infection to their infants (Oshitani et al., 1996, Rouet et al., 2004).  
The likelihood of vertical transmission of HBV from an infected mother to her infant is about 
70-90% when the mother is seropositive for HBsAg and HBeAg (Beasley et al., 1977, 
Shepard et al., 2006). These data showed that hepatitis B continues to be an important public 
health issue despite the HBV vaccine being included in the South African national infant 
immunisation programme. Achieving a 90% HBV vaccination coverage with the first dose 
being given at birth would result in 84% decrease in mortality arising from HBV-related liver 
disease, which includes HCC, worldwide (Goldstein et al., 2005). Unfortunately, this level of 
HBV vaccine coverage is not being met in South Africa and in many African countries. The 
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number of African countries achieving >90% of third dose vaccine coverage of HBV is low, 
with South Africa consistently achieving <79% third dose coverage since launching HBV 
immunisation in 1996 (World Health Organisaion, 2015).  
Untreated HBV infection among pregnant women coupled to the current schedule for HBV 
infant vaccination in South Africa leaves infants at risk of perinatal transmission particularly 
from highly infectious HBV-infected mothers because the first dose is only administered at 6 
weeks of age and not at birth as recommended by the World Health Organisation (WHO). The 
HBV vaccination schedule in South Africa is based on the premise of very little perinatal 
transmission and was designed to prevent horizontal transmission early in life, but not 
perinatally (Guidozzi et al., 1993). However, available data shows that vertical transmission 
of HBV continues to occur in sub-Saharan countries especially from HIV- and HBV- co-
infected mothers to their infants (Sangare et al., 2009, Hoffmann et al., 2014, Chotun et al., 
2015). As long as some infants continue to acquire hepatitis B through vertical transmission 
due to the existing vaccination protocols, it also implies that there will always remain a pool 
of persons with CHB that are at risk of HBV-associated HCC within South Africa. 
Perinatally- and childhood-acquired hepatitis B infections are known to commonly result in 
chronic infection because of the inability to effectively control infection probably due to 
infants’ immune systems being set towards general immune tolerance during development in-
utero (Prendergast et al., 2012). Also, the liver as an “immune organ” is generally biased 
towards immune tolerance because of its constant exposure to antigens and neoantigenic 
metabolites delivered through the hepatic portal vein (Gao, 2016, Grakoui and Crispe, 2016). 
Considering hepatitis B epidemiology in pregnant women, it is expected that HCC will 
continue to be a major cause of morbidity and mortality for decades to come, especially given 
the immune dysregulation that is associated with HIV co-infection despite the use of 
antiretroviral therapy. There are reports of an increase in liver disease and HCC among HIV-
infected patients in the era of effective antiretroviral therapy (Brau et al., 2007, Rosenthal et 
al., 2009, Kew et al., 2010, Merchante et al., 2013). The likely explanation is the increased 
survival of HIV-infected patients is allowing the progression of underlying hepatitis B 
infections which was not happening when there was no treatment of HIV and patients died 
due to opportunistic infections seen in AIDS. An aging effect will therefore increase the 
incidence of malignancy among HIV-infected patients that have been shown to have rapid 
immunoaging due to chronic systemic immune activation associated with HIV infection 
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(Appay and Kelleher, 2016). HCC cases are increasingly being seen presenting at a much 
younger age due to HBV/HIV co-infection but the precise mechanisms behind the change in 
age at presentation are unknown. Even though HCC is classified as a non-AIDS defining 
cancer, HIV infection seems to have an effect on the epidemiology of the malignancy. 
Sub-Saharan Africa, including South Africa, represents an intersection point between the HIV 
epidemic and endemic CHB. The mechanism by which liver disease arises especially in 
HBV-infected patients in the context of HIV is complex and an under-investigated area with 
most research focussing on HCV/HIV co-infected patients in resource-rich settings. HCV is 
not as prevalent as HBV in Southern Africa and pathogenesis of the two viral hepatitis 
infections is not similar. Despite the limited data on HBV/HIV co-infection and its association 
with liver inflammation/fibrosis, it is known that the pathology surrounding HIV infection is 
immune driven. HIV infection, especially when untreated, is accompanied by elevated levels 
of inflammation and immune activation/dysregulation, a component of which is mediated by 
translocation of microbial products across the gastrointestinal tract into the systemic 
circulation (Crane et al., 2012). Microbial products such as lipopolysaccharide (LPS) may 
directly mediate liver fibrosis through stimulating Kupffer cells (KCs) and hepatic stellate 
cells (HSCs) to produce fibrogenic cytokines and fibrogenic extracellular matrix proteins. In 
addition, microbial translocation may also indirectly cause liver fibrosis through immune 
activation-induced apoptotic cell death of hepatocytes (Page et al., 2011). As more data 
emerges concerning liver inflammation and fibrosis, it is clear that the fibrogenesis process is 
complex and involves a number of cell types and biomarkers that were previously not 
recognized as crucial in the pathogenesis of HBV-driven liver disease. For example, recent 
data using mice models showed that interferon-gamma (IFN-γ) produced by HBV-specific 
CD4+ T cells is also responsible for tolerance in CHB and persistence of hepatitis B (Zeng et 
al., 2016). Even more data of the different role players in pathogenesis of liver fibrosis is 
expected to emerge as hepatocyte co-culture models to investigate hepatitis B become more 
widely available. 
This study sought to provide information on the epidemiology and presentation of HCC in 
HBV/HIV co-infected patients. In addition to providing epidemiological evidence, the study 
also aimed to provide an immunological explanation for how HIV may contribute to HCC 
pathogenesis and liver disease by investigating the role of immune dysregulation (driven by 
microbial translocation) towards the pathogenesis of liver fibrosis which is a checkpoint along 
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the CHB to HCC pathway. The HCC Epidemiology component of this study hypothesized 
that HIV co-infection increases the risk of HBV-associated HCC reflected by differences in 
the demographic and clinical characteristics between HIV-infected and HIV-uninfected HCC 
patients. The study found that HBV/HIV co-infected HCC patients presented at a younger age 
compared to HIV-uninfected HCC patients and that this difference was particularly evident 
among females. 
The hypothesis of the Liver Fibrosis and Immune Markers component of this study was that 
HIV infection leads to higher systemic levels of microbial products, increased immune 
activation causing stimulation of key liver cells and the promotion of hepatic fibrosis. 
Although the data from this study observed an increased level of microbial translocation and 
systemic immune dysregulation, there seemed to be no increased liver fibrosis in HBV/HIV 
co-infected patients and antiretroviral therapy also effective against HBV might be the reason 
for these findings. 
 




2 Literature review 
This literature review covers the epidemiology of hepatocellular carcinoma (HCC) with 
emphasis on sub-Saharan African (SSA) countries. This is followed by discussion of the risk 
factors associated with hepatocarcinogenesis with a focus on hepatitis B infection. Literature 
on liver fibrosis and its pathogenicity in hepatitis B infection together with the effect of HIV 
infection and microbial translocation is also reviewed followed by the link between HCC and 
liver fibrosis. Also covered are the diagnostic modalities for HCC and liver fibrosis and also 
treatment for chronic hepatitis B. 
2.1 HCC epidemiology in Africa 
HCC is the second most common cause of cancer mortality, following only after lung cancer, 
in all sexes combined worldwide (Ferlay et al., 2010). HCC contributes 85-90% of all primary 
liver cancers (Zhang and Cao, 2011). SSA has the second highest number of HCC cases 
worldwide after South East Asia (Bosch et al., 2004). It is estimated that there were over 
37,000 deaths in 2012 from primary liver cancer within SSA, with the modal age group being 
30-49 years old for both males and females (World Health Organization, 2014). In SSA, HCC 
has the second highest incidence and mortality among men and the third highest in women 
(Ferlay et al., 2013). The mortality rate of HCC matches the incidence rate, highlighting the 
fatality of the malignancy and also the inadequacy of current screening protocols for the 
malignancy (Cole and Morrison, 1980). 
The distribution of HCC across Africa varies according to geographical region, as appears in 
Table 2.1. Western Africa has the highest incidence and mortality rates, closely followed by 
North Africa while East Africa has the lowest according to the 2012 estimates (Ferlay et al., 
2013). There are also inter-country differences within the geographical regions as shown in 
Table 2.2. Among the top 20 countries in Africa with the highest incidence of HCC, all are 
found in SSA, except for Egypt which is in North Africa (Ferlay et al., 2013). It should be 
pointed out that even with these available statistics, the true incidence and mortality rates 
associated with HCC in SSA are not definitively known because most cancer registries in 
Africa are incomplete and are virtually non-existent in other countries (Kew, 2013). There are 
also challenges associated with diagnosis of the malignancy because of the scarcity of 
resources needed for the clinical investigation of HCC (Kew, 2013). The GLOBOCAN 2012 
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report shows poor data quality for both incidence and mortality of different cancers for most 
African countries and this makes it difficult to obtain reliable estimates of HCC (Ferlay et al., 
2013). The highest weighted age standardized rates (ASR) for HCC incidence of 10.1% was 
found in Swaziland within the Southern Africa region where a total of 75 incident cases were 
reported and these were matched by mortality of 71 cases. 
Table 2.1 Regional age-standardised incidence and mortality rates of HCC. Data from the International 
Agency for Research on Cancer (IARC) GLOBOCAN 2012 tables (http://globocan.iarc.fr/) 
 Incidence Mortality 
Number of people ASR (w) Number of people ASR (w) 
Global 554 369 15.3 521 031 14.3 
Western Africa 23 040 12.1 22 181 11.5 
North Africa 19 653 12.3 18 704 11.8 
East Africa 7 947 4.0 7 530 3.8 
Middle Africa 5 508 8.0 5 515 7.5 
Southern Africa 2 232 4.8 2 127 4.7 
 
Table 2.2 Age standardized rate (ASR) for incidence and mortality for selected African countries for 2012.  
Incidence Mortality 5-year prevalence 
Number (%) ASR (W) Number (%) ASR (W) Number (%) Prop 
Western Africa 
Gambia 238 42.7 25.8 225 49.7 24 173 20.2 16.8 
Guinea 1102 20.8 19.5 1050 24.8 18.5 733 6.8 12.2 
Ivory Coast 2237 18.6 17 2141 23 16.1 1514 6.4 12.3 
Burkina Faso 1254 16.2 14.4 1219 19.6 13.9 898 5.7 9.4 
Ghana 1923 12.2 11.1 1856 17.4 10.7 1329 4 8.4 
Nigeria 12047 11.8 11.5 11663 16.3 11 8477 3.7 8.9 
Niger 516 8.7 6 489 10.5 5.6 355 2.8 4.2 
Eastern Africa 
Uganda 1351 4.6 7.9 1292 6 7.4 921 1.6 5 
Zimbabwe 548 3.5 6.9 520 4.6 6.5 280 0.9 3.5 
Mozambique 658 3 4.5 606 3.6 4.2 441 1 3.2 
Kenya 1120 2.7 5.4 1037 3.6 5 768 0.9 3.1 
Zambia 230 2.2 3.2 221 2.9 3.1 147 0.7 2 
Tanzania 595 1.8 2.1 565 2.4 2 406 0.6 1.5 
Ethiopia 996 1.6 2 926 2.1 1.8 653 0.5 1.3 
Southern Africa 
Botswana 75 4.6 5.4 73 7.1 5.3 54 1.7 3.9 
Namibia 27 2 1.7 27 3.4 1.7 21 0.7 1.4 
South Africa 1972 2.5 4.8 1877 4 4.6 1158 0.7 3.2 
Swaziland 75 8.3 10.1 71 11.3 9 52 2.9 6 
Central Africa 
Congo 235 10.7 8.6 225 15.1 8.1 163 3.3 6.5 
Cameroon 727 5.3 4.8 716 7.6 4.6 506 1.7 4.2 
Gabon 28 2.7 2.3 28 4.5 2.3 20 0.9 2 
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2.2 Hepatitis viruses as risk factors for HCC in Africa 
A major risk factor for HCC is chronic infection with hepatitis B virus (HBV) which has a 
high intermediate endemicity (5-7%) among adults in Southern SSA (Ott et al., 2012). The 
high incidence of HCC in SSA reflects the distribution of HBV and other risk factors such as 
chronic hepatitis C virus (HCV) infection, aflatoxin exposure, non-alcoholic steatohepatitis, 
hereditary hemochromatosis, autoimmune hepatitis and also excessive alcohol consumption 
(Kew, 2010). It is estimated that 60% of all HCC cases in developing countries are due to 
hepatitis B infection which is preventable through the administration of a safe and effective 
vaccine (Han et al., 2011). Global statistics suggest that the risk of developing HCC is about 
20 times more in people that are seropositive for HBV surface antigen (HBsAg) compared to 
those that do not have the marker (Beasley, 1988). It is for this reason that HBV is classified 
as a Group 1 carcinogen by the International Agency for Cancer Research (IARC) (IARC, 
1994). Group 1 carcinogens are those for which there is enough evidence showing them to be 
a cause of human cancer. 
In contrast to most sub-Saharan Africa countries, HCC in Egypt is mainly driven by infection 
with HCV, with hepatitis B having a less prominent yet still significant contribution (Darwish 
et al., 1997, Lehman and Wilson, 2009, Ferlay et al., 2013). Data suggests that the 
contribution of HCV infection towards HCC is also significant considering that the WHO 
Africa region has the second highest anti-HCV prevalence of 3.2% after South East Asia 
which has a population seroprevalence of 4.7% (Lavanchy, 2011). Within sub-Saharan Africa, 
countries such as Cameroon and Burundi have the highest prevalence of HCV at 13.8% and 
11.3% respectively (Lavanchy, 2011). In total, it is estimated that there are just under thirty 
million Africans infected with HCV, a significant proportion of whom will develop HCC 
following chronic infection (Lavanchy, 2011). With regards to gender, HCC in SSA has a 
predilection for male patients who also have a higher prevalence of chronic hepatitis B 
infection (CHB) (Blumberg et al., 1966, Ryder et al., 1992). Indeed, according to the latest 
statistics there were almost 2-3 times as many deaths from HCC in males compared to 
females with the highest mortality seen in the 30-49 years age group (Parkin et al., 2001, 
World Health Organization, 2014). In contrast to the observations from SSA, HCC in the 
developed countries of Europe and North America is usually seen in patients above 50 years 
of age (Kew, 2013, World Health Organization, 2014).  
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2.3 Non-viral risk factors for HCC 
Apart from the oncogenic hepatitis viruses (HBV and HCV) which pose the most prevalent 
risk factors for HCC, other environmental and hereditary factors are also known to favour the 
development of hepatocellular malignancy. The non-viral factors for hepatocarcinogenesis 
include- 
 Exposure to hepatotoxins such as aflatoxin and alcohol.  
 Cirrhosis arising from alcoholic liver disease, non-alcoholic fatty liver disease 
(NAFLD), non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, dietary 
iron-overload and autoimmune hepatitis (AIH).  
 Hereditary diseases such as tyrosinemia, α1-antitrypsin deficiency and hereditary 
hemochromatosis. 
 Obesity and diabetes mellitus. 
2.3.1 NAFLD/NASH 
NAFLD includes a wide spectrum of hepatic disorders that range from uncomplicated fatty 
liver (pure steatosis) to progressive NASH which may ultimately lead to cirrhosis and HCC 
(Bertolotti et al., 2014, Rinella, 2015). Fatty liver is histologically defined by increased 
hepatocellular storage of triglycerides and involves more than 50% of hepatocytes (Zoller and 
Tilg, 2016). Meanwhile, steatosis is a histological finding of lipid deposits in more than 5% of 
hepatocytes (Tannapfel et al., 2011, Zoller and Tilg, 2016). NASH is considered to be a 
progression of NAFLD which can be distinguished from the latter by the presence of 
hepatocellular injury with or without fibrosis (Rinella, 2015). HCC development in NAFLD is 
increased by the presence of obesity, diabetes, high iron and also alcohol consumption (Zoller 
and Tilg, 2016). The increasing incidence and prevalence of NAFLD-associated HCC mirrors 
the increasing prevalence of type-2 diabetes and obesity (Kew, 2015). A study on HCC risks 
from the United States reported that 14.1% of 4929 HCC cases were NAFLD-related 
(Younossi et al., 2015). These NAFLD-related HCC cases tended to be older but with a 
shorter survival time (Younossi et al., 2015). Obesity in men with a body mass index (BMI) 
greater than 35 has been described to increase the risk of death from liver cancer by 4.5 times 
relative to men with normal BMI (Calle et al., 2003). Lipid accumulation which is the 
hallmark of NAFLD results in increased free fatty acids and other lipid metabolites 
accumulation in hepatocytes which leads to hepatocyte injury, endoplasmic reticulum stress 
Stellenbosch University  https://scholar.sun.ac.za
9 
 
and inflammation (Page and Harrison, 2009). This results in hepatocyte death which triggers 
compensatory regeneration and proliferation that initiate hepatocarcinogenesis. 
2.3.2 Aflatoxin exposure 
The environmental hepatotoxin aflatoxin B1 (AFB1) is a natural fungal metabolite that is 
hepatocarcinogenic and is produced by fungi of the Aspergillus species, specifically A. flavus 
and A. parasiticus (Kew, 2003). These fungal species are normally found in hot and humid 
climates that are characteristic of many sub-Saharan countries where they contaminate human 
and animal food during harvest time and storage (Henry et al., 1999). Aflatoxins may 
contaminate foods such as peanuts, maize, rice, dried fruit and tree nuts. They may also be 
found in milk and milk products of dairy cows that are fed with contaminated feed (Henry et 
al., 1999). The metabolism of AFB1 after absorption is known to lead to the formation of 
AFB1-guanine complexes in hepatic DNA leading to the development of mutations in the p53 
gene, specifically a missense mutation at codon 249 (Hussain et al., 1994). Exposure to AFB1 
in combination with CHB has a synergistic effect toward the development of HCC (Kew, 
2003). Within sub-Saharan Africa, exposure to aflatoxin is mostly seen in rural populations 
who are then placed at increased risk of HCC development. A report from China suggested 
that exposure to aflatoxin in HBV-infected males triples the risk of HCC development (Ming 
et al., 2002). Within sub-Saharan Africa, rural populations are at increased risk of HCC 
development due to the fact that the prevalence of CHB is also highest in these settings 
coupled with greater exposure to aflatoxin compared to urban dwellers (Kew et al., 1986). 
Earlier studies point to high aflatoxin exposure with concomitant CHB as being the greatest 
contributing factors of a high HCC prevalence in some African countries (Alpert et al., 1971, 
Van Rensburg et al., 1975, Wogan, 1975, Peers et al., 1976, Peers and Linsell, 1977). 
2.3.3 Iron overload  
Dietary iron overload is a risk factor that is common in rural Africa where people consume 
traditional beer that is brewed in iron pots or drums resulting in iron leaching into the brew 
(Walker and Arvidsson, 1953). Excess iron in the hepatocytes can lead to malignancy through 
a number of mechanisms which may include: oxidative stress of hepatocytes initiating an 
inflammatory cascade which progresses to cirrhosis and finally HCC and; increased lipid 
peroxidation causing formation of by-products that are cytotoxic and capable of impeding 
cellular function and protein synthesis (Gordeuk et al., 1996, Kew, 2009). 
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2.3.4 Alcohol misuse 
Ethanol found in alcoholic beverages in also listed as a Group 1 carcinogen by IARC and 
heavy consumption (≥80g/ day for 10 years or more) poses as an important risk factor for 
HCC (IARC, 1988, Vineis et al., 2004). Apart from exerting an independent effect, alcohol 
has an additive relationship with CHB towards HCC development (IARC, 1988, Mohamed et 
al., 1992, Morgan et al., 2004). The effect of alcohol misuse on HCC development in South 
Africa was found to be more pronounced amongst urban men over the age of 40 years 
compared to women that did not consume as much alcoholic beverages (Mohamed et al., 
1992).  
2.4 Virology of HBV 
Globally, the incidence of HCC mirrors the prevalence of chronic hepatitis B (Beasley, 1988). 
The precise molecular mechanisms that lead to the development of HCC are incompletely 
understood and this is compounded by the lack of an HBV-encoded dominant oncogene 
(Neuveut et al., 2010). 
2.4.1 Taxonomy of HBV 
HBV is prototypic of the Hepadnaviridae family of hepatotropic DNA viruses that replicate 
through an RNA intermediate. HBV naturally infects humans and is a member of the genus 
that infects mammals (Orthohepadnavirus) while the Avihepadnavirus genus infects birds. 
Presently, there are at least 10 HBV genotypes (annotated A-J), with genotypes A, B, C, D 
and F having several subtypes (Lin and Kao, 2011). The genotypes differ from each other by 
8% of the nucleotide sequence of the entire genotype. However, most genotyping algorithms 
use only the surface antigen region. Of the 10 genotypes, only 8 (A-H) are widely described 
in literature. Genotypes I and J are thought to have recently arisen from recombination events 
(Olinger et al., 2008, Lin and Kao, 2011). The different genotypes and subtypes have distinct 
geographical distribution and also clinical implications with regards to response to therapy 
and pathogenicity. HBV genotype A is the most abundant and is widely distributed within 
sub-Saharan Africa followed by genotype D while genotype E is restricted to West Africa 
(Kramvis et al., 2005). Genotype A is most hepatocarcinogenic among South African patients. 
It is the most frequently detected genotype among patients with HCC in much of Southern 
Africa (Kew et al., 2005). In Asian countries, genotype C is associated with a greater risk of 
HCC development compared to genotype B (Kew et al., 2005). 
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2.4.2 Structure of HBV 
HBV has one of the smallest known viral genomes and has a 3.2 kilobases (kb) long circular 
DNA genome. HBV is the only hepatitis virus to possess a DNA genome (Ganem and Prince, 
2004). The circular DNA of the HBV genome is partially double-stranded because of an 
incomplete positive sense strand (Howard, 1986). The complete, infectious hepatitis B virion, 
also known as the Dane particle has a diameter of 42 nm and is composed of an icosahedral 
nucleocapsid core of 27 nm diameter that is surrounded by a lipoprotein envelope composed 
of a lipid bilayer derived from host’s internal membrane with embedded viral surface proteins 
(Howard, 1986).  
In addition, HBV also exists in two other subviral forms which are the filamentous and 
spherical particles. The spherical subviral particles have a diameter of 22nm while the 
filamentous particles have variable sizes and can get up to a length of 200nm. The subviral 
particles are produced in much greater quantities than the Dane particle. A schematic diagram 
of the Dane particle and the associated non-infectious sub-viral particles is shown in Figure 
2.1. 
 
Figure 2.1 Morphology of HBV particles. The infectious particle (Dane particle) is shown in Figure A with the 
HBV surface proteins (HBsAg) surrounding a nucleocapsid core that encloses the relaxed circular DNA with an 
incomplete positive sense strand and complexed with the polymerase enzyme (Pol protein). The membrane of 
the infectious particle is derived from the host plasma membrane during budding from infected hepatocytes 
Figure B shows the filamentous particle while Figure C is a representation of the spherical particle. Both of these 
particles are aggregates of HBsAg. Used with permission from Richard Hunt 
(http://www.microbiologybook.org/virol/hepatitis-virus.htm). 
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2.4.3 Genetic organization of HBV 
The HBV genome contains four open reading frames (ORFs) that overlap each other in a 
frame-shifted manner to produce seven proteins. These four open reading frames are C, P, S 
and X (Lüsebrink, 2009). ORF-C (core/precore) codes for the HBV core protein (HBc) and 
the HBV e antigen (HBeAg). The core protein is necessary for viral assembly and makes the 
nucleocapsid that encapsulates the viral DNA and the polymerase. HBeAg has no role in viral 
assembly but is known to induce immunotolerance. Although HBeAg does not have a role in 
viral assembly and is a secreted protein, its detection in blood serves to show active 
replication of HBV and is a surrogate marker of high infectivity (Harrison et al., 2008). ORF-
P codes for the polymerase enzyme that is involved in replication and also has transcriptase 
and RNAse H activity. ORF-S (preS-S) contains genetic information for the three 
polypeptides of the surface antigen (preS1, preS2 and S). Surface antigen proteins of different 
lengths are produced depending on which translation site has been read for initiation within 
the gene but all share the same C-terminus (Ganem and Prince, 2004, Harrison et al., 2008, 
Lüsebrink, 2009). ORF-X codes for the HBV X protein (HBx) which is a transactivator of 
viral transcription (Pawlotsky, 2006, Lüsebrink, 2009). HBx is non-specific and modulates 
expression of both viral and host cellular genes (Ganem and Prince, 2004). A schematic of the 
genetic organization of HBV is shown in Figure 2.2. 
 
Figure 2.2 Genome organisation of HBV and its transcripts. The precore protein is the smallest of the HBV 
transcripts being only 29 amino acids long whilst the polymerase protein also containing the reverse transcriptase 
domain is the longest with 832 amino acids. The polymerase ORF completely overlaps the surface antigen ORF 
and this has implications for mutations that emerge due to treatment with anti-viral agents. Used with permission 
(Malik and Lee, 2000). 
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2.5 Immunology of hepatitis B 
Primary infection with HBV causes hepatic inflammation that may or may not be 
asymptomatic (Chang and Lewin, 2007). Asymptomatic hepatitis explains why many patients 
are undiagnosed because they have no need to seek medical care. Whether infection is cleared 
or becomes chronic is dependent on the age and immune status of the infected individual. 
CHB most commonly occurs in childhood-acquired infection following vertical or horizontal 
infection as well as in adults that are immunosuppressed as occurs in untreated HIV infection 
(Ganem and Prince, 2004). The likelihood of primary hepatitis B becoming chronic in 
immunocompetent adults is very low (<5%) (Hou et al., 2005). All arms of the immune 
response (innate, cellular and humoral) are important in determining the outcome of hepatitis 
B (Guidotti and Chisari, 2006, Chang and Lewin, 2007, Chisari et al., 2010). 
2.5.1 Acute hepatitis B 
Antiviral cytokines produced by innate and adaptive immune cells are important for the non-
cytolytic control of HBV replication in the acute phase of infection of individuals that are able 
to clear infection (Chang and Lewin, 2007, Bertoletti et al., 2009). Interferon (IFN)-γ, tumor 
necrosis factor (TNF)-α and IFN- α/β secreted by CD8+ cytotoxic T lymphocytes (CTLs) 
have been described to lead to inhibition of HBV DNA replication without the cytolytic 
damage of infected cells using transgenic animal models (Guidotti et al., 1994, Protzer et al., 
1999). The influx of HBV-specific and non-specific T-cells into the liver during the 
incubation/acute phase is associated with a further decrease of HBV DNA that eventually 
results in symptomatic hepatitis (Webster et al., 2000, Thimme et al., 2003). Clearance of 
HBV following acute infection is associated with resolution of inflammation that is 
punctuated by normalization of serum alanine transaminase (ALT) and also the appearance of 
antibodies to the core (HBc), precore (HBeAg) and surface antigen (HBsAg) proteins of HBV 
(Chang and Lewin, 2007) A schematic summary of the interplay between serological, 
immunological and molecular markers in acute hepatitis B is shown in Figure 2.5. 




Figure 2.3 Serological and molecular changes in acute hepatitis B. Following acute infection, there is rapid 
replication of HBV DNA within hepatocytes. Before the influx of HBV-specific T-cells, there is control of HBV 
replication by non-cytolytic mechanisms from cytokines. The influx of the HBV-specific T cells eventually leads to 
symptomatic hepatitis shown by increased serum ALT (released from hepatocyte lysis). This leads to a further 
decrease of HBV DNA and the appearance of HBcAb, HBeAb and HBsAb. The HBc core protein is part of intact 
viral particles and is not freely detected in serum. Reprinted by permission from Macmillan Publishers Ltd: 
Immunology and Cell Biology (Chang and Lewin, 2007).  
2.5.2 Chronic hepatitis B  
CHB is defined as the detection of HBsAg in the serum of an infected individual for a period 
exceeding 6 months after acute infection. Unlike in resolved acute hepatitis B, antibodies to 
HBsAg do not become detectable and HBV DNA continues to be detected in CHB. 
Dependent on the phase during chronic infection, ALT levels fluctuate as shown in Figure 
2.6. Childhood-acquired hepatitis B infections tend to become chronic perhaps as a reflection 
of the immaturity of a child’s immune systems (Pungpapong et al., 2007). It is thought that 
the immune system in infants is set to be tolerant to hepatitis B, failing to mount the typical 
antibody and T cell response resulting in high levels of HBV DNA with no attendant liver 
inflammation (Prendergast et al., 2012). However, tolerance does not completely explain the 
propensity for infants to develop CHB as some infants have been reported to develop early 
clinical hepatitis B disease that is probably associated with variants of HBV that do not 
produce HBeAg and also the fact that infants are able to respond to HBV vaccine after birth 
(Beasley et al., 1983, Prendergast et al., 2012, Hong et al., 2015). HBeAg has been described 
to cross the placenta rendering HBsAg-positive infants borne to HBV-infected mothers 
tolerant to HBV in-utero by inducing  HBV specific T cell tolerance (Zhu et al., 2003, 
Heathcote, 2008, Trehanpati et al., 2013). It has been described that HBsAg-positive neonates 
have higher levels of immunosuppressive T regulatory cells and CD8+ T cell dysfunction that 
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signify the established chronic and immune tolerant state of hepatitis B at birth during vertical 
transmission (Trehanpati et al., 2013). 
Viral factors also contribute to the establishment of chronicity following acute hepatitis B. 
HBV has been described as a stealth virus in the sense that it does not induce the host 
hepatocytes (which are the primary targets of infection) to express innate immune response 
genes, specifically the type 1 interferons, primarily IFN-α/β (Wieland and Chisari, 2005, 
Vierling, 2007). The fact that the virus is non-cytopathic enables it to form some sort of “non-
harmful” symbiotic-type relationship with the host hepatocyte such that damage associated 
molecular patterns (DAMPs) may fail to be displayed, shielding the virus from the host 
immune system. HBV inhibits the expression of toll-like receptor-2 (TLR2) and TLR9 on 
innate immune cells, especially plasmacytoid dendritic cells (pDCs), leading to reduced 
induction of inflammatory cytokines, primarily the type 1 IFNs following TLR stimulation 
(Ma et al., 2015). TLR-9 is a pattern recognition receptor (PRR) that recognises viral and 
bacterial DNA motifs and leads to the secretion of type 1 IFN by pDCs via IRF7 activation 
(Ma et al., 2015). HBV proteins also suppress TLR signalling in hepatocytes from producing 
IFN-α which would normally cause induction of innate immune cells (Zhang and Lu, 2015). 
 
Figure 2.4 Serology of chronic hepatitis B. HBV replication is high yet ALT levels remain normal in the immune 
tolerant phase. During the immune active phase of CHB, the frequency and activity of HBV-specific CTLs 
increase and there is also recruitment of other non-specific immune cells into the hepatic environment with lysis 
of infected hepatocytes and an increase in serum ALT activity. The immune active phase is accompanied by a 
change in seroconversion from HBeAg with subsequent detection of HBeAg and anti-HBc. HBeAg negativity may 
arise from the establishment of mutants with a precore change that eliminates HBeAg synthesis. However, 
replication of HBV does not cease and HBsAg continues to be produced in excess of HBsAb production. 
Reprinted by permission from Macmillan Publishers Ltd: Immunology and Cell Biology (Chang and Lewin, 2007) 
copyright 2007. 
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(Rehermann and Bertoletti, 2015). A high replication rate permits infection of almost all 
hepatocytes thereby overwhelming of the immune system. The production of high quantities 
of HBsAg is also thought to subvert the immune response from responding to the actual 
infectious virions. In addition, the high rate of replication and the use of non-proofing reverse 
transcriptase also lead to the introduction of mutations, some of which may be responsible for 
immune escape, analogous to the scenario which is well-described in HIV infection 
(Rehermann and Bertoletti, 2015). Indeed it has been shown that many of the mutations occur 
in regions coding for epitopes that are recognized by HBV specific T cells (Vierling, 2007). 
HBV also produces tolerogenic HBeAg which aids in the establishment of chronicity 
(Harrison et al., 2008). 
Much work has been done in investigating the role of the host, primarily the immune system, 
towards the establishment of CHB. Different cells of the immune system including DCs, 
cytotoxic T lymphocytes (CTLs), regulatory T cells (Tregs) and natural killers (NK) cells 
have been described to contribute to the development of chronicity. T cell clonal anergy leads 
to hyporesponsiveness to HBV (Vierling, 2007). During CHB, HBV-specific CTLs exhibit a 
decreased capacity to secrete IFN-γ and express immune exhaustion markers such as 
cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein-1 (PD-1). 
The binding of PD-1 to its ligands PD-L1 or PD-L2 transmits a negative signal that causes a 
reduction of cytokine production (starting with IL-2) and cell proliferation (Li et al., 2014, 
Zhou et al., 2014). HBV-specific T cells of patients with CHB have been shown to express 
high levels of PD-1 and PD-L1 and these cells were hyporesponsive when stimulated using a 
wide range of HBV-specific T cell epitopes (Boni et al., 2007). Despite the 
hyporesponsiveness, these HBV-specific T cells are found in the liver where they are 
responsible for a persistent inflammatory response that is ineffective for viral clearance yet 
may lead to fibrosis (Maini et al., 2000). However, blocking of PD-1 restores functional 
responses and may lead to clearance of infection.  
In addition, patients with CHB were described to have a high percentage of CD4+ FoxP3+ 
regulatory T-cells (CD4+ Tregs). CD4+ Tregs suppress the function of effector HBV-specific 
T cells, perhaps as a way of protecting against immune-driven liver disease. Patients with 
CHB were shown to have high circulating CD4+CD25+ Treg frequency that significantly 
correlated with serum viral load (Xu et al., 2006). Similar association between CD4+ Tregs 
and chronicity were also shown in a study that described a higher percentage of CD4+ Tregs 
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that stain positively for CD25, CD45RO, and CTLA-4 in the circulating blood of CHB 
patients compared to healthy controls and individuals with resolved hepatitis B (Stoop et al., 
2005). The CHB patients also had higher levels of forkhead/winged helix transcription factor 
(FoxP3) messenger ribonucleic acid (mRNA) per CD4+ cell compared to controls. Tregs 
supress the ability of HBV-specific T-cells to proliferate upon stimulation with HBV antigens 
and their depletion leads to stronger responses as demonstrated by production of IFN-γ (Stoop 
et al., 2005). As in vertically-infected infants, the presence of HBeAg was associated with a 
higher percentage of Tregs compared to healthy subjects (Stoop et al., 2005). This may also 
explain the mechanisms through which perinatally infected infants tend to develop CHB. 
About 15% of the CD4+ T cell population during foetal life is composed of Tregs which 
declines to about 5% by the time of birth and finally to around 2% in teenage/adulthood 
(Prendergast et al., 2012). In the context of hepatitis B, this leads to suppression of HBV-
specific CTL responses by Tregs. This means that the infected hepatocytes are not targeted 
and killed and virus is not eliminated even as the frequency of Tregs is reduced later on in 
life.  
Apart from T-cells, circulating blood DCs (total DC population) from CHB patients have 
been reported to have decreased maturation and frequency compared to normal individuals 
and that this may be associated with disease progression (Balmasova et al., 2014). However, 
there is some controversy with regards to frequency and function of DCs of CHB patients due 
to conflicting findings by different research groups, partly as a result of the assays used. A 
review by Gehring and Ann D’Angelo suggests that the only distinction between the DCs 
from CHB patients and those from healthy donors is that the former’s plasmacytoid DC 
(pDCs) subset has reduced IFN-α production (Gehring and Ann D'Angelo, 2015).   
NK cells are the main effector cells that are involved in innate immune responses against 
intracellular microbes, such as viruses, and also tumour cells through cytolysis and cytokine 
production. In CHB, NK cells assume a negative effect on the host by inducing exhaustion of 
HBV-specific CD8+ T cells through production of immunosuppressive cytokines, 
upregulation of apoptosis and reducing the capacity of antigen presenting cells function. The 
depletion of NK cells leads to control of the persistent viral infection (Wang et al., 2015). 
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The contribution of B cells in CHB is not as clear as that of T cells, mostly as a result of the 
limited techniques for studying B cells (Xu et al., 2015). Despite the limited amount of data, it 
is accepted that B cells are important for the clearance of hepatitis B and preventing re-
infection. Anti-HBs neutralizes circulating HBsAg and clears infectious HBV particles in 
vivo and the detection of serum anti-HBS is considered to indicate resolution of CHB 
signifying the importance of anti-HBs in the clearance of HBV infection (Xu et al., 2015). 
Recent reports have shown that in CHB there is increased total B-cell activation and 
decreased HBsAg-specific B-cell responses (Oliviero et al., 2011, Xu et al., 2015). Figure 2.7 
shows the different cells of the immune system and the roles that they play in hepatitis B 
being cleared or establishing chronicity. 
 
Figure 2.5 HBV infection and the immune system. The figure which highlights several important pathways (but 
is not comprehensive) shows that the innate and adaptive (cellular/humoral) all contribute to the clearance of 
HBV infection or its establishment of chronicity. The boxes within the figure highlight potential mechanisms by 
which persistence of infection is established. The role of the KCs and the chemokines that they produce following 
induction by IFN-γ is indicated. When HBV loses its stealth ability, infection of hepatocytes is followed by 
production of IFN-α/β which activates immune cells that are responsible for clearance and/or immune-mediated 
damage. Modified with permission from Macmillan Publishers Ltd: Immunology and Cell Biology, (Chang and 
Lewin, 2007)  
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2.6 Pathogenesis of HBV-driven HCC  
HBV is not directly cytopathogenic and this allows it to survive within host cells without 
overt pathology. Instead, host immune responses induced by viral persistence are responsible 
for liver pathology in HBV infections (Zhang et al., 2012). It is known that HBV-specific T 
cell impairment leads to failure of HBV clearance, while the infiltration of non-HBV-specific 
inflammatory cells into the liver may actively participate in pathogenesis (Zhang et al., 2012). 
Persistent inflammation due to hepatitis B is known to lead to fibrosis and cirrhosis which 
may progress to HCC (Brechot, 2004). The direct ways in which HBV may lead to HCC 
include integration of its DNA into the host genome, the activities of HBx and truncated 
HBsAg proteins that possess trans activating properties (Lai et al., 1997, Ganem and Prince, 
2004, Kim et al., 2005, Kew, 2011). The integration of HBV DNA into host chromosomal 
DNA may lead to chromosomal instability. Also, integration may occur within or near 
functional cellular genes that are involved in signal transduction pathways associated with cell 
cycling and proliferation, thereby increasing the chances of hepatocarcinogenesis (Brechot, 
2004). HBx is a non-specific transcriptional transactivator and may influence expression of 
both viral and host promoter genes (Kim et al., 2005). Specifically, HBx has been reported to 
interfere with host cellular signalling processes that are responsible for cell proliferation, 
apoptosis and responses to cell damage (Brechot, 2004). Truncated HBsAg proteins are 
thought to be retained in the endoplasmic reticulum causing cellular stress, leading to 
oxidative damage of chromosomal DNA and subsequently in oncogenesis (Hsieh et al., 2004, 
Lin et al., 2007).  
Whether HBV plays a direct or indirect role towards hepatocarcinogenesis, the common 
underlying theme is that there is always presence of unresolved inflammation (that may 
present as fibrosis/cirrhosis) that promotes clonal expansion of hepatocytes. It should be 
pointed out that a significant proportion of African patients develop HCC without detectable 
underlying cirrhosis (Paterson et al., 1985, Kew, 1989, Yoshida et al., 1994). Viral agents 
have been shown to be responsible for initiating carcinogenesis in many cancers because of, 
amongst other mechanisms, the associated immune-mediated persistent “smouldering” 
inflammation that results in cell proliferation and death (Grivennikov et al., 2011). 
Inflammation per se is not pathogenic but rather useful for containment and clearance of 
pathogens. However, failure to regulate the immune system appropriately can have 
unintended consequences, one of which is an increased risk of malignancy. Hepatocyte 
damage and compensatory regeneration due to chronic inflammation induced by viral 
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infections such as HBV and HCV provides a potential environment for initiation of HCC 
through the introduction of genetic and epigenetic mutations that lead to the transformation of 
normal cells to cancer cells. In addition, some products of inflammation, such as reactive 
oxygen species and nitrous species, may induce DNA damage that precedes cancer 
development (Hussain et al., 2003). Figure 2.3 summarises the mechanisms of HBV-induced 
HCC as well as hepatocarcinogenesis arising from other risk factors. 
 
Figure 2.6 Mechanisms of hepatocarcinogenesis. HBV-induced hepatocarcinogenesis arises from a number 
of possible mechanisms, including the activities of HBV proteins (HBx, truncated HBsAg), integration into the host 
genome and host immunity-driven inflammation. Reprinted by permission from Nature Publishing Group: Nature 
Reviews Cancer (Farazi and DePinho, 2006).  
2.7 Liver fibrosis in hepatitis B 
Chronic viral hepatitis due to infection with HBV, which is highly endemic in SSA, may 
cause liver fibrosis which may lead to cirrhosis and ultimately to the development of HCC 
(Pellicoro et al., 2012). Liver fibrosis refers to the excessive deposition of extracellular 
proteins including collagen, and this usually occurs in the setting of a chronic liver disease 
(Bataller and Brenner, 2005). Apart from viral causes, liver fibrosis may also be caused by 
chronic alcohol abuse, NASH and autoimmune hepatitis (Pellicoro et al., 2012). HCV is also 
a major viral cause for development of hepatic fibrosis, cirrhosis and HCC. However, the 
prevalence of HCV in sub-Saharan Africa is lower than that of HBV which has intermediate-
high prevalence in sub-Saharan Africa (Sitas et al., 2008, Kew, 2010). In order to understand 
the pathogenesis of liver fibrosis, there is need to first appreciate the pathogenesis and 
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immunology of HBV with regard to correlates that permit establishment of chronicity of 
infection. 
2.8 Pathogenesis of liver fibrosis in hepatitis B 
Clearance of HBV and disease pathogenesis is mediated by the adaptive immune response 
(Guidotti and Chisari, 2006). Patients that are able to clear the infection have a vigorous, 
polyclonal T-cell response to multiple antigenic epitopes (Chisari et al., 2010). However, the 
adaptive immune response can only be strong following an effective innate immune response 
(Boltjes et al., 2014). Meanwhile, patients that develop active chronic infection with HBV 
have a weak adaptive immune response that causes chronic hepatocyte injury, regeneration, 
non-resolving inflammation, DNA damage and dysregulation of cell growth genes that may 
lead to liver cirrhosis and HCC (Chisari et al., 2010). Liver fibrosis is reversible but may 
progress to cirrhosis and eventually to hepatocellular carcinoma if the underlying stimuli are 
not eliminated (Crane et al., 2012). The majority of cases of HBV-related HCC take place 
after many years of chronic immune-mediated hepatitis with continuous cycles of low-level 
hepatocyte destruction and regeneration (Guidotti and Chisari, 2006). 
In essence, liver fibrosis occurs as a scarring response to liver damage, usually following 
either acute or chronic liver insult by both infectious and non-infectious agents. The process 
of liver fibrosis is driven by a particular cell type found in the hepatic environment called 
hepatic stellate cells (HSCs) (Friedman, 2008a). The HSCs are situated within the space of 
Disse in the normal liver where they are usually restive, their principle function being the 
storage of vitamin A within cytoplasmic droplets (Friedman, 2008a). However, following 
injury to hepatocytes and biliary cells, the usually quiescent HSCs are activated and acquire a 
contractile, proinflammatory and fibrogenic phenotype following their activation through 
inflammatory and injury-associated signals that are released by the damaged cells (Friedman, 
2008b). The inflammatory and injury signals that are secreted causing the activation of HSCs 
include fibrogenic cytokines such as transforming growth factor beta (TGF-β) and angiotensin 
II and angiogenic factors such vascular endothelial growth factor (VEGF) and angiopoetin. In 
addition to being secreted by liver parenchymal cells, HSC-stimulating factors are also 
produced by Kupffer cells (KCs) that are resident liver macrophages, monocyte-derived liver-
infiltrating macrophages, B and T lymphocytes, natural killer T (NKT) cells and liver 
sinusoidal endothelial cells (LSECs) (Gao and Radaeva, 2013). Literature suggests that liver-
infiltrating macrophages play a greater role in chronic inflammation and liver fibrosis than 
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resident KCs that are usually tolerogenic but are essential for the initial inflammatory 
response and sensing of tissue injury (Tacke and Zimmermann, 2014, Ju and Tacke, 2016).  
There are also anti-fibrogenic factors that are produced by platelets and NK cells and these 
include nitric oxide, FasL and TNF-related apoptosis inducing ligand (TRAIL) that result in 
the death of activated HSCs and subsequent reversal of the fibrotic process (Seki et al., 2007). 
In hepatic fibrosis, activated HSCs trans-differentiate into myofibroblast-like cells that 
produce excess fibrillar extracellular material (ECM), primarily type 1 collagen, which is the 
hallmark of liver fibrosis (Seki et al., 2007). Also upregulated during development of liver 
fibrosis are tissue inhibitors of matrix metalloproteinases (TIMPs) which as the name suggests 
are inhibitors of matrix metalloproteinases (MMPs). MMPs are fibrolytic enzymes whose 
function is to degrade ECM (Han and Lang, 2003, Lebensztejn et al., 2007). As a result of the 
inhibition of MMPs accumulation of ECM ensues. Underlying the importance in the balance 
between MMPs and TIMPs in CHB is the finding that administration of lamivudine or IFN-
α2b for treatment of hepatitis B was associated with a significant decrease of TIMP-2 and 
increase of MMP-9 level accompanied by an improvement of liver histology (Han and Lang, 
2003, Lebensztejn et al., 2007). A schematic of the interactions between immune cells and 
HSCs and the development and maintenance of liver fibrosis is shown in Figure 2.8. 




Figure 2.7 Development of liver fibrosis in hepatitis B (mouse model). Following infection with hepatitis B, 
hepatocytes display damage associated molecular patterns (DAMPs) which stimulate Kupffer cells (KCs) and 
dendritic cells (DCs).  KCs release chemokines that result in chemotaxis of bone-marrow derived monocytes into 
the liver where they differentiate into infiltrating liver-infiltrating Ly-6C+ macrophages that have a pro-inflammatory 
phenotype. These liver-infiltrating macrophages release cytokines that result in quiescent hepatic stellate cells 
(HSCs) transforming into activated HSCs that differentiate to become myofibroblast producing fibrogenic 
collagen. Meanwhile, LSECs lose their differentiation and become capillarised causing further activation of HSCs 
and development of fibrosis. In addition, there is upregulation of tissue inhibitors of matrix metalloproteinases 
(TIMPs) (TIMP-1 and TIMP-2) that inhibit matrix metalloproteinases (MMPs) (1, 8/13) further promoting 
extracellular matrix (ECM) accumulation resulting in liver fibrosis. Ly-6Chigh monocytes correspond to the CD14high 
monocytes in humans while the Ly-6Clow monocytes are the equivalent of CD14dimCD16++ monocytes in humans. 
LPS, lipopolysaccharide; LSEC, liver sinusoid endothelial cells. Modified with permission from Macmillan 
Publishers Ltd: Cellular & Molecular Immunology (Ju and Tacke, 2016). 
2.8.1 Immune cells in the pathogenesis of liver fibrosis 
As HBV-driven pathogenesis is mostly immune-mediated, different immune cell types and 
associated molecules have a role in the development of liver fibrosis in HBV infection (Sun et 
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al., 2012). The virus, host immunity and hepatocytes all interact in the development of liver 
disease. The increased range of immune cells that are seen in livers exhibiting inflammatory 
activity are thought to play critical roles in the genesis of liver injury (Wang, 2007). KCs 
which are resident liver macrophages that have been described to play a role in development 
of liver fibrosis through secretion of pro-inflammatory and fibrogenic mediators such as TGF-
β during the injury phase of chemically-induced liver fibrosis in a mouse model (Duffield et 
al., 2005). However, KCs are equally important for the resolution of liver fibrosis as their 
depletion during recovery in the murine model is associated with persistent accumulation of 
ECM because of the absence of TRAIL that would otherwise result in apoptosis of activated 
HSCs thereby inhibiting the production of TIMP-1 (Duffield et al., 2005).  
NK cells also play a role in liver fibrosis by the killing of fibrogenic HSCs. Depletion of NK 
cells was reported to enhance hepatic fibrosis in a murine model of carbon tetrachloride 
(CCl4)-induced liver fibrosis, implying that these cells play an anti-fibrogenic role mediated 
by the cytokine IFN-γ (Radaeva et al., 2006). NKT cells have been described to play 
contrasting roles in liver fibrosis whereby they exhibit a pro-fibrogenic role through the 
secretion of type 2 pro-fibrogenic cytokines such as interlekin-4 (IL-4) and IL-13 while the 
anti-fibrotic capabilities are evidenced by their secretion of IFN-γ in certain conditions (Gao 
and Radaeva, 2013). T lymphocytes, depending on their polarity, have diverse contributions 
in liver fibrosis. T-helper-1 (Th1) lymphocytes have been described as anti-fibrotic due to 
their secretion of IL-2 and IFN-γ while Th2 are described as pro-fibrogenic secreting IL-4, IL-
5, IL-6 and IL-10 (Xu et al., 2012b). Th17 lymphocytes have also been described to play a 
role in the development of liver fibrosis, particularly in CHB where positive correlation exists 
between the number of liver infiltrating as well as circulating Th17 cells and their associated 
cytokines and the amount of liver damage (Zhang et al., 2010). Dendritic cells have complex 
roles in liver fibrosis which are not well-understood although it has been reported that there is 
a change in the quality and quantity of DCs during liver fibrosis (Xu et al., 2012b).  
2.8.2 Soluble immune mediators and pathogenesis of liver fibrosis 
Cytokines are the mediators through which the effects of each cell type involved in liver 
fibrosis are carried out. Cytokines are a component of the immune system that determine the 
characteristics of the response to any pathogen or injury and as such are an integral 
component in the development of a chronic inflammatory state. They may either potentiate or 
downregulate the inflammatory response. Several pro-inflammatory cytokines such as TNF-α, 
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IL-1α, IL-1β, IL-6, and IL-8 have been associated with chronic inflammation in the liver 
environment and may be important in the relationship between inflammation and liver 
disease, including fibrosis and hepatocellular carcinoma (Budhu and Wang, 2006). The 
expression of these pro-inflammatory cytokines has been shown to increase with exposure to 
lipopolysaccharide (LPS) while secretion of potentially protective anti-inflammatory 
cytokines is reduced (Jirillo et al., 1991). Cytokines that are involved in the development or 
reversal of liver fibrosis are produced by immune cells as well as hepatic parenchymal and 
non-parenchymal cells. The most important cytokines produced in the liver during the 
pathogenesis of liver fibrosis are produced by liver-resident macrophages, mainly KCs. The 
effects of some cytokines towards the development or resolution of liver fibrosis are variable 
and are thought to depend upon the responding cell and also the signalling pathway that is 
triggered within the particular cell type. An example is IL-6 which is pro-fibrotic when acting 
on HSCs but is anti-fibrotic through its effect on hepatocytes (Kong et al., 2012). TGF-β 
which is predominantly recognized as a pro-fibrotic cytokine has been described to exhibit 
anti-fibrotic properties when secreted by Tregs (Kitani et al., 2003). It is apparent that the net 
effect of each cytokine is dependent on the net difference between the pro-fibrotic and anti-
fibrotic signals that it elicits. Despite the contributions of many of these cytokines towards 
liver fibrosis being known, most data has come primarily from murine models of carbon 
tetrachloride (CCl4)-induced liver disease and also HCV-associated liver disease with very 
little data known about HBV-driven liver fibrosis. A summary of the effect of some cytokines 
and their effect in the pathophysiology of liver fibrosis is shown in Figure 2.9. 




Figure 2.8 Role of cytokines in liver fibrosis. The figure shows the role of some selected cytokines and their 
roles in the pathogenesis of liver fibrosis. Cytokines such as IL-10 are anti-inflammatory and hepatoprotective 
against liver fibrosis. CXCL10 (IP-10) whose expression is stimulated by IFN-γ (not shown in the figure) are pro-
inflammatory and their secretion in the hepatic environment is associated with increased liver fibrosis. The roles 
of the different cytokines shown in the figure were determined from experiments using different mouse models. 
Eo, eosinophilic granulocyte; hepa, hepatocyte; ILC, innate lymphoid cell; KC, Kupffer cell; LSEC, liver sinusoidal 
endothelial cell; MFB, myofibroblast; TC, T cell; Th, T helper. Republished with permission of Dove Medical 
Press, from Clinical and Experimental Gastroenterology, Hammerich and Tacke, Volume 2014:7 (Hammerich and 
Tacke, 2014).  
2.8.3 HIV infection in the pathogenesis of liver fibrosis 
The central feature of HIV infection pathogenesis is chronic inflammation (Utay and Hunt, 
2016). Markers of inflammation and immune activation such as CD38 and HLA-DR 
expression by CD8+ T cells are elevated in chronic HIV infection and are not normalized to 
the same state as in HIV-uninfected persons even with HAART (Giorgi et al., 1993, Deeks, 
2012, Utay and Hunt, 2016). The increase in activated cells and inflammation/activation-
associated cytokines has a profound effect on multiple cells and organ systems such as the 
cardiovascular system and the central nervous systems. Among the important contributing 
factors in the continuous immune activation process is translocation of GIT-associated 
components into the systemic circulation, persistence of HIV especially in lymphoid tissue 
and presence of co-infecting viruses (Brenchley et al., 2006). Early HIV infection is 
characterized by dramatic loss of gut-associated memory CD4+ T cells. The events leading to 
this loss also lead to damage of gut epithelium, particularly destruction of tight junctions 
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(Brenchley et al., 2004). This initiates leakage of gut components into the circulation (Sandler 
and Douek, 2012). Apart from stimulating innate cells via toll-like receptors (TLRs), which 
results in a pro-inflammatory milieu, the increased levels of GIT components are bound to 
have a profound effect in the liver.  
The liver is linked to the gut via the hepatic portal vein and as such the liver is the first organ 
to be exposed to high levels of LPS and other gut components. Kupffer cells which are 
resident liver macrophages are located in liver sinusoids and sample the blood for pathogenic 
bacteria or bacterial components. On detection of these components the Kupffer cells are 
capable of inducing both immunogenic and tolerogenic responses. In cases of liver injury (as 
occurring in active HBV infection), there is a shift from Kupffer cell predominance to 
monocyte-derived macrophage predominance indicating an influx of monocytes from the 
peripheral blood (Pellicoro et al., 2012). Pro-inflammatory monocyte/macrophages are highly 
phagocytic and capable of producing large amounts of pro-inflammatory and pro-fibrotic 
cytokines. These include myofibroblast activators such as TGF-β and galectin-3 which 
activate HSCs to become myofibroblasts (Brenner et al., 2012). Pro-survival cytokines such 
as TNF-α and IL-1β, and PDGF work together to maintain myofibroblast activity. The net 
outcome of this process is deposition of collagen and scar formation. Under normal 
conditions, removal of the injury stimulus would lead to homeostatic shift back to Kupffer 
cell predominance and removal of factors driving HSCs transformation into myofibroblasts 
(Bilzer et al., 2006, Boltjes et al., 2014). Chronic viral infection in the liver precludes 
complete homeostatic reversion.  
Apart from increased microbial translocation, other factors such liver toxicity associated with 
some highly-active antiretroviral therapy regimens and also the associated metabolic changes 
may lead to an increased propensity to develop liver fibrosis in HIV/HBV co-infected 
patients. A study on Asian patients co-infected with HBV and HIV has suggested that 
increased apoptosis rather than inflammation is the driver of progressive liver disease, at least 
in therapy-naïve patients with severe immunosuppression (Iser et al., 2011). The question of 
whether the extent of hepatocyte apoptosis remains the same when retroviral multiplication is 
controlled by the administration of HAART remains unanswered.  
It has also been shown that the Gp120 protein of HIV induces apoptosis of human 
hepatocytes through the HIV co-receptor chemokine receptor type 4 (CXCR4) that is also 
expressed on the cell surfaces of hepatocytes. It is postulated that HIV-induced hepatocyte 
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apoptosis could then lead to development of hepatic fibrosis and/or cancer (Vlahakis et al., 
2003). In addition, HIV directly infects activated HSCs stimulating the production of type 1 
collagen and monocyte chemoattractant protein-1 (MCP-1), a chemokine which promotes 
lymphocyte infiltration into the liver (Tuyama et al., 2010). A schematic of the different 
mechanisms by which HIV infection may cause liver fibrosis is shown in Figure 2.10.  
 
Figure 2.9 Mechanisms of HIV-induced liver fibrosis. HIV infection causes disruption of the gut barrier and a 
profound loss of CD4+ T cells resulting in the immune deficit that contributes to accelerated fibrosis. Use of 
HAART may also give rise to dyslipidaemia as well as insulin resistance. Some of the antiretrovirals may also be 
hepatotoxic in some individuals leading to development of hepatic fibrosis. Figure used with permission 
(Mastroianni et al., 2014). 
2.8.4 HBV/HIV co-infection and pathogenesis of liver fibrosis 
Chronic HBV mono-infection causes localised immune suppression in the liver. Patients with 
CHB have decreased expression of IFNα/β from pDCs (Xu et al., 2012a). The secretion of 
IFNα/β from pDCs is important for inhibiting replication of virus-infected cells and activation 
of other immune cells to control hepatitis B (Vincent et al., 2011). However, HBV/HIV co-
infection may lead to the loss of localized immune tolerance in the liver because of the non-
specific immune activation that drives HIV pathology. HIV infection may also lead to 
reactivation of previous HBV infections (Hoffmann and Thio, 2007). Altered gut permeability 
and increased levels of serum LPS have been associated with progression of liver disease of 
various aetiologies such as chronic misuse of alcohol and non-alcoholic steatohepatitis and is 
thought to contribute to liver pathology (Crane et al., 2012). However, the question arises as 
to whether LPS is the cause or the result of a diseased liver since this is the organ responsible 
for the clearance of endotoxins. Within the liver environment, LPS binds to TLRs, 
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specifically to TLR-4 on Kupffer cells and hepatocytes (Chow et al., 1999). The interaction of 
LPS with TLR-4 initiates secretion of proinflammatory and fibrogenic cytokines culminating 
in hepatic stellate cell activation and collagen deposition (Chow et al., 1999, Tilton et al., 
2006, Crane et al., 2012). It has been proposed that chronic exposure to elevated LPS in 
individuals with HBV/HIV co-infection could contribute to a loss of tolerance in TLR4 
signalling in the liver leading to an inflammatory response that is punctuated by upregulation 
of pro-fibrotic cytokines. This includes increased levels of TGF-β as well as chemotactic and 
adhesive cytokines (Seki et al., 2007). The ensuing chronic inflammation causes liver fibrosis 
which may in turn increase the risk of progression to HCC. Another potential mechanism by 
which tolerance could be lost in HBV/HIV co-infection is through the loss of CD4+ 
lymphocytes. A recent study using transgenic HBV-carrier mice and IFN-γ–deficient (GKO) 
mice showed that the carrier mice failed to respond to vaccination as evidence of systemic 
tolerance toward HBsAg. Meanwhile, the GKO mice had robust responses against peripheral 
HBsAg vaccination. These findings are taken as evidence that IFN-γ produced by HBV-
specific CD4+ T cells in CHB is essential for the maintenance of tolerance to hepatitis B 
(Zeng et al., 2016).  
2.9 HIV and HBV co-infection and pathogenesis of HCC 
In addition to being highly endemic for hepatitis B, sub-Saharan Africa has the highest 
number of people living with the human immunodeficiency virus (HIV) infection (UNAIDS, 
2015). Figure 2.4 shows the number of deaths due to hepatitis B as well as the prevalence of 
HIV on a global scale. The role of HIV infection has been clearly shown in other virus-driven 
malignancies such as Kaposi's sarcoma (due to Human Herpes Virus-8 infection), human 
papilloma virus-associated anal and cervical cancer and also non-Hodgkin’s lymphoma which 
are all classified as being AIDS-defining cancers and usually develop in untreated HIV 
infection (Deeks and Phillips, 2009, Tanon et al., 2012b). However, with the availability of 
highly-active antiretroviral therapy (HAART), HIV infection has become a manageable 
chronic infection but there is now development of serious non-AIDS-related events (SNAEs) 
that are normally seen with aging (Deeks and Phillips, 2009, Pathai et al., 2013, Appay and 
Kelleher, 2016). HCC is included among the list of SNAES (Weber et al., 2006, Monforte et 
al., 2008, Salmon-Ceron et al., 2009).  




Figure 2.10 Population maps of HBV-related deaths and HIV prevalence. Map A shows the proportion of 
deaths attributed to HBV infection per year for each geographical region while Map B shows the prevalence of 
HIV infection. The maps show that Africa has the second highest number of HBV deaths and the greatest 
prevalence of HIV infection. (Source: http://www.worldmapper.org/) 
 
HIV infection may also have an effect of HBV-driven HCC but this is not well demonstrated. 
Existing data from HBV/HIV co-infected patients suggests that HIV hastens the progression 
of CHB to HCC (Brau et al., 2007). It has been shown that HIV causes higher HBV 
replication rates, leading to higher HBV viral loads, and also delays seroconversion from 
HBeAg antigen positivity to anti-HBe antibody positivity (Thio, 2009). The important 
question of whether HIV alters the risk of HCC in patients already infected with HBV or in 
those that are HIV-mono-infected remains largely unanswered. A case-controlled study 
conducted within the Swiss HIV Cohort Study reported that decreased CD4+ cell counts were 
associated with an increased risk of HCC development among HIV-infected patients that were 
also co-infected with HBV (Clifford et al., 2008). There is very limited data on whether the 
incidence of HCC is increased among HIV-infected patients within sub-Saharan Africa. A 
meta-analysis study reported an increased standardised incidence ratio (SIR) of HCC among 
HIV-infected patients of 5.6 (95% confidence interval: 4.0 to 7.0) compared to the general 
population (Shiels et al., 2009). The SIR was only slightly alleviated in patients on HAART 
compared to those not on HAART but still higher than the general population. Perhaps telling 
of the lack of African data on HCC incidence in HIV-infected patients is the fact that only one 
African study was incorporated into the meta-analysis by Shiels et al. Earlier data from a 
retrospective study conducted in USA and Canada suggested patients infected with HIV 
presented at a younger age but with similar tumour stage of HCC compared to those without 
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HIV infection (Brau et al., 2007). Among the few sub-Saharan Africa studies investigating the 
differences in epidemiology of HCC between HIV-infected and HIV-uninfected cases, Tanon 
et al. reported a significant difference in median age of 32 years (interquartile range (IQR): 31 
to 44) in those with HIV compared to 49 years (IQR: 44 to 59) among those without HIV 
infection (Tanon et al., 2012a). However, the results must be interpreted with caution because 
the study had a very limited number of HIV-infected individuals (only 7/60 of HCC cases) 
and there was no indication of their viral hepatitis status. 
2.10 HBV/HIV co-infection and hepatocarcinogenesis 
A direct effect of HIV on hepatocarcinogenesis is yet to be established although a few case 
studies have reported HCC in HIV-infected patients without any other known risk factors 
(Tanaka et al., 1996, Murillas et al., 2005, Venkataramani et al., 2010, Parikh et al., 2012). It 
has been suggested that HIV may directly facilitate the process of malignant transformation 
(Wistuba et al., 1999, Kew et al., 2010). HIV is known to cause persistent systemic immune 
activation which results in fibrosis of the lymph nodes, but its role in immune activation and 
fibrosis in the liver environment in humans is not known (Mehandru et al., 2005). In HIV 
infection, the persistent stimulation of T lymphocytes and their destruction leads to 
recruitment of other immune cells including monocytes (which become phagocytic 
inflammatory macrophages) to the lymph nodes. These cells, in attempting to remove dead 
cells and repair tissue damage in a chronic non-resolving disease, actually cause collagen 
deposition and fibrosis. Localised production of pro-fibrotic cytokines such as TGF-β is 
elevated in lymph nodes in HIV mono-infection (Estes et al., 2008). The production of TGF-β 
is also elevated in the liver in HBV mono-infection and probably amplified in HBV/HIV co-
infection. The development of fibrosis seen in the lymph nodes of HIV-infected individuals 
may well be analogous to the fibrotic process that occurs in the liver due to HBV mono-
infection where antigen non-specific cells drive pro-inflammatory activity which leads to liver 
pathogenesis. Regardless of the initial stimuli to chronic liver disease, hepatic fibrosis is the 
common endpoint and may consequently and directly lead to cancer development. 
An epidemiologic study from Uganda reported a statistically significant higher prevalence of 
liver fibrosis of 17% in HIV-infected patients compared to 11% in HIV-uninfected patients 
using transient elastography (Stabinski et al., 2011). Other previous studies have shown that 
patients co-infected with HIV and either HBV or HCV present with a more rapidly 
progressive liver disease and when they reach cirrhosis are also at increased risk of HCC 
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(Benhamou et al., 1999, Pineda et al., 2005). Furthermore, it appears that HBV/HIV co-
infected individuals are more likely to develop HCC compared to those with HBV mono-
infection. A retrospective study using a limited number of samples from South Africa 
reported a higher prevalence of HIV infection in patients with HBV-related HCC compared to 
healthy HBV carriers (Kew et al., 2010). Since HBV-associated inflammation leads to liver 
fibrosis and the pathology surrounding HIV infection is also inflammation-driven, co-
infection with both viruses may lead to exacerbated inflammation and increase the risk of 
liver fibrosis eventually leading to HCC. 
2.11 Diagnosis of liver fibrosis 
It seems beneficial that before HCC develops and is subsequently diagnosed, it would be 
beneficial to be able to diagnose liver fibrosis and cirrhosis using non-invasive markers. 
These have an advantage in that they can be performed serially and thus it will be easier to 
track changes over time compared to using an invasive procedure. There is much interest in 
the drive to identify non-invasive markers of liver fibrosis. Currently available methods are 
able to identify severe fibrosis and minimal fibrosis from normal tissue, but the specificity 
required to differentiate between intermediate grades of fibrosis is still lacking (Bataller and 
Brenner, 2005).  
2.11.1 Liver biopsy 
Biopsy remains the gold standard, although it has considerable limitations (Ratziu et al., 
2006). It is invasive and may cause complications such as severe bleeding and hypotension in 
some patients (Ratziu et al., 2006). Liver biopsy also has a significant limitation of sampling 
error that may lead to misdiagnosis and erroneous classification of the stage of fibrosis and 
the interpretation is subjective and is highly dependent on the experience of the 
histopathologist (Kruger et al., 2011). Traditionally, a raised ALT has been used to screen 
patients for active liver disease but newer results suggest that this may result in individuals 
with significant liver disease being missed as they may not even considered for liver biopsy or 
treatment for HBV (Martinot-Peignoux et al., 2002, Mohamadnejad et al., 2006, Kumar et al., 
2008).  It has been described that a needle biopsy will only avail 1/50 000 of the entire liver 
thereby posing a serious risk of sampling error (Manning and Afdhal, 2008). The invasive 
nature of the liver biopsy makes it difficult to be serially repeated for liver disease 
surveillance purposes (Ratziu et al., 2006). As a result there is a push towards non-invasive 
tests for liver fibrosis. 
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2.11.2 Non-invasive tests for liver fibrosis 
The use of non-invasive markers for liver fibrosis such as transient elastography (Fibroscan) 
and serum-based markers such as the Fibrotest, aspartate to platelet ratio index (APRI) and 
Fibrosis-4 (FIB-4) test should also be considered for SSA in the monitoring of patients with 
HBV/HIV co-infection which may assist in early detection of liver disease and help in HCC 
screening efforts. By being able to first diagnose liver disease including HBV infection, 
decisions can be taken on whom to place under HCC surveillance and also the frequency of 
surveillance testing. The Fibrotest, APRI and FIB-4 are among a group of serum biomarkers 
that are considered to be indirect markers of liver fibrosis (Manning and Afdhal, 2008). These 
tests are classified as indirect markers of liver fibrosis because they reflect changes in hepatic 
function but do not directly inform on the accumulation or degradation of ECM in the hepatic 
environment. The APRI and FIB-4 indices make use of widely available routine clinical 
laboratory tests and are thus easy to employ. Direct serum markers of liver fibrosis such as 
hyaluronic acid, procollagen type III amino-terminal peptide (PIIINP) and laminin reflect the 
deposition or removal of ECM (Afdhal and Nunes, 2004, Manning and Afdhal, 2008). 
However, the direct markers of liver fibrosis are mostly used for research and have rarely 
been used in the routine clinical setting.  
There are currently efforts to combine both the direct and indirect markers of liver fibrosis to 
improve the non-invasive diagnosis of hepatic fibrosis. One such combination is the Fibro-
check which was shown to have higher accuracy for the staging of liver fibrosis and superior 
efficiency compared to the APRI and Fibrosis index (a test using a combination of platelet 
count and serum albumin) among Egyptian patients infected with HCV (Attallah et al., 2015). 
Transient elastography is one of the newer imaging modalities for liver fibrosis. Other newer 
imaging modalities include magnetic resonance elastography, acoustic radiation force impulse 
imaging and real-time shear wave elastography (Nightingale et al., 2002, Manning and 
Afdhal, 2008, Ferraioli et al., 2012). In order for these non-invasive tests of liver fibrosis to be 
considered as reliable alternatives to the current gold standard, liver biopsy, further validation 
needs to be carried out especially among HBV/HIV co-infected patients because most of the 
available data on the sensitivity and specificity of these tests has mostly been derived from 
HCV mono-infected patients in resource-rich settings. The fact that little data is available for 
African patients with hepatitis B and by extension those with HBV/HIV co-infection, reflects 
the lack of information with regards to true estimates of the burden disease, its diagnosis, 
prognosis and care. 
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2.12 Diagnosis of HCC 
The diagnosis of HCC is made using histological examination of liver tissue and detecting 
malignant cells. Alternatively, the diagnosis may also be made using dynamic contrast-
enhanced radiological studies and/or serological tests. Frequently, a diagnosis of HCC is 
made using a combination of clinical history, physical examination and an imaging modality. 
An elevated serum alpha fetoprotein (>400 ng/ml) may also be taken into account (Jelic et al., 
2010). 
2.12.1 Radiological examinations for HCC 
A number of options are available for the radiological diagnosis of HCC which include 
ultrasound (US), computed tomography (CT), magnetic resonance imaging (MRI) and 
positron emission tomography (PET). Although there have been technological advancements, 
the capacity of these tests to detect tumorous lesions <2 cm still remains challenging (Patel et 
al., 2012). 
2.12.1.1 Ultrasound 
Ultrasound is the first line diagnostic modality for the detection of HCC lesions, primarily due 
to its low cost and ease of use although it has limitations (Patel et al., 2012). The sensitivity of 
US varies with the size of the tumour with rates of 70% for tumours <1 cm and 90% for those 
>5 cm (Patel et al., 2012). The sensitivity of the test is also subject to the experience of the 
operator while reproducibility is poor (Saar and Kellner-Weldon, 2008). The diagnostic 
sensitivity and specificity is greatly improved when US is used in conjunction with CT or 
MRI although this comes at a cost and also increases the radiation dose to the patient. Hyper-
vascularized nodular HCC lesions can be identified using contrast-enhanced US (CEUS) as 
their blood supply is predominantly arterial rather than portal venous (Saar and Kellner-
Weldon, 2008, Patel et al., 2012). An early, intense and homogenous enhancement followed 
by ‘washout’ in the portal venous or delayed phases is considered characteristic of HCC 
tumours. It is recommended that all focal liver lesions suspected on US should be verified 
using: CT and/or MRI (Stefaniuk et al., 2010). 
2.12.1.2 Computed tomography 
Similar to CEUS, CT using contrast agents identifies HCC tumours, based on their early 
arterial enhancement and late portal venous ‘washout’. The grade and stage of the tumour as 
well as metastasis of HCC can also be determined using CT (Patel et al., 2012). Despite the 
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advantages of being able to grade and stage the tumour, CT, has limited resolution for 
tumours <2 cm and contrast agents are potentially nephrotoxic (Patel et al., 2012). MRI has a 
better safety profile than CT and can equally be used for HCC staging. 
2.12.1.3 Magnetic resonance imaging 
MRI is useful for the detection and characterization of regenerating and dysplastic nodules 
and HCC (Digumarthy et al., 2005). Regenerating liver nodules are non-malignant nodules 
that are seen in cirrhotic patients while dysplastic nodules are focal nodular regions that are 
over 1mm in size but have no definitive evidence of malignancy. MRI has been shown to be 
superior to CT for detection and characterisation of HCC lesions (Yamashita et al., 1996, 
Semelka et al., 2001). 
2.12.2 Serological diagnosis of HCC 
In addition to the use of serum alpha-fetoprotein (AFP), newer biomarkers such as des-
gamma carboxyprothrombin, glypican-3, Golgi protein 73 and human hepatocyte growth 
factor have been proposed for the diagnosis of HCC (Liebman et al., 1984, Marrero and Lok, 
2004, Spangenberg et al., 2006). The majority of these newer biomarkers have mostly been 
investigated in HCV-driven HCC and among non-African patients. However, AFP remains 
the widely used serum biomarker in the diagnosis of HCC. Serum AFP is a glycoprotein that 
has a molecular weight of about 70 kDa and is produced by cells of the yolk sac and the liver 
during foetal development. AFP is usually absent or detected at very low levels in the serum 
of adult patients (Spangenberg et al., 2006). It is the most commonly used biomarkers for 
HCC surveillance. AFP has been used for decades in the diagnosis of HCC although it is 
known to have low sensitivity with ranges between 40 to 65%, at least among those with 
HCV-related malignancy (Gupta et al., 2003). Furthermore, the levels of serum AFP are 
raised in viral hepatitis infections even in the absence of HCC (Spangenberg et al., 2006). 
AFP levels greater than 400 ng/ml are used as a cut-off for diagnosis of HCC in combination 
with a radiological examination suggestive of HCC. However, not all HCC cases will have an 
elevated AFP and it has been reported that as much as 35% of small tumours will have normal 
serum AFP concentration (Chen et al., 1984, Lok et al., 2010). AFP has three variants, AFP-
L1, AFP-L2 and AFP-L3, based on the sugar chain. Of these three variants, AFP-L3 has been 
described as a “more reliable and better HCC marker than total AFP and an excellent 
prognostic parameter in patients with HCC” (Spangenberg et al., 2006). 
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2.13 Treatment of chronic hepatitis B 
Apart from using vaccination to prevent hepatitis B, slowing the progression of CHB and 
prevention of HCC development is also achievable through the use of potent therapy that 
suppresses HBV replication without causing development of drug resistance. The primary 
goals of CHB therapy are to prevent cirrhosis and HCC (Khokhar and Afdhal, 2008). 
However, current guidelines are that not all HBV-infected patients need therapy unlike in 
HIV infection. The benefits and risks of therapy for each patient must be evaluated before 
initiation of treatment through balancing the risk of untreated hepatitis B (morbidity and 
mortality) against the likelihood of achieving sustained viral control. The decision to treat is 
primarily based on HBeAg status, serum ALT and the HBV viral load. Other factors that may 
be taken into consideration include the histological activity, age and also family history of 
HCC. The long-term desired outcomes for initiating hepatitis B therapy include the clearance 
of HBsAg, delaying/preventing the development of HCC and improving survival of infected 
patients (Khokhar and Afdhal, 2008).  
A number of agents are currently approved and in use for CHB therapy in adults and these 
include: interferon (IFN) α-2b (also known as standard IFN), pegylated IFN α-2a (PEG-IFN), 
lamivudine, adefovir, telbivudine, emtricitabine, entecavir and tenofovir disoproxil fumarate 
(Khokhar and Afdhal, 2008, Bhattacharya and Thio, 2010). Standard IFN and PEG-IFN are 
cytokines and act as immune modulators that also have antiviral activity (Khokhar and 
Afdhal, 2008, Bhattacharya and Thio, 2010). The IFNs have the advantages of having a finite 
duration, do not cause emergence of drug-resistance mutations and achieve HBsAg 
seroconversion rates in about 10% of CHB patients (Brahmania et al., 2016). The 
disadvantages of IFN-based therapy include: need for subcutaneous injections, low sustained 
response rates, adverse events and high cost. Lamivudine, emtricitabine and telbivudine are L-
nucleosides that are phosphorylated intracellularly to form active nucleotides and cause 
premature termination of HBV DNA synthesis by competing with natural substrates for 
binding to HBV DNA polymerase (Bhattacharya and Thio, 2010). Tenofovir and adefovir are 
acyclic disphosphonates (nucleotide analogues) that are intracellularly prosphorylated to form 
active metabolites that inhibit HBV DNA polymerase through competitive inhibition causing 
premature DNA chain termination (Bhattacharya and Thio, 2010). Tenofovir is one of the 
most potent agents against HBV while adefovir is the least potent. The major limitation to use 
of tenofovir is its nephrotoxicity but this has since been rectified by the development of a 
newer tenofovir alafenamide fumarate (TAF) (Ray et al., 2016). Entecavir is a guanosine 
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analogue that inhibits HBV DNA polymerase in three ways: inhibits the HBV priming 
reaction, inhibits reverse transcription of negative strand from pregenomic mRNA and also 
replication of the HBV DNA positive-strand (Seifer et al., 1998, Levine et al., 2002). Despite 
the several options for treating CHB, the three most prominent international liver 
organisations American Association for the Study of Liver Diseases, European Association 
for the Study of the Liver, and Asian Pacific Association for the Study of the Liver 
recommend only PEG-IFN, entecavir and tenofovir as first-line agents for treatment of 
therapy-naïve patients (Brahmania et al., 2016). 
In addition to anti-HBV activity, lamivudine, emtricitabine, tenofovir, adefovir and entecavir 
are also active against HIV and can thus be used in HBV/HIV co-infected patients. 
Lamivudine is potent against HBV but its use particularly as monotherapy for HBV is 
associated with rapid emergence of viral drug-resistance mutations (Bhattacharya and Thio, 
2010). Although active against HIV, entecavir is not used in HBV/HIV co-infected patients 
that have uncontrolled viraemia because it leads to the development of HIV lamivudine 
resistance mutations (Hirsch, 2007, McMahon et al., 2007, Sasadeusz, 2007, Bhattacharya 
and Thio, 2010). Also, entecavir has potential drug-drug interaction with other antiretrovirals 
used against HIV such as abacavir which is also a guanosine analogue with potential for 
inhibitory competition (Soriano et al., 2008a, Soriano et al., 2008c). Therefore, entecavir is 
rarely used in HBV/HIV co-infected patients. A combination of tenofovir and emtricitabine as 
the nucleotide reverse transcriptase inhibitors is the preferred choice of treatment for 
HBV/HIV co-infected patients although lamivudine can be used in place of emtricitabine 
(Soriano et al., 2008b).  
2.13.1 Development of HBV drug-resistance mutations 
Development of drug-resistance due to the error-prone nature of HBV reverse transcriptase is 
a major limitation in treatment of CHB and should always be borne in mind when selecting 
the appropriate treatment modality (Khokhar and Afdhal, 2008). Primary antiviral failure is 
defined as less than one log10 reduction in serum HBV-DNA within the first 3 months of anti-
HBV therapy and this may be a result of poor pharmacokinetics or infection with an already 
drug-resistant strain of HBV. Secondary anti-HBV therapy failure arises from poor drug 
adherence or drug resistance or both, and is defined by an increase of greater than one log10 in 
HBV DNA from nadir in patients who initially responded to therapy (Soriano et al., 2008b). 
HBV drug-resistance mutations are classified as being either primary or secondary. Primary 
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resistance mutations are those that render the virus less susceptible to therapy but these may 
come at a cost of loss of fitness for the virus leading to the development of secondary 
mutations that are compensatory by improving or restoring fitness of the mutated virus 
(Soriano et al., 2008b). The rate of resistance to anti-HBV agents develops rapidly, first to the 
L-nucleosides (lamivudine> emtricitabine > telbivudine) followed by adefovir > entecavir > 
tenofovir. Development of the single mutation methionine to isoleucine or valine change at 
amino acid 204 of the reverse transcriptase region (M204I/V) renders HBV resistant to 
lamivudine,  emtricitabine and telbivudine (Minuk, 2002, Soriano et al., 2008b). In contrast, 
entecavir and tenofovir require a number of mutations to be present in the HBV genome 
before they lose potency hence their classification as being drugs with a high genetic barrier 
to resistance. For example the mutations L180M+M204V+T250V must be present in order 
for HBV to be resistant to entecavir (Soriano et al., 2008b). 
The best strategy to prevent or delay the emergence of drug-resistant HBV is by achieving 
complete viral suppression and adherence to therapy. A combination of anti-HBV agents has 
also been described to reduce the risk of developing drug-resistance mutations (Soriano et al., 
2008b). Due to the overlapping nature of the reverse transcriptase/polymerase ORF with the 
surface antigen ORF, there are also valid concerns that the emergence of drug-resistance 
mutations may also lead to simultaneous development of HBV strains that are able to escape 
detection in diagnostic tests and also lead to vaccine escape thereby posing a risk of infection 
to already-vaccinated individuals (Minuk, 2002, Colson et al., 2007, Sheldon and Soriano, 
2008, Soriano et al., 2008b, Clements et al., 2010).  
2.14 Treatment of HIV 
South Africa recently adopted the “universal test and treat” (UTT) programme for HIV 
according to the 2015 guidelines of the WHO (WHO, 2015, Health_e-News, 2016). Under the 
UTT programme, all patients that test positive for HIV infection are placed on therapy 
regardless of their CD4+ cell count. The aim of highly active antiretroviral therapy (HAART) 
(UTT in particular) is to ensure that HIV-infected patients achieve viral suppression to levels 
below detection and also to ensure that the chances of transmission of the infection are 
significantly lowered. The current first line HAART regimen in South Africa for adolescents 
and adults including pregnant and breastfeeding women is a fixed dose combination (FDC) of 
tenofovir, emtricitabine and efavirenz (SADoH, 2015). The FDC was adopted to strengthen 
adherence and retention of patients to HAART. This regimen is also particularly beneficial for 
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HBV/HIV co-infected patients because it contains two NRTIs that are also effective against 
HBV. The South African Department of Health recommends that patients that shows evidence 
of virological failure, defined as HIV viral load >1000 copies/mL on at least two occasions 
two months apart despite good adherence, be switched to a combination of zidovudine + 
lamivudine + ritonavir-boosted lopinavir (LPV/r). Co-infected patients should be placed on 
second-line combination of zidovudine+ tenofovir + lamivudine + LPV/r to suppress the 
emergence of lamivudine-resistant HBV and prevention of fatal hepatitis flares that may 
occur upon withdrawal of tenofovir in patients with CHB (SADoH, 2015).  
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2.15 Aims and objectives 
This PhD research project is presented as two studies with the first study focussing on the 
epidemiology of HCC designated the HCC Epidemiology Study (HCC Study). The second 
study investigated the association between liver fibrosis, inflammation and microbial 
translocation and will from hereon be referred to as the Liver Fibrosis and Immune Markers 
Study (Immune Study). The two studies, although interlinked, had independent Study 
Hypotheses, Aims and Objectives. 
2.15.1 HCC Study Hypothesis 
 HIV co-infection increases the risk of HBV-associated HCC.   
2.15.2 HCC Study Aim 
 To describe the occurrence of HIV and/or HBV infection in patients presenting with 
HCC at oncology departments of selected teaching hospitals in South Africa. 
2.15.3 HCC Study Objectives 
 To determine the prevalence of HBV infection in HIV-infected and HIV-uninfected 
patients with HCC. 
 To determine the HBV genotypes and mutations in HIV-infected and HIV-uninfected 
patients with HBV-related HCC. 
The HCC Study was performed as a cross-sectional study using data collected from a 
prospective study in which patients with a diagnosis of HCC were recruited from the 
oncology units of selected teaching hospitals in the Western Cape and Gauteng provinces of 
South Africa.  
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2.15.4 Immune Study Hypothesis 
 HIV/HBV co-infection is associated with increased liver fibrosis compared to HBV 
mono-infected through increased immune activation. 
2.15.5 Immune Study Aim 
 To measure and compare levels of serum and cell-associated markers of immune 
activation/suppression associated with fibrosis in HBV mono-infected patients (HBV), 
HBV/HIV co-infected patients (HBV/HIV), HIV mono-infected patients (HIV) and 
HBV- and HIV-uninfected individuals (controls). 
2.15.6 Immune Study Objectives 
 To measure and compare levels of serum markers of translocated gut microbial 
products in HBV, HBV/HIV, HIV and HBV- and controls. 
 To measure the presence and degree of hepatic fibrosis using non-invasive methods in 
HBV, HBV/HIV, HIV and HBV- and controls. 
The Immune Study was performed as a multi-group, cross-sectional study in which patients 
were recruited from the Infectious Diseases Clinic and the Gastroenterology Clinic at 
Tygerberg Hospital. 
 




3 Methods and materials 
3.1 Ethical Approval and participant recruitment 
3.1.1 HCC study 
Patients diagnosed with HCC were recruited from oncology units at Tygerberg Hospital and 
Groote Schuur Hospital in the Western Cape Province and from Chris Hani-Baragwanath 
Hospital, Charlotte Maxeke Hospital and Steve Biko Academic Hospital in Gauteng Province. 
Recruitment took place between December 2012 and August 2015. Diagnosis of HCC was 
based on serum AFP results in combination with radiological imaging examinations, these 
being any one or a combination of contrast-enhanced computed tomography (CT), abdominal 
ultrasound scan (USS) or magnetic resonance imaging (MRI). For some of the HCC cases, 
diagnosis of malignancy was also aided by results of histological examination. Participants 
were recruited after informed written consent according to the Declaration of Helsinki 2008. 
Consent forms were provided in English, Afrikaans and isiXhosa which are the three official 
languages of the Western Cape Province (see Appendix 1). Consent forms were also provided 
in the appropriate languages spoken in Gauteng Province The recruiting healthcare workers 
interviewed each participant according to a written questionnaire attached in Appendix 2. 
Ethical approval was obtained from the Health Research Ethics Committees (HREC) at 
University of Stellenbosch, University of Cape Town, University of Witwatersrand and the 
University of Pretoria (see Appendices 3-6). 
3.1.2 Immune study 
Ethical approval to conduct the study was obtained from the HREC at Stellenbosch 
University (ethics clearance number S13/04/072) (Appendix 7). HBV/HIV co-infected and 
HIV-mono-infected patients were recruited from the Infectious Diseases Clinic while HBV-
mono-infected and HBV-/HIV-uninfected patients (hospital-based controls) were enrolled 
from the Gastroenterology Clinic at Tygerberg Hospital, following informed written consent 
according to the Declaration of Helsinki 2008. Controls were patients attending the 
Gastroenterology Clinic for other conditions that were not liver-related such as 
gastrointestinal reflux disease. Patients with other known liver diseases or HCV infection 
were excluded from the study. The consent form for the immune study was provided in three 
languages. Following informed consent, participants were interviewed according to a 
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questionnaire designed for the study (Appendix 8). Study participants had their 
anthropometric measurements taken for weight (in kilograms) and height (in centimetres) 
using the MDW-300L Person Scale (Adam Equipment Inc., Danbury, CT, USA) that provides 
measurements for both parameters. Following anthropometric measurement, participants had 
liver stiffness measurements taken using the Fibroscan 402 instrument (Echosens, Paris, 
France) employing a medium probe. (Refer to section 3.10.1.1 for principle and operation of 
the instrument).  
3.1.3 Blood collection and processing for the HCC study 
HCC cases had blood drawn for laboratory testing into a single 5 ml EDTA-anticoagulated 
tube (Becton Dickinson Biosciences, San Jose, CA, USA) and two 7 ml BD Vacutainer SST 
II tubes with clot activator (Becton Dickinson Biosciences). In addition, urine specimens were 
also collected in a clean, sterile 50 ml container. The blood and urine specimens were 
transported to the laboratory within 4 hours of collection. Following delivery of the samples 
to the laboratory, both SST tubes were centrifuged at 2,310 rcf (3,000 rpm) for 10 minutes 
using the Rotanta 460R centrifuge (Hettich Zentrifugen, Tuttlingen, Germany) in order to 
separate the serum from the blood cells. The EDTA tube was centrifuged for 10 minutes at a 
speed of 1,020 rcf (2,000 rpm) using the Rotanta 460R centrifuge in order to separate the 
plasma from the cells. Upon separation of plasma from cells, peripheral blood mononuclear 
cells (PBMCs) were harvested using density gradient centrifugation using Ficoll Histopaque-
1077 (Sigma, St Louis, MO, USA) for possible future studies. Plasma and serum samples for 
the HCC study were stored at -70°C until testing. 
3.1.4 Blood collection and processing for the Immune study 
Following informed consent, study participants had venous blood drawn into one 10 ml BD 
Vacutainer EDTA-anticoagulated tube one 10 ml sodium heparinized tube and one 8.5 ml BD 
Vacutainer SST II tube that contains silicone and micronized silica particles that act as clot 
activators and cell-separating gel to separate serum from cells during centrifugation. In 
addition to the three mentioned tubes, additional blood was drawn into a 5 ml EDTA-
anticoagulated tube for platelet count determination and also into a 5 ml SST II Advance tube 
for serum AST and ALT measurements. The platelet counts as well as AST and ALT activity 
values were used to calculate the APRI and FIB-4 indices.  
Participants’ blood specimens were processed within 3 hours. Aliquots of EDTA whole blood 
were prepared for flow cytometry experiments with the rest of the blood being used to extract 
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plasma and PBMCs by centrifugation and density gradient centrifugation respectively. 
PBMCs were collected and stored for possible future studies. SST tubes were centrifuged at 
3,000 rpm for 10 minutes on the Rotanta 460R centrifuge to separate the serum from the 
blood cells. Serum was aliquoted in labelled 2 ml cryovials and frozen at -70°C until testing. 
Whole blood remaining after aliquots for flow cytometry had been removed was centrifuged 
at 2,000 rpm for 10 minutes using the Rotanta 460R centrifuge to separate plasma from cells. 
3.2 Serological tests for HBV 
Serological tests were performed for HBsAg, HBeAg, and anti-HBe using manual ELISA kits 
(Murex Diasorin) as previously described (Maponga, 2012). 
3.2.1 HBsAg 
The HBsAg test was performed using the Diasorin Murex HBsAg Version 3 immunoassay kit 
(Diasorin, Sallugia, Italy). Each well is pre-coated with mouse monoclonal antibody to 
HBsAg that capture any HBsAg in a sample/control (Abbott Murex version 3 kit insert). A 
volume of 25 μL of sample diluent was added to each well of the microplate, followed by 
addition of 75 μL of the patient’s sample. The plate was covered with a lid and left to incubate 
for 60 minutes at 37°C. 
After the one hour incubation, 50 μL of conjugate was added to each well. The conjugate is 
composed of horseradish-peroxidase labelled goat antibody to HBsAg. The sides of the 
microplate were tapped gently for 10 seconds to release any air bubbles from the wells. The 
plates were covered with a lid again and incubated for 30 minutes at 37°C. At the end of the 
incubation time, the plate was washed five times on a Mindray MW-IZA microplate washer 
(Shenshen Mindray Biomedical Electronics, Hamburg, Germany) using a wash fluid volume 
of 500 μL in each well. The wash step serves to remove excess of unbound HBsAg and 
conjugate from the well.  
After washing was completed, the plate was inverted and tapped onto absorbent paper to 
remove any residual wash fluid. Substrate solution of 100 μL was immediately added to each 
microwell, the plate was covered with a lid and incubated for 30 minutes at 37°C to allow for 
colour development. The substrate solution contains hydrogen peroxide and TMB. The TMB 
turns a purple colour when oxidised by the breakdown of hydrogen peroxide catalysed by the 
horseradish-peroxidase and antibody conjugate in the positive samples. Stop solution made of 
50 μL of 1M sulphuric acid was then added to each well. Colour intensity for each well was 
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measured on a microplate reader at 450 nm using 650 nm as the reference wavelength on the 
ELx800 universal microplate reader (Bio-Tek Instruments, VT, USA). The HBsAg reactivity 
in each well was then measured by comparing its absorbance to the cut-off value. The cut-off 
value for each run was calculated using the following formula that is provided by the kit 
manufacturer (Abbott Murex version 3 kit insert): Cut-off value = Mean of the Negative 
Control replicates + 0.05.  
3.2.2 HBeAg Testing 
The DiaSorin ETI-EBK PLUS assay is a direct, non-competitive assay and is based on the use 
of polystyrene microwells coated with mouse monoclonal antibodies to HBeAg (DiaSorin 
ETI-EBK PLUS kit insert). A volume of 50 µL of patient specimen/controls/calibrator was 
incubated with 50 µL of incubation buffer in antibody-coated microwells. The plates were 
sealed using a cardboard cover and left to incubate for two hours in a 37°C incubator. If 
HBeAg is present in a specimen or control, it binds to the anti-HBe antibody coated on the 
microwell. Excess sample was removed by a wash step on Mindray MW-IZA microplate 
washer, composed of five wash cycles using 400 µL of wash buffer.  
A volume of 100 µL of enzyme tracer was then added to the microwells and allowed to 
incubate for one hour in a thermostatically-controlled 37°C incubator. The enzyme tracer 
contains antibodies to HBeAg conjugated to horseradish peroxidase and binds to any antigen-
antibody complexes present in the microwells. Excess enzyme tracer was removed by a wash 
step as previously described above. A 100 µL volume of TMB/hydrogen peroxide 
(chromogen/substrate) solution was added to the microwells and allowed to incubate for 30 
minutes at ambient temperature in the dark. Wells containing HBeAg bind to the antibody-
enzyme conjugate whose enzyme then reduces the hydrogen peroxide, which then oxidizes 
the chromogen to a blue colour (DiaSorin ETI-EBK PLUS kit insert). The blue colour of 
oxidised TMB was converted to a more stable yellow by adding 100 μL of 0.4N aqueous 
sulphuric acid stop solution into all wells maintaining the order and rate in which 
chromogen/substrate had been added. The wells of samples without HBeAg remained 
colourless after addition of both the hydrogen peroxide/TMB solution and aqueous sulphuric 
acid (stop solution).  
Colour intensity of each well was measured spectrophotometrically using the ELx800 
universal microplate reader at 450 nm, using 650 nm as the reference wavelength, within 15 
minutes of the addition of stop solution. The intensity of the yellow colour quantified using 
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the spectrophotometer indicates carriage of HBeAg in the patient’s sample (DiaSorin ETI-
EBK PLUS kit insert). Optical density values for study samples were compared to a cut-off 
value derived from the average optical density of the calibrator. The cut-off value was 
calculated by adding 0.060 to the average absorbance for the calibrator values after 
subtraction of the substrate blank absorbance value (DiaSorin ETI-EBK PLUS kit insert).  
3.2.3 Anti-HBe Testing 
The Diasorin ETI-AB-EBK PLUS assay is a competitive test based on the use of polystyrene 
microwells coated with mouse monoclonal antibodies to HBeAg (Diasorin ETI-AB-EBK 
PLUS kit insert). In the procedure, 50 μL of incubation buffer was added into all wells except 
for the blank well. Calibrator, negative and positive controls and samples at volume of 50 µL 
were pipetted into their respective wells followed by addition of 50 μL of neutralizing 
solution into all wells except for the blank well. The neutralization solution has, among other 
components, recombinant HBeAg (produced in transfected Escherichia coli bacteria) that 
provides the basis for the competitive assay (Diasorin ETI-AB-EBK PLUS kit insert). A 
cardboard sealer was then used to cover the plate in order to prevent evaporation followed by 
gentle tapping of the reaction wells to release any air bubbles trapped in the liquid. The plates 
were incubated for two hours in a 37°C thermostatically-controlled incubator. Excess sample 
was removed by a wash step on the Mindray MW-IZA microplate washer, composed of five 
wash cycles using 400 µL of wash buffer for each well.  
Following the wash step, 100 μL of working enzyme tracer solution was added into all wells 
except for the blank well. The enzyme tracer solution is a conjugate of antibody to HBeAg 
(mouse monoclonal) and horseradish peroxidase (HRP) and attaches to unbound HBeAg that 
is coated on the microwell plate (Diasorin ETI-AB-EBK PLUS kit insert). A cardboard sealer 
was applied onto the plate to prevent evaporation followed by gentle tapping of the reaction 
wells to release any air bubbles trapped in the liquid. The plate was incubated for one hour at 
37°C in a thermostatically-controlled incubator. After lapsing of the incubation period, the 
plates were washed again as previously described.  
Thereafter, 100 μL of TMB/H2O2 substrate solution was pipetted into all wells followed by 
incubation of the plate for 30 minutes at room temperature, away from direct or intense light. 
This was followed by addition of 100 μL stop solution into all wells. The absorbance of each 
well was measured using the ELx800 universal microplate reader at 450 nm, using 650 nm as 
the reference wavelength within 15 minutes of adding the stop solution. The presence or 
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absence of anti-HBe antibodies in each sample was determined by comparing the absorbance 
value of unknown samples to that of the cut-off value (Diasorin ETI-AB-EBK PLUS kit 
insert). The cut-off value was calculated using the manufacturer’s provided formula which is 
determined by multiplying the mean absorbance of the calibrator values by 0.500 after 
subtraction of the substrate blank absorbance value (Diasorin ETI-AB-EBK PLUS kit insert). 
3.3 Molecular tests for HBV 
Extraction of HBV DNA, performance of viral loads and genotyping for both HCC- and 
Immune Study were performed as previously described (Garson et al., 2005, Maponga, 2012). 
3.3.1 HBV DNA extraction 
HBV DNA was extracted from the serum specimens using the QIAamp MinElute Virus Spin 
kit (QIAGEN, Hilden, Germany) according to the manufacturer’s protocol. The kit allows 
purification of nucleic acids and removal of PCR inhibitors.  
A volume of 3.5 µL of murine CMV internal control at a concentration of 400 copies/µL was 
added to each 200 µL of lysis buffer. A 200 µL aliquot of serum was added to 25 µL 
QIAGEN protease solution in a sterile 1.5 ml microcentrifuge tube. Two-hundred microlitres 
of the mCMV and buffer AL (lysis buffer) mixture was then added to the tube and mixed by 
pulse-vortexing for 15 seconds. The sample was then incubated at 56°C for 15 minutes in 
order to release a maximum yield of DNA from the degraded virions. The tube was then 
briefly centrifuged to remove liquid droplets from the cap. A volume of 250 µL of 99.99% 
ethanol (Sigma-Aldrich, St Louis, MO) was then added to the tube and the mixture was mixed 
by pulse-vortexing. The mixture was incubated for five minutes at room temperature. 
The lysate was applied to a QIAamp MinElute column in a 2 ml collection tube and 
centrifuged at 5,900 rcf (8,000 rpm) for one minute using an Eppendorf 5415D 
microcentrifuge (Eppendorf, Hamburg, Germany). This enabled the adsorption of the DNA 
onto the silica gel membrane of the spin column while allowing the rest of the liquid to pass 
through the column. The tube containing the filtrate was discarded and replaced with a clean 2 
ml collection tube, and the QIAamp MinElute column was then washed with 500 µL Buffer 
AW1 and centrifuged at 8,000 rpm for one minute. The wash step was repeated using 500 µL 
Buffer AW2 and centrifugation at 8,000 rpm for one minute in order to remove any residual 
contaminants. Again, the collection tube with the flow-through was discarded and replaced 
with a new collection tube and the column was subsequently washed using 500 µL of 99.99% 
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ethanol. Since residual ethanol in the eluate may inhibit downstream applications, the spin 
column was centrifuged again at full speed 16,100 rcf (14,000 rpm) for three minutes in a 
clean 2 ml collection tube. To ensure complete removal of any residual ethanol, the columns 
were placed onto clean collection tubes and incubated on a dry heat block at 56°C for three 
minutes to evaporate the ethanol completely. The MinElute columns were then transferred to 
sterile, labelled 1.5 ml microcentrifuge tubes followed by application of 60 µL elution buffer 
(buffer AVE). The columns were allowed to incubate at room temperature for five minutes 
followed by centrifugation at 14,000 rpm for one minute to elute the DNA from the columns. 
The eluted HBV DNA was stored at -20°C. Known HBV positive samples and normal human 
plasma that was negative for HBV markers were used as positive and negative controls for the 
extraction procedure. 
3.3.2 HBV viral load 
Quantitative detection of HBV DNA was performed using real-time PCR on the Rotor Gene 
6000 real-time PCR machine (Corbett Sciences, Australia) according to the protocol 
developed by Garson et al. (Garson et al., 2005). Serial dilutions of a HBV standard (1 x 10
8 
IU/ml) were made in HBV DNA negative human plasma to give a range from 1 x 10
2
 – 1 x 
10
7
 IU/ml. The HBV standard was calibrated against the WHO HBV DNA standard (NIBSC, 
UK) with a viral load of 1 x 10
6
 IU/ml before use. Table 3.1 shows the primer and probe 
sequences that were used to amplify a highly conserved segment of the surface antigen gene 
as well the primer and probe sequences that were employed to amplify and detect the mCMV 
internal control. All primers and TaqMan probes were used at a concentration of 100µM 
supplied by Applied Biosystems. A reaction volume of 25 µL was used. The PCR master mix 
reagents and their volumes are shown in the Table 3.2.  




Table 3.1: Oligonucleotide primers used for quantitative detection of HBV DNA 
Primer/Probe Sequence 
HBV Primer 1 5'- GTGTCTGCGGCGTTTTATCA-3' 
HBV Primer 2 5'- GACAAACGGGCAACATACCTT-3' 
HBV Probe 5'-FAM-CCTCTTCATCCTGCTGCTATGCCTCATC-TAMRA 
mCMV Primer 1 5’-AACCCGGCAAGATTTCTAACG-3’ 
mCMV Primer 2 5’-ATTCTGTGGGTCTGCGACTCA -3’ 
mCMV Probe 5’-VIC-CTA GTC ATC GAC GGT GCA CAT CGG C-3'TAMRA 
 
Table 3.2 Reagent components of the quantitative HBV PCR reaction mix 
Reagent Concentration (pmol/μL) Volume/sample (μL) 
HBV primer 1 100 0.1 
HBV primer 2 100 0.1 
HBV probe 100 0.05 
mCMV primer 1 100 0.1 
mCMV primer 2 100 0.1 
mCMV probe 100 0.05 
2X QuantiTect QPCR mastermix N/A 12.5 
Nuclease-free water N/A 2 
Template  Variable 5 
 
The 2X QuantiTect qPCR master mix was sourced from QIAGEN (QIAGEN, GmbH, Hilden, 
Germany). Amplification and detection was carried out under the following cycling 
conditions: 1 cycle of 95C for 15 minutes and 45 cycles of 95C for 15 seconds and 60C for 
60 seconds. After completion of each run, results were analysed using the Rotor-Gene 6000 
Series Software 1.7 (Corbett Life Sciences, Australia). For quality control of each run, 
negative and positive working controls were used. The positive control was supplied by 
NIBSC (NIBSC, UK). Nuclease-free water (QIAGEN, Hilden, Germany) was also used as a 
non-template control. 
Stellenbosch University  https://scholar.sun.ac.za
50 
 
3.3.3 HBV polymerase and X/PreCore  
All samples that had detectable HBV DNA during quantitative detection of HBV DNA were 
subjected to direct sequencing using dideoxynucleic acid chain termination technology. The 
remaining extract from the quantitative detection assay was used for sequencing of the 
polymerase/surface antigen and X/PreCore regions of the HBV genome. The list of reagents 
used for HBV molecular assays and their suppliers are shown in Table 3.3. Pre-nested and 
nested PCR were performed using the primer sequences shown in the Table 3.4.  
Table 3.3: List of reagents used for HBV sequencing and their suppliers 
Reagent Supplier 
Taq Polymerase (includes MgCl2, 10x PCR buffer) Invitrogen, CA, USA 
10mM dNTP mix Bioline, London, United Kingdom 
Primers IDT, Iowa, USA 
Seakem agarose powder Lonza, Rockland, ME, USA 
6X Novel Juice GeneDirex, USA 
Wizard® SV Gel and PCR Clean-Up System Promega, WI, USA 
Big-Dye Terminator kit, v3.1 Applied Biosystems, CA, USA 
Big-Dye Xterminator Purification kit Applied Biosystems, CA, USA 
O’GeneRuler 1 kb molecular markers Fermentas, Lithuania 
 
Table 3.4: Oligonucleotide primers used for pre-nested PCR amplification of the HBV polymerase gene 
Region Primer Sequence Nucleotide position on 
HBV genome  
Polymerase HBV Z 5' AGCCCTCAGGCTCAGGGCATA  1179 - 1199 
HBV 3 5' CGTTGCCKDGCAACSGGGTAAAGG 2478 - 2455 
HBV M 5’ GACACA CTTTCCAATCAATNGG  2306 - 2287 
HBV P 5’ TCATCCTCAGGCCATGCAGT  1292 - 1311 
X/PreCore  H4072 5'- TCTTGCCCAAGGTCTTACAT  1602 - 1621 
Inner core 5'- CAGCGAGGCGAGGGAGTTCTTCTT  2422 - 2445 
Outer core 5'- TCCCACCTTATGAGTCCAAG  2468 - 2449 
Nucleotide positions of primers are numbered according to Pugh et al. (Pugh et al., 1986).  
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For the polymerase region, first round PCR was performed as previously described using 
primers HBV3 and HBVZ. The first round PCR master mix for the polymerase/surface 
antigen region was constituted as shown in Table 3.5. Five microliters of template was added 
to the master mix. The cycling conditions were 95°C for 5 minutes, 35 cycles of 94°C for 30 
seconds, 55°C for 30 seconds 72°C for 60 seconds followed by a final extension cycle at 72°C 
for two minutes. All PCR reactions were performed on ABI 9700 thermocyclers (Applied 
Biosystems, CA, USA). PCR reaction mix for first round PCR of the PreCore/Core region 
was constituted as shown in Table 3.6.  
Table 3.5: PCR master mix components for first round for polymerase region 
Reagent Volume (µL) 
10X PCR Buffer 2.5 
50mM Mg Cl2 0.75 
10mM dNTP mix 0.5 
Taq Polymerase 0.1 
HBV 3 (20pmol/µL) 0.5 
HBV Z (20pmol/µL) 0.5 
dH2O 15.15 
Total Volume 20 
 
Table 3.6. PCR Master mix for First Round PCR for the X and Precore region 
Reagent Volume (µL) 
10X PCR Buffer 2.5 
50mM Mg Cl2 0.75 
10mM dNTP mix 0.5 
Taq Polymerase 0.1 
H4072 (20pmol/µL) 0.5 
Outer Core (20pmol/µL) 0.5 
dH2O 15.15 
Total Volume 20 
 
The cycling conditions for the first round PCR for PreCore/Core were similar to those of the 
polymerase region with a hold at 95°C for 5 minutes, 35 cycles of 94°C for 30 seconds, 55°C 
for 30 seconds 72°C for 60 seconds followed by a final extension cycle at 72°C for two 
minutes and an indefinite hold at 4°C. A second round PCR was performed for the 
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polymerase region and also for the PreCore/Core. The master mix for the second round PCR 
of the polymerase region is as shown in Table 3.7 while that for the PreCore/Core is shown in 
Table 3.8. A volume of 1 µl from the first round PCR was added to the master mix.  
The cycling conditions for the second round PCR of the polymerase region were as follows: 
denaturation at 95°C for 5 minutes, 34 cycles of 94°C for 30 Seconds, 50°C for 30 Seconds, 
72°C for 60 seconds followed by a final extension at 72°C for 2 minutes. The PreCore/Core 
region used an annealing temperature of 55°C instead of 50°C .The other temperatures and 
times were identical. 
Table 3.7. Polymerase second round master mix 
Reagent Volume (µL) 
10X PCR Buffer 5 
50mM Mg Cl2 1.5 
10mM dNTP mix 1 
Taq Polymerase 0.2 
HBV P (20pmol/µL) 1 
Outer Core (20pmol/µL) 1 
dH2O 39.3 
Total Volume 49 
 
Table 3.8. X and PreCore second round master mix 
Reagent Volume (µL) 
10X PCR Buffer 5 
50mM Mg Cl2 1.5 
10mM dNTP mix 1 
Taq Polymerase 0.2 
H4072 (20pmol/µL) 1 
Inner Core (20pmol/µL) 1 
dH2O 39.3 
Total Volume 49 
PCR products were visualized using 2% Seakem agarose gel (Lonza, Switzerland) using Tris-
acetate-ethylene diamine tetra acetic acid (TAE) as running buffer. A 2% gel was prepared by 
adding 2 g of Seakem agarose to 100 ml of deionized water. The suspension was heated in a 
microwave oven on high power for five minutes to completely dissolve the agarose powder 
and then allowed to cool at room temperature while sitting on a magnetic stirrer. The cooled 
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gel was poured onto an assembled electrophoresis tank with combs to make the loading wells. 
Samples were wet-loaded onto the cast gel wells using 6X Novel Juice (GeneDirex, USA) 
which also stains the DNA for visualisation under UV illumination. For loading PCR products 
onto the gel wells, 5 µL of the PCR product was mixed with 1 µL of the Novel Juice solution 
before pipetting onto the wells. O’GeneRuler 1 kb DNA ladder (Fermentas, Lithuania) was 
used as the molecular marker for determining the size of amplicons. TAE buffer was used as 
the running buffer. Electrophoresis was then performed using a voltage of 60V for 45 
minutes. The gels were then viewed on the UVI Prochemi (UVItec, Cambridge, UK) image 
acquisition system. Images captured were enhanced and edited using UVIband software 
(UVItec). For the polymerase gene region, a 1 kb fragment was expected on samples positive 
for PCR and an example of the pictures obtained is shown in Figure 3.1. For the X/PreCore 
region, PCR products for positive samples had an approximately 840 bp fragment. 
 
Figure 3.1 Gel electrophoregram for polymerase and X/PreCore regions. The polymerase product being 
larger (~1kb) compared to the X/PreCore (~840kb) travelled a shorter distance on the electrophoresis gel 
3.3.3.1 PCR product clean-up 
PCR reactions with visible bands on gel electrophoresis were purified using the Wizard® SV 
Gel and PCR Clean-Up System (Promega, WI, USA). To 45 µL of the PCR product 45 µL of 
membrane binding solution was added and mixed by pipetting up and down for 4-5 times. 
Thereafter, the mixture was loaded onto an assembled mini-column and allowed to incubate 
for a single minute so that the DNA could be adsorbed onto the silica membrane. Following 
incubation, the mini-column assembly was centrifuged for 1 minute. The mini-column was 
initially washed using 700 µL of Membrane Wash Solution followed by a final wash with 500 
µL of the same wash solution. The DNA was then eluted using 50 µL of nuclease free water 
into a clean 1.5 ml microcentrifuge tube.  
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3.3.3.2 Measurement of purified PCR product 
The purity and concentration of the cleaned PCR product was determined 
spectrophotometrically on the NanoDrop 1000 spectrophotometer (Thermofisher Scientific, 
USA). Briefly 1 µL of the purified product was loaded onto the instrument pedestal and the 
concentration of DNA in each sample was determined. Pedestals were wiped clean with tissue 
paper between each measurement. 
3.3.3.3 Nucleotide sequencing of HBV DNA from purified DNA 
All purified samples for the three HBV regions were sequenced using the BigDye Terminator 
v3.1 Cycle Sequencing Kit (Applied Biosystems, CA, USA). The primers used to sequence 
the three gene regions and their sequences are shown in Table 3.9. 
Table 3.9: Primers employed for the direct sequencing reactions 
Region Primer Sequence Nucleotide 
positions on HBV 
genome 
Polymerase HBV P 5' TCA TCC TCA GGC CAT GCA GT 1292 - 1311 
HBV M 5' GAC ACA CTT TCC AAT CAA TNG G 2306 - 2287 
HBV H             5’ TAT CAA GGA ATT CTG CCC GTT TGT CCT 1767 - 1793 
HBV N             5’ ACTGAGCCAGGAGAAACGGACTGAGGC 1991 - 1965 
X/PreCore H4072 5'- TCTTGCCCAAGGTCTTACAT  1602 - 1621 
Inner core 5'- CAGCGAGGCGAGGGAGTTCTTCTT  2422 - 2445 
CSeqR 5’-GGAGGAGTGCGAATCCACACT  2314 - 2334 
RSP 5’- GTTCAAGCCTCCAAG  1830 - 1844 
 
A reagent mix was prepared for the sequencing reaction according to Table 3.10. All 
sequencing primers were used at a concentration of 2 pmol/µL. Each PCR template was used 
at a concentration between 10-30 ng/µL in order to obtain optimal peaks on the 
chromatograms.   
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Table 3.10: Components and volumes for sequencing PCR. 
Reagent Volume/reaction (µL)  
Terminator ready mix 1 





Cycling conditions for the sequencing PCR were 30 cycles of denaturation at 96°C for 20 
seconds; annealing at 50°C for 20 seconds and elongation at 60°C for 4 minutes. After 
completion of the sequencing reaction, products underwent cleaning with the Big-Dye 
Xterminator Purification kit to separate excess unincorporated dye terminators, salt ions and 
dNTPs from the dye-labelled extension products before loading on the ABI 3130xL genetic 
analyser (Applied BioSystems, CA, USA). The Big-Dye Xterminator Purification mixture 
was made by adding together 49.5 µL of SAM solution and 11 µL of Xterminator suspension 
followed by thorough mixing with vortexing. A total of volume of 55 µL of the reconstituted 
solution was then added to each well. The plates with the reactions were placed on a Genie 
Multi-Microplate shaker (Scientific Industries Inc., NY, USA) for 30 minutes at maximum 
speed after which the plate was centrifuged for 3 minutes at 1,000 rpm using the Rotanta 
460R centrifuge before loading onto the ABI 3130xl genetic analyser. 
3.3.3.4 Sequencing data and phylogenetic analysis 
Sequence analysis and assembly of contiguous sequences was performed using Sequencher 
software, version 5 (GeneCodes USA). Trace files were exported from the ABI3130xl 
Genetic Analyzer and imported into Sequencher software, v5. The consensus sequences were 
exported from Sequencher. Genotypes and sub genotypes were obtained using online 
genotyping databases of Stanford University 
(http://hivdb.stanford.edu/HBV/HBVseq/development/HBVseq.html), the Max Planck 
Institute for Informatics (http://www.geno2pheno.org) and National Library of Medicine 
HBV genotyping tool (http://www.ncbi.nlm.nih.gov/projects/genotyping/formpage.cgi).  
For detection of amino acid mutations in the polymerase/surface antigen and the X/PreCore 
regions, sequences were aligned with references sequences using Clustal W in MEGA 5.2 
software (Institute of Molecular Evolutionary Genetics. PA, USA). Translation of sequences 
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and detection of the presence of amino acids that are not known to be natural polymorphisms 
for that position were recorded as mutations. Analysis of mutations was performed in BioEdit 
software (Ibis Biosciences, CA). The frequency of mutations on a particular codon was 
recorded. Phylogenetic trees were constructed using MEGA 5.1 software. The evolutionary 
history was inferred using the Neighbor-Joining method (Saitou and Nei, 1987). Bootstrap 
testing was performed using 1000 replicates (Felsenstein, 1985). The evolutionary distances 
were computed using the p-distance method and are in the units of the number of base 
differences per site.  
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3.4 HCV testing of HCC samples 
HCC samples were tested for antibodies against HCV and for HCV RNA in the event of a 
positive anti-HCV result. Samples that had detectable HCV RNA underwent sequencing to 
determine the HCV genotype using previously described primers targeted at the NS5B region 
(Mellor et al., 1995). 
3.4.1 HCV serology 
Antibodies to HCV were tested using the ARCHITECT Anti-HCV test on the Abbott 
Architect i2000SR immunoanalyzer (Abbott Laboratories, Abbott Park, Illinois, USA). The 
ARCHITECT Anti-HCV assay is a two-step chemiluminescent microparticle immunoassay 
that is based on the general principles of an enzyme immunoassay principle. The reactions of 
the ARCHITECT Anti-HCV assay occur in the following sequence: in the first step, patient 
sample, assay diluent and HCV antigen coated paramagnetic microparticles are combined. 
The HCV antigens used in this assay are recombinants, derived from NS3, NS4 and the core 
region of the HCV genome. Anti-HCV present in the sample binds to the HCV coated 
microparticles. After washing, anti-human acridinium-labeled conjugate is added in the 
second step. Following another wash cycle, pre-trigger and trigger solutions are added to the 
reaction mixture. The resulting chemiluminescent reaction is measured as relative light units 
(RLUs). ARCHITECT Anti-HCV has been designed to detect antibodies to structural and 
non-structural proteins of the HCV genome (NS3, NS4, core). The ARCHITECT Anti-HCV 
assay cut-off value is calculated by the following formula: calibrator 1 mean relative light 
units (RLU) value × 0.074 = cut-off RLU. ARCHITECT HCV delivers specimen results as a 
ratio of the specimen signal (in RLU) to the cut-off value (S/CO). S/CO ratios of greater than 
or equal to 1.0 are considered reactive for anti-HCV; ratios less than 1.0 are nonreactive for 
anti-HCV. 
3.4.2 HCV RNA detection and quantification 
Samples testing positive for anti-HCV underwent testing for HCV viral load using the 
COBAS AmpliPrep/COBAS TaqMan HCV Quantitative Test, version 2.0 test in the Division 
of Medical Virology NHLS Laboratory at Tygerberg Campus. The assay uses reverse 
transcription of HCV RNA to complementary DNA (cDNA) and simultaneous PCR 
amplification of cDNA and detection of cleaved dual-labelled oligonucleotide probes that are 
targeted to the highly conserved region of the 5′-untranslated region of the HCV genome. The 
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lower limit of detection for the assay is 15 IU/ml and it is able to detect HCV genotypes 1-6. 
The HCV viral load assay is South African National Accreditation System (SANAS)-
accredited. 
3.4.3 HCV sequencing 
HCV sequencing was performed on samples with detectable HCV RNA. The same nucleic 
acid extract from HBV viral load experiments was used for HCV sequencing. Complementary 
DNA (cDNA) synthesis and the first round PCR were performed using SuperScript™ III RT/ 
Platinum® Taq High Fidelity Enzyme Mix (Life Technologies, CA, USA) and the primers 
P1203 and P1204 (20 pmol/µL) that are directed at the NS5B region of the HCV genome. The 
PCR mastermix was made up as shown in Table 3.11. The cycling conditions for the one-step 
reverse transcription and first round PCR are shown in Table 3.12. 
Table 3.11: PCR components for HCV first round PCR 
Component Volume (µL) 
2X Reaction Mix 25.0 
Template 10 
P1203 (20pmol/µL) 0.5 
P1204 (20pmol/µL) 0.5 
SuperScript™ III RT/ Platinum® Taq High Fidelity Enzyme Mix 1.0 
Nuclease Free Water 13 
 
Table 3.12. Cycling conditions for reverse transcription and first round PCR 
Products from the first round PCR were then put through a second round PCR using the 
primers NS5B2 and P1204 and MyTaq DNA Polymerase (Bioline, Germany). The reaction 
master mix for the second round PCR was made according to Table 3.13 and the PCR cycling 
conditions are shown in Table 3.14.  
A: cDNA synthesis B: PCR amplification C: Final extension  
1 cycle :  
45°C for 20 minutes  
94°C for 2 minutes 
40 cycles  
Denature, 94°C for 15 seconds  
Anneal, 55°C for 30 seconds  
Extend, 68°C for 1 minute 
1 cycle  
68°C for 5 minutes  




Table 3.13: Mastermix preparation for second round PCR for HCV sequencing 
Reagent Volume/reaction (µL) 
5x MyTaq Reaction Buffer 10 
P1204 (20 pmol/µL) 1 
NS5Bn2 (20 pmol/µL) 1 
MyTaq DNA Polymerase 0.5 
Water (ddH2O) 35.5 
Template 2 
 
Table 3.14. Cycling conditions for second round PCR for HCV 
 
PCR products were visualized on 2% Seakem agarose gel (Lonza) as previously described for 
HBV (refer to section 3.3.3). Samples with a visible band on gel electrophoresis as shown in 
Figure 3.2 were cleaned up using the Wizard® SV Gel and PCR Clean-Up System 
(Promega). DNA content and purity in cleaned up PCR products was measured using the 
NanoDrop 1000 spectrophotometer (Thermofisher Scientific) as previously for HBV 
sequencing (refer to section 3.3.3.2).  
 
Figure 3.2: Electrophoresis picture of HCV PCR. A band size of around 450 bp was observed for the first 
round PCR product while the second round product was about 400 bp long. 
A: cDNA synthesis B: PCR amplification C: Final extension  
1 cycle :  
95°C for 1 minutes 
30 cycles  
Denature, 95°C for 15 seconds  
Anneal, 60°C for 15 seconds  
Extend, 72°C for 10 seconds 
1 cycle 
72°C for 3 minutes  
4°C hold 
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Cleaned-up PCR products were sequenced bidirectionally using the second round PCR 
primers and Big Dye Terminator v3.1 sequencing kit as shown in Table 3.15. The cycling 
conditions for the sequencing reaction were 25 cycles of denaturation at 96°C for 20 seconds, 
annealing at 55°C for 15 minutes followed by elongation at 60°C for 4 minutes. 
Table 3.15: HCV sequencing PCR with Big Dye Terminator. 
Reagent Volume/reaction (µL)  
Terminator ready mix 1 
5X Sequencing buffer 3 




Following the sequencing PCR, products were cleaned up using the BigDye Xterminator 
Purification kit as previously described for HBV sequencing. The plate was loaded for 
sequence analysis on the ABI 3130xl genetic analyser as described previously. Contiguous 
sequences were generated using Sequencher 5.0 software (GeneCodes Corp, MI, USA) and 
exported as FASTA files. The genotypes were determined from the online NCBI genotyping 
tool for HCV (NIH, USA) and also Geno2pheno (Max Planck Institute for Informatics, 
Germany). 
3.5 HIV serology 
Serology was performed on serum specimens of HCC cases whose HIV status was not known 
at the time of recruitment into the study. Testing was performed using the ARCHITECT HIV 
Ag/Ab Combo assay on the Abbott Architect i2000SR immunoanalyzer (Abbott Laboratories, 
Abbott Park, Illinois, USA). The ARCHITECT HIV Ag/Ab Combo test is based on a two-
step immunoassay that determines the presence/absence of HIV p24 antigen and antibodies to 
HIV-1 and HIV-2 in human serum or plasma specimens using chemiluminescent 
microparticle assay technology. Samples testing positive on the ARCHITECT HIV Ag/Ab 
Combo had a repeat test done on the Mini Vidas (BioMérieux, Marcy l’Etoile, France) to 
confirm the result.  
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3.6 HIV-1 Viral Load 
Viral loads were performed only for the Immune Study subjects. EDTA blood was 
centrifuged at 2,000 rpm for 10 minutes using the Rotanta 460R centrifuge. Thereafter, 1ml of 
plasma was decanted into a clean, sterile 2 ml microcentrifuge tube and the sample was 
submitted for viral load testing using the COBAS/Ampliprep TaqMan HIV-1 version 2.0 on 
the COBAS TaqMan Analyser (Roche Molecular Systems, CA, USA). This is an HIV-1 RNA 
quantitative assay that monitors viral load by automated detection of amplified 
complementary DNA (cDNA) using TaqMan probes. The cDNA is generated from reverse 
transcription of HIV-1 RNA contained in patient’s plasma. This is the routine method 
employed for HIV-1 viral load testing in the Division of Medical Virology, Faculty of Health 




3.7 CD4 T-cell count 
CD4 cell counts were performed on EDTA-anticoagulated blood of Immune Study 
participants using the BD TruCount™ Assay on the BD FACSCalibur instrument (Becton 
Dickenson Biosciences, San Jose, CA, USA). Briefly, the 10 ml EDTA tube was inverted 
gently for 8 times to thoroughly mix blood. Thereafter, 1 ml of blood was transferred using a 
sterile transfer pipette into a clean and sterile 2ml microcentrifuge tube and submitted for 
CD4 T cell counting. CD4 T cell counts were performed in the Division of Medical Virology 
at the Faculty of Medicine and Health Sciences, Stellenbosch University. The CD4 T cell 
counting assay in the Division of Medical Virology is South African National Accreditation 
System (SANAS)-accredited. 
3.8 AST and ALT measurements for Immune Study 
BD Vacutainer SST II Advance tubes with Immune Study participants’ blood were submitted 
to the Chemical Pathology Department of the National Health Laboratories Service (NHLS) 
at Tygerberg Hospital for determination of serum aspartate transaminase (AST) and ALT. 
AST and ALT levels were measured on the Siemens Advia 1800 clinical chemistry analyser 
(Siemens AG., Munich, Germany). Measurement of serum AST and ALT is based on the 
spectrophotometric detection of the rate of change of NADH concentration as it is broken 
down due to the activity of activated enzymes. The NHLS Chemical Pathology Laboratory at 
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Tygerberg Hospital is SANAS accredited. AST and ALT measurements were used in the 
calculation of APRI and FIB-4 test score. 
3.9 Platelet measurement 
Platelet counts were measured in the Haematopathology Division of the NHLS at Tygerberg 
Hospital on EDTA whole blood using the Siemens ADVIA 2120 haematology analyser 
(Siemens AG., Munich, Germany). The measurement of platelet count on the Siemens 
ADVIA 2120 system is based on the principle of flow cell technology. The platelet count test 
performed in the Haematopathology Division of the NHLS at Tygerberg Hospital is SANAS-
accredited. Platelet count was used for the calculation of APRI and FIB-4 scores (refer to 
sections 3.8.1.2 and 3.8.1.3. 
3.10 Assessment of liver fibrosis  
Liver fibrosis was assessed using transient elastometry on the Fibroscan 402 and also using 
the aspartate-to-platelet ratio index (APRI) test, and Fibrosis-4 (FIB-4) test.  
3.10.1.1 Transient elastography using Fibroscan® 402 
Liver stiffness measurements were taken on study participants using the Fibroscan 402 
instrument (Echosens, Paris France) employing a medium transducer probe. The Fibroscan 
operates on the principle of measuring the velocity of a shear wave as it travels through the 
liver. In the procedure, a 50-MHz wave is passed into the right lobe of the liver from a small 
transducer on the end of an ultrasound probe that is held on an intercostal space of the patient 
lying on their back with the right arm behind the head in order to enlarge the intercostal space 
as much as possible (see Figure 3.3). The shear wave is generated from a mechanical impulse 
derived from a servo-controlled vibrator which is initiated by gently pressing the transducer 
probe against the patient’s skin and then pressing the trigger button on the handheld probe. 
The shear wave then propagates through the sub-cutaneous tissue and into the liver. Ultrafast 
ultrasounds are then also generated from the probe and passed onto the liver to measure the 
velocity at which the shear wave is propagated through the liver.  
An inbuilt algorithm within the instrument receives the ultrasonic signals measuring 
propagation of the shear wave through the liver and converts these into kilo Pascal (kPa). The 
volume of liver tissue measured using the Fibroscan can be as much as 3 cm
3 
which is more 
than 100 times the volume that would normally be provided in a liver biopsy. The more 
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fibrosis there is in the liver, the greater the speed that the shear wave travels. The velocity of 
the shear wave is thus reported by the instrument in kPa as a function of the stiffness of the 
liver. Figure 3.3 shows the correct positioning of the patient and the probe during 
measurement of liver stiffness using the Fibroscan. 
 
Figure 3.3 Positioning of patient during the Fibroscan procedure. A minimum of 10 valid measurements 
were taken for each patient from which a median liver stiffness value is calculated by the instrument. For quality 
control, the interquartile range/median for each patient had to be less than 30% for the result to be considered 
valid and at least 70% of the reading taken had to be valid.  
3.10.1.2 APRI score 
The APRI score was calculated using the formula: APRI= [(serum AST concentration ÷ upper 
normal limit)/platelet counts (10
9
/L)] × 100. The upper normal limit used was 40 U/L as is 
reported by the Chemical Pathology Division of the NHLS at Tygerberg Hospital. The APRI 
score has previously been used in African patients with HBV and HIV co-infection (Bonnard 
et al., 2010, Vinikoor et al., 2015).  
3.10.1.3 FIB-4 score 
The FIB-4 score employs a combination of 4 parameters, these being patient’s age, AST 
levels, ALT levels and also platelet count in a mathematical formula expressed as 
 FIB-4 score = [(Age years x AST) / (PLT x √ALT)].  
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The FIB-4 score test was originally developed for assessing liver fibrosis in patients co-
infected with HCV and HIV but it has also been used in patients co-infected with HBV and 
HIV (Sterling et al., 2006, Bonnard et al., 2010, Ive et al., 2013). 
3.11  Calculation of Child-Pugh scores 
Child-Pugh scores which are used to predict the prognosis of cirrhosis were calculated using 
online tools freely available from the University of Washington (www.hepatitisc.uw.edu). 
These were calculated for all the HCC study cases. The Child-Pugh calculator uses a 
combination of 5 clinical measures of disease, these being total bilirubin, serum albumin, 
INR, presence/severity of ascites and presence/severity of encephalopathy. Each parameter is 
assigned between 1-3 points depending on the severity of derangement with 3 being the worst 
score. The sum of the points assigned to each of the 5 clinical measures is used to classify into 
one of the three Child–Pugh scores A, B or C. The parameters and the scores assigned are as 
shown in Table 3.16. HCC cases were assigned to Child-Pugh A if the sum of the 5 
parameters was 5-6, B when 7-9 and C for sum score in the range of 10-15. 
Table 3.16 Calculation of Child-Pugh scores 
Parameter  1 point 2 points 3 points 
Total bilirubin (µmol/L) <34 34-50 50 
Serum albumin (g/L) >35 28-35 <28 
INR <1.7 1.7-2.3 >2.3 
Ascites none mild-moderate severe 
Hepatic encephalopathy none mild-moderate severe 
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3.12 Six Colour Flow Cytometry for expression of markers of activation (38 and HLA-
DR) and exhaustion (PD-1 and CTLA-4) expression on CD8+ T-cells 
3.12.1.1 Flow Cytometry panels design 
Two panels were designed and designated as Immune Activation Panel and Immune 
Exhaustion Panel. The Immune Activation Panel consisted of the following markers and 
fluorochromes: CD3-Fluorescein isothiocyanate (FITC); CD4-PhycoerythrinTexas Red-X 
(ECD); CD8-PhycoerythrinCyanin-7 (PC-7); CD45-Krome Orange (KO); CD38-
Phycoerythrin (PE) and; HLA-DR-Allophycocyanin (APC). The Immune Exhaustion Panel 
was made of the following markers and fluorochromes: CD3-FITC; CD4-ECD; CD8-PC7; 
CD45-KO; CTLA-4-PE and; PD-1-APC. All antibodies used for the study were procured 
from Beckman Coulter (Beckman Coulter, MI, USA).  
3.12.1.2 Instrument set-up 
Flow cytometry data acquisition was performed using a Navios flow cytometer (Beckman 
Coulter, MI, USA). Optimal voltages for acquisition of flow cytometry events were 
established before beginning experiments on processed patient samples. In addition, 
compensation parameters were established and fluorescence minus one (FMO) analyses was 
performed. 
3.12.1.2.1 Voltage set-up 
Flow-Set Fluorospheres (Beckman Coulter, MI, USA) that are fluorescent microbeads were 
used to standardize light scatter, fluorescence intensity and ensure optimal hydrodynamic 
focusing of the instrument. An unstained fresh blood sample was used to set the voltages for 
the forward scatter (FSC) and side scatter (SSC). Flow-Check Pro fluorescent beads 
(Beckman Coulter, MI, USA) of known size were used to verify the optics and fluidics of the 
cytometer.  
3.12.1.2.2 Compensation 
The use of multiple fluorescent antibodies is associated with spectral overlap where the signal 
from one fluorochrome is read together with the emission of another. To counter this 
phenomenon of spectral overlap, a process of fluorescence compensation is used to ensure 
that only the emission of the fluorescent marker of interest is reported (i.e. overlap 
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eliminated). Essentially, compensation is performed by subtracting a portion of one detector's 
signal from another, leaving only the desired signal. Initial compensation settings were 
established using VersaComp beads (Beckman Coulter, MI, USA). These were then further 
adjusted/optimised using stained and unstained EDTA whole blood.  
3.12.1.2.3 FMO analyses 
FMO analyses were performed to correctly gate cells in the context of data spread due to the 
multiple fluorochromes in the designed panels and also to precisely distinguish between 
positive and negative marker expression. Whole blood from a healthy donor were used as 
FMO controls and stained with all the fluorochromes minus each of the fluorochromes of 
interest (CTLA-4-PE, PD-1-APC, CD38-PE, and HLA-DR-APC). By excluding each of the 
markers under investigation, gates were placed in the correct places to distinguish between 
positive staining cells from the negative cells. An example of the FMO analysis for PD-1 on 
CD8+ T cells is shown in Figure 3.4. 
 
Figure 3.4 FMO analysis for PD-1. Figure A is a histogram of CD8+ T cells without PD-1-APC in the staining 
cocktail and showing the gate limits with no cells staining for the antigen of interest (0% of CD8+/PD-1+ in gate 
L). Figure B shows the same sample but stained with an antibody cocktail that included PD-1-APC. The 
percentage of CD8+ T cells staining for PD-1 APC appear in gate L and these were 21% in this example. Figure 
3.3 C shows CD8+ cells without PD-1 staining while Fig 3.3 D shows the same cells staining positive for PD-1. 
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3.12.1.3 Monoclonal antibody titration 
A titration series of the backbone antibodies was performed in order to have the optimal 
concentration of each antibody for staining thereby minimising wastage of unbound antibody 
(Lamoreaux, Roederer, & Koup, 2006). To a volume of 100 μL of whole blood in a 12 x 7.5 
mm sample preparation tube (Beckman Coulter, MI, USA) was added the amount of antibody 
as recommended by the manufacturer. This was mixed by vortexing and incubated at room 
temperature for 15 minutes in a dark environment. The procedure was repeated using 
doubling dilutions of the recommended antibody volume (i.e. 1/2 recommended volume, 1/4 
recommended volume, 1/8 recommended volume). The tubes with the different antibody 
titrations were then processed on the TQ-Prep and acquired on the Beckman Coulter Navios 
(Beckman Coulter, MI, USA). The highest dilution which provided comparable signal 
intensity to the recommended volume was used in the final experiment. The final volumes 
that were chosen for the experiments are shown in Table 3.17. 
Table 3.17: Antibody and fluorochrome combinations used for flow cytometry experiments. The 
Activation and Exhaustion Panels all contained the backbone markers. 





Backbone Markers CD3 FITC UCHT1 IgG1 Mouse 5 
CD4 ECD SFCI12T4D11 IgG1 Mouse 2.5 
CD8 PC7 SFCI21Thy2D3 IgG1 Mouse 5 
CD45 KO J.33 IgG1Κ Mouse 5 
Immune Activation 
Panel Markers 
CD38 PE LS198-4-3 IgG1 Mouse 10 
HLA-DR APC Immu-357 IgG1 Mouse 5 
Immune Exhaustion 
Panel Markers 
CTLA-4 PE BN13 IgG2a Mouse 10 
PD-1 APC PD1.3 IgG2b Mouse 10 
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3.12.1.4 Staining and acquisition protocol 
After determining the optimal monoclonal antibody volume, antibody cocktails were prepared 
for each staining panel according to the final volumes shown in Table 3.17. Two 100 μL 
aliquots of EDTA whole blood underwent a stain-lyse-no wash protocol for determination of 
CD38 and HLA-DR expression on CD8+ T-cells in one tube and PD-1 and CTLA-4 on CD8+ 
T-cells in the second tube. Pre-optimised cocktails for the Immune Activation Panel and 
Immune Exhaustion Panel were added to a 7.5 mm sample preparation tube (Beckman 
Coulter, MI, USA) containing 100 μL EDTA whole blood and allowed to incubate for 15 
minutes at room temperature in the dark. Following this, the tube underwent automated 
processing on the TQ Prep (Beckman Coulter, MI, USA) which makes use of the 
ImmunoPrep Reagent System (Beckman Coulter, MI, USA). On the TQ Prep, red blood cells 
in the sample are lysed by formic acid contained in Bottle A followed by dispensing of 
sodium bicarbonate to neutralize the acid. Finally, paraformaldehyde is added from Bottle C 
to fix the antibody-antigen binding in preparation for acquisition. After processing on the TQ-
Prep, 500 μL of EPICS sheath fluid (Beckman Coulter, MI, USA) was added to the processed 
sample in order to dilute out the cells and reduce the likelihood of coincidental events being 
interrogated by the flow cytometer.  
3.12.1.5 Acquisition parameters 
Samples underwent acquisition on the Beckman Coulter Navios using medium pressure flow 
rate. Navios software (Beckman Coulter, MI, USA) was used during acquisition stages of the 
study. A total of 100,000 events were acquired or a maximum acquisition of 600 seconds 
depending on whichever occurred first. Since all HIV patients were on therapy, a total of 
100,000 events generally resulted in approximately 20,000 CD3+ cells being gated in most 
samples within the 600 seconds. 
3.12.1.6 Daily quality controls 
Flow Check-Pro Fluorospheres (Beckman Coulter, MI, USA) which are beads of known size 
and fluorescence intensity were run on each day that an experiment was performed to verify 
that the optics and fluidics systems on of the instrument were working within expected 
ranges. Compensation was also performed following instrument service and when new 
antibody vials were opened. 
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3.12.1.7 Gating strategy 
A plot of Forward Scatter (FS) integral against FS peak was made and a gate placed to include 
only the singlet cells and exclude doublets and larger multiplets that are caused by clumping 
(Fig 3.5A) (Wood, 2001). A SS INT vs. FS INT plot was also constructed to visualize the 
location of the CD45 gated events according to standard size and granularity spread (Fig 
3.5B). A plot of SS versus CD45-KO was constructed and a gate was placed on the 
population that corresponds to lymphocytes based on their expected size (refer to Fig 3.5C). 
The CD45 gate was used to construct of a plot of SS against CD3-FITC in order to show the 
T lymphocyte subset (Fig 3.5D). A plot of CD4-ECD versus CD8-PC7 was constructed from 
the CD3-FITC positive events in order to separate between the CD4+ and CD8+ T 
lymphocytes (Fig 3.5E). Quadrants were placed for HLA-DR-APC and CD38-PE (PD-1-APC 
and CTLA-4-PE for the Immune Exhaustion panel using the previously defined FMO regions 
on the CD4+ and CD8+ T lymphocyte populations (Fig 3.5F). The gating strategy is shown 
graphically on Figure 3.5. 
 
Figure 3.5 Gating strategy for Immune Activation panel. Plot A shows the singlet population gating while Plot 
B represents the SSC against FSC plot indicating the position of the singlet cells of the lymphocyte population. 
Plot C shows the lymphocyte population as shown by less complexity (SS) and intense staining for CD45-KO in a 
plot of side scatter against CD45-KO. Plot D shows the CD3+ population (Gate G) as gated from Gate F shown in 
Plot C. Using colour precedence and back gating, Plot D also shows the non-lymphocyte population (red colour) 
that is included within gate F based on use of complexity (SS INT) and staining for CD45. Picture E shows the 
CD4+ in the blue colour (gate H) and the CD8+ lymphocytes in the magenta colour (gate I). Plot F shows the 
CD8+ population staining for CD38-PE and HLA-DR-APC gated from gate I.  
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3.12.1.8 Analysis of flow cytometry data 
Post-acquisition analysis of data was performed using Kaluza software version 1.3 (Beckman 
Coulter, MI, USA). Flow cytometric data was expressed as percentage of gated T 
lymphocytes (either CD4+ or CD8+ T lymphocytes) staining positive for each marker as 
shown on Figure 3.1. Gate statistics expressed in percentage were exported from Kaluza into 
an Excel Spreadsheet for storage and subsequent statistical analysis. Statistical analysis was 
performed as described in section 3.16. 
3.13 Measurement of soluble CD14 
Plasma soluble CD14 (sCD14) levels were measured using the HK320 Human sCD14 ELISA 
kit (Hycult Biotech, Uden, Netherlands) which is a ready-to-use solid phase ELISA based on 
the sandwich principle.  
3.13.1 Dilution of standards and subjects’ specimens 
A standard dilution series was first prepared before the assay was performed. The dilution 
series was prepared by reconstituting a vial of lyophilized human sCD14 standard in a 
specified dilution buffer (Db) volume as stated in the certificate of analysis (CoA). Seven 
propylene microcentrifuge tubes were labelled as Tube 2 to Tube 8 and 225 µL of Db was 
pipetted into each of the tubes. A total volume of 225 µL was then transferred from the 
reconstituted standard vial into Tube 2 and mixed by vortexing. After mixing, 225 µL was 
pipetted from Tube 2 into Tube 3. The process was repeated until Tube 7. Tube 8 served as 
the blank and nothing else was added to the Db. A scheme of how the standard dilution series 
was prepared is shown in Figure 3.6. Participants EDTA plasma samples were also diluted by 
factor of 100 using Db before testing. Briefly a 100x dilution was made by adding 10 µL of 
the subject’s sample to 990 µL of Db and mixing by vortexing. All dilutions were made in 
polypropylene tubes as recommended by the manufacturer. 
 
Figure 3.6: Preparation of human sCD14 standard dilution series. The concentration of the standard was 
halved at each further dilution point. 
Stellenbosch University  https://scholar.sun.ac.za
71 
 
3.13.2 Soluble CD14 procedure 
A total volume of 100 µL of diluted standards/samples was added to micotitre plates whose 
wells were coated with antibodies that bind to human sCD14. Each standard/ sample was 
assayed in duplicate. The plate was covered with a seal and tapped gently to eliminate any air 
bubbles. The plate was then incubated for one hour at an air-conditioned room temperature of 
18°C. After the incubation, the plate was washed four times manually using a volume of 200 
µL/well. A volume of 100 µL of biotinylated tracer antibody solution was then added to each 
well. The plate was again covered and incubated for one hour at room temperature. The wash 
procedure was repeated as described previously followed by the addition of 100 µL of 
streptavidin peroxidase to each well on the plate. This was followed by an incubation period 
of one hour after which the plate was again washed. A TMB volume of 100 µL was then 
added to each well followed by incubation for one hour. The enzymatic reaction was then 
stopped by the addition of 100 µL of stop solution. Optical density readings were measured 
using the Biochrom EZ Read LED microplate (Biochrom Limited, Cambridge, UK) reader at 
a single wavelength of 450 nm. An overview of the sCD14 assay is shown in Figure 3.7.  
  
Figure 3.7: Overview of the human sCD14 procedure. 
 
Standard curves were obtained by plotting the absorbance (linear) versus the corresponding 
concentrations of the human sCD14 standards (logarithmic scale) using an online ELISA 
analysis application available from http://elisaanalysis.com/app (Elisakit.com Pty Ltd). The 
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amount of sCD14 in subjects’ samples were then determined from the standard curve by 5-
Parameter Logistic Regression formula using the online tool. An example of the standard 
curve obtained for the sCD14 assay is shown in Figure 3.8. 
 
Figure 3.8 Typical standard curve for sCD14 using the Hycult Biotech assay. The figure shows the sCD14 
standard concentrations on the x axis using a logarithmic scale and the corresponding optical density on the y 
axis in linear scale. Standards and samples were analysed in duplicate. The samples are not included on the 
standard curve. 
3.14 Measurement of lipopolysaccharide binding protein (LBP) 
LBP levels were assayed using HK315 Human LBP ELISA kit (Hycult Biotech, Uden, 
Netherlands). The HK315 Human LBP ELISA assay is identical to the sCD14 assay (refer to 
section 3.8) except for different dilution factors and diluents that are used. 
The LBP standard dilution series was prepared by reconstituting a vial of lyophilized human 
LBP standard by pipetting the amount of wash/dilution buffer (W/Db) following the volume 
stated in the certificate of analysis (CoA). Seven propylene microcentrifuge tubes were 
labelled as Tube 2 to Tube 8 and 225 µL of (W/Db) was pipetted into each of the tubes. A 
total volume of 450 µL was then transferred from the reconstituted standard vial into Tube 2 
and mixed by vortexing. After mixing, 450 µL was pipetted from Tube 2 into Tube 3. The 
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process was repeated until Tube 7. Tube 8 served as the blank and nothing else was added to 
the W/Db. A scheme of how the standard dilution series was prepared is shown in Figure 3.9.  
 
Figure 3.9: Preparation of human LBP standard dilution series. The standard concentration decreased by 1/3 
at each dilution point. 
 
Participants EDTA plasma samples were diluted to a factor of 1000x using W/Db. Briefly a 
10x pre-dilution was made by adding 25 µL of EDTA plasma to 225 µL of W/Db and mixing 
by vortexing. A final 1000x dilution was then made by adding 10 µL of the 10x pre-diluted 
sample to 990 µL of W/Db and mixing by vortexing. All dilutions were made in 
polypropylene tubes as recommended by the manufacturer. After dilution of samples and 
standards, the procedure was the same as described for sCD14. Standard curves were obtained 
by plotting the absorbance (linear) versus the corresponding concentrations of the human LBP 
standards (logarithmic scale) using an online ELISA analysis application available from 
http://elisaanalysis.com/app (Elisakit.com Pty Ltd). The amount of LBP in subjects’ samples 
were then determined from the standard curve by 5-Parameter Logistic Regression formula 
using the online tool. An example of the standard curves that were obtained for LBP is shown 
in Figure 3.10. 




Figure 3.10 Standard curve for the Hycult Biotech LBP assay. The curve shows the LBP standard 
concentrations on the x axis (logarithmic scale) and the optical densities on the y axis (linear scale). Samples and 
controls are not included in the curve. 
3.15 Cytokine measurement by Luminex technology 
Luminex technology is a combination of ELISA and flow cytometry principles. The 
technology is based on the use of capture antibodies (directed at the analyte of interest) that 
are covalently coupled to fluorescently dyed microspheres (beads). Each microsphere has a 
unique colour code that allows distinction of individual targets within a multiplex system. The 
coupled antibodies react with the cytokine of interest within the sample. After a wash step to 
remove unbound protein, the beads are washed and biotinylated detection antibodies are 
added that create a sandwich complex. A detection complex of streptavidin-PE is added. The 
PE serves as the reporter or indicator fluorochrome during interrogation of the beads on the 
reader. Serum cytokines and chemokines were measured using the premixed Bio-Plex pro 
Human Cytokine Grp 1 panel 27-plex and the Bio-Plex Pro TGF- β Panel 3-plex assays (Bio-
Rad Laboratories, CA, USA). The Bio-Plex pro Human Cytokine Grp 1 panel 27-plex kit 
contains the analytes; IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8. IL-9, IL-10, IL-
12(p70), IL-13, IL-15, IL-17,  basic Fibroblast Growth Factor (FGF), eotaxin, granulocyte-
colony stimulating factor (G-CSF), Granulocyte Macrophage-colony stimulating factor (GM-
CSF), interferon gamma (IFN-γ), IFN-γ-inducible protein 10 (IP-10), Macrophage 
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Chemoattractant Protein 1 (MCP-1), Monocyte Inflammatory Protein 1 alpha (MIP-1α), 
Monocyte Inflammatory Protein 1 beta (MIP-1β), platelet derived growth factor-BB (PGDF-
BB), regulated on activation, normal T cell expressed and secreted (RANTES), TNF-α and 
vascular endothelial growth factor (VEGF). The Bio-Plex Pro TGF- β Panel 3-plex kit assays 
for the three TGF-β isoforms TGF- β1, TGF-β2 and TGF-β3. Serum samples were thawed at 
room temperature and tested within 2 hours of thawing. The assays were performed according 
to the supplier instructions. Briefly for the 27-plex assay, 20x premixed antibody-conjugated 
beads of the 27 individual cytokines were diluted to 1x working concentration added 50µL 
were added to each well of a 96-well flat-bottom plate that was placed on a washer with a 
magnetic plate holder and washed twice. There is no pre-wetting of the plate necessary as 
would be required using a filter plate and filter washer. Serum samples were diluted 4x using 
Bio-Plex sample diluent and added to the plate containing the premixed beads. The plate was 
then sealed and covered with aluminium foil and allowed to incubate for 30 minutes at room 
temperature on an Orbit P4 microplate shaker (Labnet International, NJ, USA) at 850 rpm. 
Thereafter, the plates were washed three times using 100 µL of wash buffer on the Bio-Rad 
BioPlex Pro Wash Station (Bio Rad Laboratories, CA, USA). A volume of 25 µL of detection 
antibody was then added to each well. The plate was covered again with sealing tape and 
sealed with aluminium foil and incubated for 30 minutes on a shaker at 850 rpm. After 
incubation, the plate was washed three times using a wash buffer volume of 100 µL. A 
volume of 50 µL of streptavidin-PE conjugate was added to each well and incubated for 10 
minutes at room temperature while seating on the shaker. Plates were washed for the last time 
for three cycles. One hundred and fifty microlitres of sheath fluid was then added to each well 
and the plate was sealed again, covered with aluminium foil and placed on the shaker for 30 
seconds. The plate was read on the Bio Plex 200 platform (Bio Rad Laboratories). The Bio-
Plex Pro TGF- β Panel 3-plex assay was also performed according to manufacturer’s 
instruction and is similar to the Human Cytokine Grp 1 panel 27-plex kit except for an 
additional step that requires pre-treatment of sample and some of the incubation times that are 
also different. For the TGF-β Panel 3-plex assay, serum samples have to be first pre-treated 
with acid in order to render TGF-β immunoreactive. Briefly, 5 µL of 1N hydrochloric acid 
was added to 25 µL of participant’s EDTA plasma, thoroughly mixed by vortexing and 
incubated at room temperature for 10 minutes. To neutralize the sample, 5 µL of a base 
composed of 1.2N NaOH/0.5M HEPES was then added and mixed by vortexing. To achieve a 
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final sample dilution of 16x, 365 µL of Bio-Plex sample diluent was added. The assay was 
performed similar to the 27-plex assay except for the differences as shown in Table 3.18. 
The activating acid and neutralising base for the TGF-β assay are not provided with the kit 
and were prepared according to the recipes recommended in the kit insert. To make 100 ml of 
1N HCl, 8.33 ml of 12N HCl was slowly added to 91.67 ml of deionized water and mixed 
well. Preparation was done on ice because of the exothermic nature of the reaction. To make 
up 100 ml of 1.2N NaOH/0.5M HEPES, 12 ml of 10N NaOH was added to 75 ml of 
deionized water and mixed by swirling. Thereafter, 11g of HEPES powder (free acid with 
molecular weight 238.3g) (Sigma Aldrich, MO, USA) was added and mixed by swirling. The 
solution was topped with deionized water to achieve a final volume of 100 ml. Luminex data 
was exported onto an Excel spreadsheet. Cytokines that were below detection limit were 
assigned a value of zero to standardize for statistical analysis. Statistical analysis for 
differences between groups was performed as described in section 3.16. 
Table 3.18: Similarities and differences between the Bio-Plex 27-plex assay and the Bio-Plex TGF-β 3-plex 
assay 
Step 27-plex TGF-β 3-plex 
Pre-treat sample No Yes 
Sample dilution 4x 16x 
Beads complexed to antibody 50 µL 50 µL 
Wash 2x 2x 
Add samples/standards 50 µL 50 µL 
Incubate 30 min, room temp, 850 rpm 2 hours, room temp, 850rpm 
Wash 3x 3x 
Detection antibody 25 µL 25 µL 
Incubate 30 min, room temp, 850 rpm 1 hour, room temp, 850rpm 
Wash 3x 3x 
Streptavidin-PE conjugate 50 µL 50 µL 
Incubate 10 min, room temp, 850 rpm 30 min, room temp, 850 rpm 
Wash 3x 3x 
Resuspend in assay buffer 125 µL 125 µL 
Shake 30 sec, 850 rpm 30 sec, 850 rpm 
Read plate Bio Plex 200 platform Bio Plex 200 platform 
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3.16 Data handling and statistical analysis 
All data entry and storage was performed in Epi-Info 7 (Centres for Disease Control, GA, 
USA) and statistical analysis was carried out in Statistica version 12 (StatSoft, Oklahoma, 
USA). Normality of data was tested using the D'Agostino-Pearson omnibus test. Non-
parametric data was described using medians and interquartile ranges and compared using the 
Mann-Whitney test where there were only two groups or the Kruskal-Wallis test in cases of 
three or more groups. Multiple comparisons were preformed using the Dunn’s post-test where 
the Kruskal-Wallis p value was significant.  
Data with normal distribution was described using means and 95% confidence intervals (95% 
CI). Comparisons were performed using the unpaired t-test when data was normally 
distributed. Categorical data was described using proportions and 95% CI and analysed using 
the χ2 test or Fisher’s test depending on the number of observations. Correlational analysis 
was performed using the Spearman rank correlation test. Graphs were constructed using 
Statistica and GraphPad Prism version 5 software (GraphPad Software, CA, USA). All 
hypothesis testing was done at 95% confidence intervals and results were regarded as 
significant if p<0.05. 





This chapter will be presented in three parts. The first part describes results from the HCC 
Epidemiology Study (HCC Study). The second part describes the results of the Liver Fibrosis 
and Immune Markers Study (Immune Study). The third part describes differences and 
similarities of the molecular character of HBV sequenced from the HCC Study and Immune 
Study. 
4.1 HCC Study 
4.1.1 Patient characteristics 
A total of 107 HCC cases were recruited between December 2012 and August 2015 A total of 
88 (83%) of the HCC cases were recruited from Tygerberg Hospital and Groote Schuur 
Hospital in the Western Cape Province of South Africa. There were fewer cases recruited 
from participating centres in Gauteng because of the unavailability of study nurses who could 
help the clinicians who had a heavy workload to devote time to research activities. The site of 
recruitment for all cases for the HCC study is shown in Table 4.1. 
Table 4.1 List of recruitment sites and number of enrolled HCC cases 
Recruitment site n (%) 
Tygerberg Hospital (Western Cape) 50 (47) 
Groote Schuur Hospital (Western Cape) 38 (36) 
Chris Hani Baragwanath Hospital (Gauteng) 10 (9) 
Charlotte Maxeke Johannesburg Academic Hospital (Gauteng) 8 (7) 
Steve Biko Academic Hospital (Gauteng) 1 (1) 
 
The majority of the cases were male patients who made up 78% (n=83) of the cohort. Of the 
107 HCC cases, 61 (57%) were born in a rural area setting. The demographic characteristics 
of the cases are shown in Table 4.2.  
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Table 4.2 Summary of demographic characteristics of HCC cases at time of recruitment 
Characteristic Descriptive statistic 
Number of HCC cases 107 















  6 (6%) 
  4 (4%) 







  8 (7%) 
 
The youngest HCC case recruited in the study was 18 years of age while the oldest case was a 
90 years old male patient. A histogram plot of the results showed that the highest number of 
HCC cases occurred between 30-40 years of age. Figure 4.1 is a histogram of the age 
distribution at HCC diagnosis. 
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Figure 4.1 Age distribution of HCC cases. The frequency histogram shows that the modal age category and 
HCC presentation for the entire cohort was between 30-40 years old where 26 cases were seen. 
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The median age at presentation for Caucasian cases was 60 years (IQR: 49-70) compared to 
41 years (IQR: 33-51) among Black Africans and 50 years (IQR: 33-57) among those of 
Mixed Descent, p=0.3. There was no significant difference in the median age of Black 
Africans and Caucasians. The mean age of rural-born cases was 47.3 years (95% CI: 43.3-
51.3) compared to 43.3 years (95% CI: 38.3-48.3) among those born in urban areas, p=0.8.  
4.1.2 Diagnosis modalities for HCC in South African patients 
A total of 80% of the recruited HCC cases were diagnosed using a combination of serum 
alpha-fetoprotein (AFP) levels plus imaging techniques. Serum AFP levels were available for 
99/107 (93%) of the HCC cases with 9 cases having no results. The most common imaging 
modality used was contrast-enhanced computed tomography (CT) scan with 77 of 107 (72%) 
of the cases having received an examination by CT alone or in combination with other 
imaging examinations. Only three HCC cases had an USS performed together with an MRI 
scan without CT. Liver histological examination was performed in 29 out of 98 cases (30%) 
with 11 cases having incomplete data as to whether histological examination was carried out 
or not. The distribution of the imaging and AFP examinations is shown in Table 4.3. 
Table 4.3 Imaging modalities used in diagnosing HCC among recruited cases 
Modalities used for HCC diagnosis Frequency* % 
AFP + CT alone 43 40 
AFP + USS alone 23 21 
AFP + USS + CT 27 25 
AFP + USS + MRI 3 3 
AFP + USS + CT + MRI 2 2 
USS alone 2 2 
USS + CT 3 3 
CT alone 4 4 
*Frequencies correspond to Boolean combinations of imaging modalities with denominator being 107 
4.1.3 Clinical laboratory features of HCC cases at presentation 
Clinical laboratory data was collected for liver function tests, full blood counts and kidney 
function tests. ALT values that were greater than twice the upper limit of normal were 
observed in 25/85 (30%) of all HCC cases. The proportion of HCC cases with serum ALT 
greater than 40 U/L at the time of HCC diagnosis was 58/85 (68%). A summary of available 
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clinical laboratory data is shown in Table 4.4. Of 98 cases that had an AFP result, 69/98 
(70%) had levels greater than 400 µg/L. 
Table 4.4 Laboratory features of all recruited HCC cases on presentation 
Laboratory Parameter Reference interval n Median (IQR) 
AFP (µg/L) 0-9.0 98 6,176 (120-47,751) 
ALT (U/L) 5-40 85 51 (35-86) 
AST (U/L) 5-40 62 91 (47-172) 
ALP (U/L) 40-120 86 241 (172-390) 






Total bilirubin (µmol/L)  0-21 92 13 (9-26) 
Conjugated bilirubin (µmol/L) 0-6.0 71 8 (4-20) 
Albumin (g/L) 35-52 87 35 (30-39) 
Platelets (x10
9
/L) 178-400 98 302 (213-414) 
MCV (fl) 79.1-98.9 80 87 (83-94) 






Creatinine (µmol/L) 49-90 72 66 (55-80) 
U/L-units per litre, fl-femtolitres  
4.1.4 Clinical characteristics of HCC cases at presentation 
The clinical characteristics investigated at time of recruitment of HCC cases included a 
known diagnosis of cirrhosis, presence of ascites, ankle oedema, abdominal mass and other 
features of liver disease including jaundice, hepatomegaly and splenomegaly. The most 
frequently observed clinical features at presentation and their frequencies are shown in Table 
4.5. The most commonly observed sign among the HCC cases was the presence of an 
abdominal mass (reported in 67% of cases) which frequently was the cause for the patients 
seeking medical attention. Other findings that were observed among the HCC patients 
included: clubbing which was reported in eight cases, leukonychia seen in five, 
gynaecomastica that was found in three cases, two had hepatic arterial liver bruit and spider 
naevi were also seen in two HCC patients of whom one self-reported alcohol dependence. 
Other rare findings that were seen in no more than one case included parotid enlargement and 
bruising.   
Stellenbosch University  https://scholar.sun.ac.za
82 
 
Table 4.5 Prevalence of clinical features at presentation 
Feature Frequency (%) 
Concomitant cirrhosis 21 (23%)* 
Abdominal mass 72 (67%) 
Ascites 35 (33%) 
Hepatomegaly 17 (16%) 
Ankle oedema 17 (16%) 
Jaundice 14 (13%) 








  8 (9%) 
*17 cases had data unreported. 
Results of the radiological examinations showed that 58% of cases had multiple liver lesions 
present within the liver at the time of HCC diagnosis. A finding of hepatomegaly on 
radiological examination was seen among 55% of cases. Cases frequently presented with 
advanced disease such that only five underwent surgical resection of the tumour. Table 4.6 
summarizes the observations made from the combination of radiological findings for all 107 
HCC cases. 
Table 4.6 Summary of findings of radiologic examinations  
Imaging Findings Frequency Percent 
Multiple liver lesions 62 58% 
Enlarged liver 59 55% 
Ascites 24 22% 
Splenomegaly 21 20% 
Single liver lesion <2 cm 13 12% 
Single lesion greater than 5 cm 11 10% 
Evidence of hypervascularity 7 7% 
Shrunken liver 6 6% 
Single lesion less/equal 5 cm 1 1% 
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Data on presence or absence of metastasis was mostly incomplete and was reported for only 
48/107 (45%) of the cases. Among the 48 with reported data, 27 (56%) cases had evidence of 
metastasis of the malignancy from/within the liver. The most common site of extrahepatic 
metastasis was the lungs which was reported in 12/27 (44%) patients. 
4.1.5 Prevalence of lifestyle and familial risk factors for HCC 
Self-reported history on alcohol dependence, smoking, consumption of traditional beer 
(proxy risk for iron overload) and peanut consumption (as a proxy for aflatoxin exposure) 
was investigated. In addition the presence of familial history of liver disease and HCC was 
also investigated (refer to Appendix 2). The frequency of these risk factors is shown in Table 
4.7.  
Table 4.7 Prevalence of familial and lifestyle risk factors among HCC patients 
Risk Factor Frequency (%) 
Family history of liver disease 12/82 (15%) 
Family history of HCC  5/97 (5%) 
Known prior diagnosis of cirrhosis 4/90 (4%) 
Self-reported alcohol dependence 22/98 (22%) 
Consumption of traditional beer 24/94 (26%) 
History of smoking 64/80 (80%) 
Consumption of peanuts 67/85 (79%) 
The mean age of HCC cases with a positive family history for liver disease was 44.0 years 
(95% CI: 33.2-54.7) compared to 45.6 years (95% CI: 41.6-49.5) in those without a family 
history of liver disease, p=0.8. Only four cases (4%) had data that indicated a prior diagnosis 
of cirrhosis. The remaining 17 cases that had cirrhosis had the date of cirrhosis diagnosis 
being the same as date of HCC diagnosis. Among the four subjects that had a confirmed prior 
diagnosis of cirrhosis, the mean lead time between cirrhosis diagnosis date and HCC 
diagnosis date was 146 days. Although only 22/98 (22%) of cases self-reported alcohol 
misuse (drinking patterns that have a negative impact on a person’s health, relationships and 
work), the overall frequency of alcohol consumption was 74/107 (69%). The frequently 
consumed alcohol type was beer 34%, followed by spirits (19%) and wine (13%). Cases that 
self-reported alcohol dependence had a significantly higher mean age (52.7 years, 95% CI: 
46.3-59.2) compared to those without alcohol dependence (44.0 years, 95% CI: 40.4-47.5), 
p=0.02 
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Of the 64 subjects that had a smoking history, 11 were current smokers, 46 were past smokers 
who had quit less than 5 years at time of recruitment and 7 had stopped smoking for over 5 
years before presentation with HCC. Males comprised 50/64 (78%) of HCC cases that had 
any history of smoking. Consumption of peanuts was evaluated as a proxy of aflatoxin 
exposure. The most commonly reported sources of peanuts were supermarkets that are 
thought to be low risk of aflatoxin contamination (n=25) and vegetable/farmers’ markets that 
are thought to have a high risk of aflatoxin contamination (n=24). Fifteen subjects reported 
that they grew their own peanuts. HCC cases consuming peanuts from supermarkets 
presented at median age 41 years (IQR: 31-52), those from vegetable/farmers’ markets had 
median age 36 years (IQR: 29.5-53.5) and those that grew their own had median age of 42 
years (IQR: 33-62) at HCC presentation, p=0.59. 
4.1.6 Prevalence of HBV serologic markers as risk factors among HCC cases 
4.1.6.1 Prevalence of HBsAg 
Of the 107 HCC cases that were recruited, HBsAg testing was performed for 106 (99.1%). 
The HBsAg status for one male subject was not determined because of the unavailability of 
serum/plasma to perform the test. Overall, seropositivity for HBsAg was seen in 68/106 
(64.1%, 95% CI: 59-77) of the HCC cases. The results of HBsAg reactivity according to 
gender are shown in Table 4.8. 
Table 4.8. Frequency of HBsAg seropositivity according to gender among HCC cases 
Gender HBsAg positive, n (%) 
Male, n (%)* 55/82 (67%) 
Female, n (%) 13/24 (54%) 
 
Although there was a higher prevalence of HBsAg positivity among male cases (67%) 
compared to females (54%), the difference in proportions was not statistically significant 
with p=0.33.  
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4.1.6.2 Prevalence of anti-HBc 
Antibodies to HBV core antigen are indicative of exposure to HBV infection regardless of 
outcome. The prevalence of anti-HBc among HCC cases was 85/103 indicating that 83% 
(95% CI: 76-90) had been exposed to HBV. Four cases were not tested due to insufficient 
serum specimen. Among the HBsAg negative cases, 17/34 (50%, 95% CI: 33-67) were 
positive for anti-HBc. The prevalence of exposure to HBV among male cases was 68/81 
(84%, 95% CI: 76-92) compared to 17/22 (77%, 95% CI: 54-95) among female cases, p= 
0.29. 
4.1.6.3 Prevalence of HBeAg 
The overall prevalence of HBeAg among the HBsAg positive cases was 20/65 (31%, 95% 
CI: 20-42). HBeAg status was not determined in three cases because of insufficient serum. 
HBeAg which is considered a marker of higher HBV infectivity occurred more frequently 
among females with 5/11 (45%, 95% CI: 15-74) compared to male HCC cases of whom 
15/54 (28%, 95% CI: 14-40) were HBeAg positive, p=0.29. 
4.1.6.4 Prevalence of anti-HBe 
From the 68 HBsAg positive cases, the anti-HBe status was determined in 64, of whom 45/64 
(70%) were anti-HBe seropositive. There was no significant difference in carriage of anti-
HBe according to gender with 8/11 (72%) of HBsAg-positive females compared to 37/53 
(70%) of males, p=1.00. 
4.1.6.5 Effect of HBsAg status and gender on age at presentation 
Overall, there was a trend towards a younger age at HCC diagnosis in the HBsAg positive 
cases compared to the HBsAg negative individuals with mean ages 44.1±13.9 years and 
48.5±17.1 years, respectively; p=0.15. The most frequent age range at HCC diagnosis among 
HBsAg positive cases was 30-35 years, 48% of HBV-related HCC cases occurred by the age 
of 40 years and 72% by the age of 50 years. There were no statistically significant differences 
in the age between the genders according to HBsAg status, p =0.44. Results of the effect of 
gender and HBsAg status on age at HCC diagnosis are reflected in Figure 4.2. 
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Figure 4.2 Age at HCC diagnosis against gender and HBsAg status. The middle line represents the median; 
the box represents the IQR; the whiskers are representative of the non-outlier range and the mean age is 
indicated by the + sign. The mean age of the HBsAg negative males (HBsAg- M) was 50.1±16.9 years compared 
to 43.8±13.4 years among the HBsAg positive males (HBsAg+ M). The mean age for HBsAg positive females 
(HBsAg+ F) was 45.2±15.6 years compared to 45.6±18.8 in those that were HBsAg negative (HBsAg- F), p=0.4. 
There was one outlier value among the HBsAg+ F group. 
 
4.1.7 Prevalence of HIV infection among HCC cases 
HIV testing was performed on 100 HCC cases. HIV status could not be determined in seven 
subjects due to non-availability of specimen. Overall, the prevalence of HIV infection among 
all the tested HCC cases was 22/100 (22%, 95% CI: 14-30). The relative risk of being female 
and HIV positive was twice as likely as that of being HIV positive male with 36% (95% CI: 
16-56) of HCC females being HIV-infected compared to only 18% (95% CI: 2-34), p=0.083. 
The breakdown in prevalence of HIV among the HCC patients according to HIV status is 
shown in Table 4.9. 
Table 4.9 Frequency of HIV infection according to gender among HCC cases 
Gender HIV-infected HIV-uninfected 
Male, n (%) 14 (18%) 64 (72%) 
Female, n (%) 8 (36%) 14 (64%) 
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4.1.7.1 CD4+ T cell count and therapy 
Among the 22 HIV-infected HCC cases, 18 (82%) had data available on the last CD4+ T cell 
count at time of HCC diagnosis. The median CD4 cell count was 293 cells/µL (IQR: 200-
602). HAART administration was reported for 14 cases. The periods between HAART 
duration and HCC diagnosis ranged from 2 weeks to more than 10 years. Of the 14 cases to 
have reported HAART, 9 were on a regimen of tenofovir, lamivudine and EFV while one 
was taking lamivudine, stavudine and nevirapine. The HAART regimen for four cases was 
not provided. Only 2/14 of the HIV-infected patients on therapy were HBsAg negative.  
4.1.7.2 Effect of HIV and gender on age at presentation 
HIV-infected cases had a mean age of 39.7 years (95% CI: 36.0-43.5). These cases were 
younger than the HIV-uninfected HCC cases whose mean was 46.4 years (95% CI: 42.8-
50.0) and there was a trend toward a significant difference, p=0.07. The mean age of HIV-
infected female HCC cases of 35.8 years (95% CI: 34.1-40.0) was 13 years (95% CI: -27 - 
1.9) younger compared to HIV-uninfected females that had a mean age of 48.5 years (95% 
CI: 37.4-59.6), p=0.08. HIV-infected male HCC cases were only slightly younger with mean 
age 42.0 years (95% CI: 36.6-47.4) compared to HIV-uninfected males whose mean age was 
45.9 years (95% CI: 42.2-49.8), p=0.4. These results are shown in graphic form on Figure 
4.3. There was no statistically significant difference in age at presentation according to 
gender and HIV status, p=0.2. 


















Figure 4.3 Age at HCC diagnosis against HIV status according to gender and HIV infection. The plot shows 
the mean age at HCC diagnosis grouped according to HIV status and gender. The middle line represents the 
median; the box represents the IQR; the whiskers are representative of the non-outlier range and the mean age 
is indicated by the + sign. HIV+ M represents HIV-infected males; HIV- M shows the HIV-uninfected males while 
HIV+ F represents HIV-infected females and HIV- F shows the HIV-uninfected HCC females. 
p=0.2 




4.1.8 Co-infection with HBV and HIV infection among HCC subjects 
Of the 22 HIV-infected HCC subjects, 18 (82%) were also infected with HBV as defined by 
seropositivity for HBsAg. Of the four HIV-infected, HBsAg negative cases, 2 (50%) were 
anti-HBc positive signifying exposure to HBV. Of the 18 HBV/HIV co-infected subjects, 12 
(67%) were male compared to 41/47 (87%) among those that were HBsAg positive only, 
p=0.01. The mean age of the HBV/HIV co-infected HCC subjects was 39.8 years (95% CI: 
31.4-40.0) compared to 45.4 years (95% CI: 40.9-49.8) in the HBV-mono-infected subjects, 
p=0.30. Table 4.10 summarises differences between HBV/HIV co-infected and HBV mono-
infected HCC subjects. 
Table 4.10 Comparison of demographic and virologic factors between HIV-infected and HIV-uninfected  





Age in years, Mean (95% CI) 39.8 (35.6-44.0) 45.4 (40.9-49.8) 0.30 
Male gender, n (%) 12 (67%) 41 (87%) 0.01 
HBeAg positivity 10/17 (59%) 9/46 (20%) 0.005 
AFP >400 11/18 (61%) 35/44 (80%) 0.20 
 
Among the female HCC cases, the 6 HBV/HIV co-infected subjects had a mean age of 36.8 
years (95% CI: 32.2-41.5) compared to 50.5 years (95% CI: 30.2-70.8) in the HBV mono-
infected cases. The mean difference in the average age between the HBV/HIV co-infected 
females compared to the HBV mono-infected females was 13.7 years (95% CI: -32 to 4.4) 
and this had a trend toward significant difference, p=0.09. Co-infected males had a mean age 
of 41.3 years (95% CI: 35.1-47.4) compared to a mean age of 45.5 years (95% CI: 40.5-50.5) 
among the HBV mono-infected males. The difference in mean age among the males 
(according to HBsAg and HIV status) of 4.2 years (95% CI: -12 to 5.7) was not statistically 
significant, p=0.7. A graphical representation in the age at diagnosis according to HBV and 
HIV infection status is shown in Figure 4.4. 
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Figure 4.4 HBV and HIV infection status and gender. No significant differences in age at presentation of HCC 
stratified according to HBsAg, HIV and gender were detected. The middle line represents the median; the box 
represents the IQR; the whiskers are representative of the non-outlier range and the mean age is indicated by 
the + sign. HBV/HIV M represents the HBV/HIV co-infected males; HBV M represents the HBV mono-infected 
males; HBV/HIV F are the HBV/HIV females and HBV F shows the HBV mono-infected females. 
 
4.1.9 Molecular characteristics of HBV in HCC patients 
4.1.9.1 HBV Genotypes 
HBV genotypes were determined from sequencing of the overlapping surface/polymerase 
gene. Sequencing was attempted for all samples with detectable HBV DNA. Genotypes were 
determined for 43 subjects, of whom 34 (79%) were infected with HBV genotype A, 7 (16%) 
had HBV genotype D and 2 (5%) carried HBV genotype E. HBV/HIV co-infected cases were 
infected with only genotype A1. Seven cases infected with HBV genotype D and two with 
genotype E were only seen in the HCC cases that were infected with HBV alone. Sub 
genotypes were obtained for sequences of genotypes A and D from the Max Planck Institute 
for Informatics web-based geno2pheno tool. Genotype A sequences were distributed as 33 
subgenotype A1 (9 from co-infected cases and 24 that had HBV mono-infection) and one sub 
genotype A2 (from a mono-infected case). The genotype D sequences were distributed as five 
subgenotype D3; a single D2 and; one D4. There are no sub genotypes described in the 
literature for HBV genotype E. The distribution of HBV genotypes according to whether 
cases were infected or not infected with HIV is shown in Figure 4.5. 
p=0.7 



























Figure 4.5 HBV genotypes according to HIV infection status among HCC cases. HCC cases with HIV co-
infection were infected by only HBV genotype A while genotypes D and E were also detected among HCC cases 
with hepatitis B infection alone. 
 
4.1.9.2 Phylogeny of HCC-derived sequences 
The reverse-transcriptase region of HCC cases was aligned with other GenBank-deposited 
sequences. The sequences clustered closely to other sequences of similar genotypes. There 
was no monophyletic clustering of sequences according to HIV status. A phylogenetic tree of 
the HBV sequences from HCC cases is shown in Figure 4.6. 




Figure 4.6 Evolutionary relationships of HBV sequences from HCC cases. The evolutionary history was 
inferred using the Neighbor-Joining method (Saitou and Nei, 1987). The optimal tree with the sum of branch 
length = 0.62396497 is shown. The percentage of replicate trees in which the associated taxa clustered together 
in the bootstrap test (500 replicates) are shown next to the branches (Felsenstein, 1985). The tree is drawn to 
scale, with branch lengths in the same units as those of the evolutionary distances used to infer the phylogenetic 
tree. The evolutionary distances were computed using the p-distance method and are in the units of the number 
of base differences per site. The analysis involved 78 nucleotide sequences. Sequences from HIV-infected HCC 
cases are annotated with a red square while those from HIV-uninfected are shown with a black square. Codon 
positions included were 1st+2nd+3rd+Noncoding. All ambiguous positions were removed for each sequence 
pair. There were a total of 546 positions in the final dataset. Evolutionary analyses were conducted in MEGA5 
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4.1.9.3 Effect of HBV genotypes on age at presentation of HCC 
HCC cases infected with HBV genotype A had a median age of 36 years (IQR: 31-48) 
compared to 53 years (IQR: 50-58) in those infected with genotype D. The difference in the 
median ages was statistically significant, p=0.008. The analysis did not include the two cases 
infected with genotype E because age at diagnosis was available for a single case only with 
the second case having incomplete data on the age at diagnosis. 
4.1.9.4 HBV reverse transcriptase mutations 
Mutations in the YMDD region of the reverse transcriptase gene of HBV are associated with 
development of resistance to NRTIs that are used for therapy. Drug resistance mutations were 
observed in only 3/43 (7%) subjects, all of whom were infected with HBV genotype A. The 
most common mutation observed (seen in 3/3 patients with drug-resistance mutations) which 
is associated with development of resistance was on codon 80 where the leucine (L) was 
replaced with either isoleucine (I) or valine (V). The L80I/V mutation is a compensatory 
mutation associated with resistance to lamivudine and telbivudine. In 2/3 cases, L80I/V 
occurred together with L180M and M204V/I mutations that are also associated with 
resistance to lamivudine, telbivudine and entecavir. A single subject had the L80I substitution 
as the solitary drug-resistance associated mutation. 
4.1.9.5 HBV surface antigen mutations 
Because of the overlapping nature of the reading frames of the RT region and the small 
HBsAg gene, mutations were also investigated in the latter. All except three samples had at 
least one mutation in the surface antigen region. The majority of surface antigen mutations 
occurred between amino acid residues 1-40; 111-129 and 175-205. Three cases were infected 
by a variant with a stop codon mutation at amino acid L216* while a single subject had a 
W182* mutation. Interestingly, the chromatograms revealed mixed virus populations in the 
four samples with stop codon mutation as there was a mixture of wildtype and mutant virus. 
A variety of mutations that have been described to cause detection and vaccine escape by the 
Max-Planck-Institute’s geno2pheno web-based genotyping tool were detected. These were 
seen in 14/43 (33%) samples. The most common change observed was the P120T substitution 
that was found in six of the fourteen samples with escape mutations. Table 4.11 shows the list 
of escape mutations that were observed together with other co-occurring substitutions in the 
surface antigen region and the genotype. 




Table 4.11 List of escape mutations in the surface antigen region of HCC cases. 
HBsAg mutations Escape 
mutations 
Genotype 
F41FS, S45A, L94LS, L109ILM, G130DGNS, A166AG, A194V, I208T 109I, 130D, 
130N 
A1 
S45P, P127PR, V177A, F220L, C221CG, V224A 127R A1 
F8FL, F20FS, S45PS, L49R, G112GR, T118AT, P120PT, G130DGNS, 




S45A, L49CR, I68IT, M133MT, V190AV, S204N,  133T A1 
S143LS 143L E 
Y100CY, T126NT, M133IM, Y161FY, S193LS,  100C, 126N, 
133I 
A1 
S45A, T118A, P120T, P211HP 120T A1 
R24K, S45P, P120T, Y206C,  120T A1 
L42R, P120T, T127P, G159A, S207T, S210R, V224A 120T D3 
S45P, P120T, K122R 120T A1 
L21LS, S45AS, L49HL, L109IL, Y161F,  109I A1 
F20FS, L21LW, Q51QR, R79HR, T127P, T131NT, M133MT, Y134NY, 




P120PT, T189IT,  120PT A1 
S45P, S132FS, W182*W, S204NS,  132F A1 
4.1.9.6 Precore mutations 
Precore stop codon mutations were observed in 10/33 (30%) patients’ plasma samples. The 
most common precore mutation seen was the W28* mutation that was in eight samples. 
Seven of eight of the HBV strains with the W28* mutation were genotype D, the eighth was 
genotype E. Two of the ten patients were infected by an HBV strain with the Q2* mutation. 
The two samples with the Q2* mutation were genotype A. 
In addition, other mutations that were not stop codon mutations were seen in five patients. 
The most frequent of these mutations were the S13T and G29D which were seen in three 
patients each. The distribution of these mutations is shown in Table 4.12. All patients with 
the precore stop codon mutations were HIV uninfected. The patients with S13T alone and 
S13T and V17F were HIV-infected. 
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Table 4.12 Combination of precore mutations and their occurrence in HCC patients 
Combination of mutations Number of cases 
Q2* alone 2 
I9V + G29D 1 
S13T alone 1 
S13T + V17F 1 
S13T + G29D 1 
W28* 7 
W28* + G25E +G29D 1 
4.1.9.7 BCP mutations 
Sequencing of the BCP region was successful in 31 HBV-infected HCC subjects. The region 
covering nucleotide positions 1700-1834 of the HBV genome were examined. Much of the 
region was conserved except the positions 1703, 1719, 1753, 1757, 1762, 1764, 1773, 1809 
and 1812 as shown in Figure 4.7.  
 
Figure 4.7 Nucleotide alignment showing the variable regions of the BCP. Dots show the conserved sites 
while the nucleotide letters show the nucleotide substitutions or the polymorphisms.  
 
The A1762T, G1764A double BCP mutation was observed in 21/33 (64%) of the sequenced 
viruses. The 1762T mutation without 1764A was seen in three cases while the 1764A alone 
without the 1762T change was observed in six cases. The patterns and frequency of 
mutations in the BCP region together with the frequency of HIV infection are shown in Table 
4.13.  
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Table 4.13 Frequency of mutation patterns in the BCP region and HIV infection 
BCP mutation pattern 
 
Frequency Number of HIV infected 
(%) 
T1753C + A1762T + G1764A 12 2 (17%) 
A1762T + G1764A 9 1 (1%) 
A1762T alone 3 2 (67%) 
G1764A alone 6 2 (33%) 
None 3 0 
With regard to the effect of the BCP mutations on the age at presentation with HCC, cases 
with the T1753C + A1762T + G1764A mutation pattern presented at median age of 53 years 
(IQR:50-60) compared to 38 years (IQR: 32-53) among those with A1762T + G1764A, 33 
years (IQR: 32-34) among those with A1762T mutation alone, 36 years (IQR: 32-45) of those 
with the G1764A mutation alone and 37 years (IQR: 29-45) among the HBV-infected HCC 
cases with no BCP mutations, p=0.07. 
4.1.9.8 Mutations in the X region of HBV among HCC cases 
The BCP region overlaps with the HBX region and as a result mutations in the former also 
result in amino acid changes in the latter. The mutations T1753C, A1762T, G1764A and 
T1768A in the BCP result in the corresponding amino acid changes I127T, K130M, V131I 
and F132Y in the X region. As a result, there were 12 cases with the triple mutation I127T, 
K130M and V131I. Six cases had the K130M and V131I double mutation. The F132Y 
mutation was seen in 12/31(40%) of the cases and it occurred in combination with the 
K130M or the V131I but never alone. 
4.1.10 Prevalence of HCV infection among HCC cases 
4.1.10.1 Prevalence of anti-HCV 
Anti-HCV serology was performed on 101 subjects of whom 10 were sero-reactive, resulting 
in a seroprevalence of 9.9% (95% CI: 4.1-15.7). Testing for anti-HCV was not performed on 
6 subjects because of insufficient sample. The mean age of the anti-HCV positive subjects 
was 57.5 years (95% CI: 45.8-69.2) and was significantly higher than in the anti-HCV 
negative cases which had a mean age of 44.6 years (95% CI: 41.8-48.0), p=0.01. HCV 
antibodies were predominantly detected from male subjects with 9/10 (90%) of anti-HCV 
positive patients being male. 
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4.1.10.2 Detection of HCV RNA in anti-HCV positive HCC cases 
HCV RNA was tested in 8/10 of the anti-HCV positive samples. Among these, 5/8 (63%) had 
detectable HCV RNA with a median of 6.27 log10 copies/ml (IQR: 5.67 log10–6.42 log10). 
Samples from 4/5 HCC cases whose plasma had detectable HCV RNA were successfully 
sequenced - two cases were infected with HCV genotype 5a while one case each had HCV 
genotype 1a and genotype 1b.  
4.1.10.3 Clinical presentation of HCV infected subjects 
Among the 10 anti-HCV positive HCC cases, 5/10(50%) were also co-infected with HBV as 
evidenced by simultaneous detection of HBsAg. In addition HCV infected subjects presented 
with advanced malignancy demonstrated by imaging examinations revealing multiple lesions 
or a single lesion greater than 5 cm within the liver in 7/10 (70%) of the subjects. Only 2/10 
of the anti-HCV positive HCC cases had a reported diagnosis of cirrhosis prior to 
presentation with HCC. The occurrence of HIV and a summary of the clinical findings 
among the 10 anti-HCV positive subjects are shown in Table 4.14. 
Table 4.14 Co-occurrence of HBV and HIV and demographic characteristics of anti-HCV positive subjects 






Male Black 90 Negative Negative 6.42 1B Multiple liver 
lesions 
Male Black 47 Negative Negative 5.67 1A Single lesion ≤5cm 




Single liver lesion 
<2cm 






Female Black 64 Not tested* Positive 4.49  not 
amplified 
Single liver lesion 
<2cm 
Male Black 71 Negative Positive 6.33 5A Multiple liver 
lesions 
Male Black 62 Not tested* Negative  Not 
tested 
 Not tested Multiple liver 
lesions 




Single lesion >5cm 
Male Mixed 57 Negative Negative 6.6 5A Multiple liver 
lesions 
Male Mixed 50 Negative Negative  Not 
tested 
 Not tested Multiple liver 
lesions 
*not tested due to non-availability of sample; Insuff -insufficient 
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4.2 Liver Fibrosis and Immune Markers Study 
4.2.1 Study population 
A total of 169 participants were recruited into the study. The distribution of the subjects was: 
46 HBV/HIV co-infected; 47 HBV mono-infected; 39 HIV mono-infected and; 37 HBV/HIV 
uninfected controls. The demographic and anthropometric characteristics of these subjects are 
shown in Table 4.15. The prevalence of alcohol consumption and current or past herbal 
medicine use is also indicated.  







Controls (n=37) p 
Age (years)*  38.5 ± 8.2 37.9 ± 12.3 37.9 ± 9.7 43.8 ± 11.4 0.04 
Males (%) 22 (47%) 22 (47%) 16 (39%) 25 (41%) 0.1 




























Body mass index  24.3 ± 5.1 28.0 ± 9.0 24.6 ± 3.5 27.0 ± 5.9 0.23 
Alcohol consumption 8/46 (17%) 9/47 (19%) 11/39 (28%) 14/37 (38%) 0.12 
Herbal medicine use 
(current/past) 
1/46 (2%) 5/47 (11%) 1/39 (3%) 5/37 (14%) 0.11 
*Mean ± standard deviation (SD) 
 
4.2.2 Immunologic and virologic characteristics 
All HIV infected subjects (co-infected and HIV mono-infected) were on therapy for at least 3 
months, median 35 months (IQR: 13-61). All co-infected subjects had a HAART regimen 
that included tenofovir plus emtricitabine or lamivudine. HIV mono-infected subjects were 
on similar therapy except that four subjects were on zidovudine and one on stavudine in 
combination with lamivudine and ritonavir-boosted lopinavir. The median duration of 
antiretroviral therapy for the co-infected cases was 36 months (IQR: 23-63) with the 
participants that had the shortest duration of therapy having received ARVs for 3 months and 
the longest for 174 months. In comparison, HIV mono-infected subjects had a median 
duration of 36 months (IQR: 12-63), with range of HAART duration being 3-156 months. 
Co-infected cases had median CD4 T lymphocyte count of 328 cells/µl (IQR: 242-562) that 
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was significantly lower than that of the HIV mono-infected participants whose median was 
528 cells/µl (IQR: 367-567), p=0.04. HIV mono-infected participants had a significantly 
elevated median CD4/CD8 ratio of 0.7 (IQR: 0.6-1.0) compared to 0.5 (0.3-0.7) among the 
HBV/HIV co-infected subjects, p=0.0003. Not all of the HBV mono-infected subjects were 
on therapy with only 12/47 (25%) receiving anti-HBV therapy. Treatment duration in this 
group varied widely from just one week to more than 24 months. Of the 12 HBV mono-
infected participants on therapy, 11 (92%) were receiving tenofovir. The outstanding 
participant had been administered lamivudine. The virological characteristics of the study 
subjects are shown in Table 4.16. 
Table 4.16 Immunologic and virologic characteristics of study participants 









HAART, months  
Median (IQR) 
 






















0.5 (0.3-0.7) 1.5 (1.1- 2.1) 0.7 (0.6-1.0) 1.6 (1.3- 2.1) <0.0001 
Detectable plasma HIV viral 
load 
10/36 (27.8%) n/a 6/33 (18.1%) n/a 0.4 
HIV viral load >1000 
copies/ml 
6/36 (17 %) n/a 3/33 (9.1%) n/a 0.48 
Detectable plasma HBV 
DNA 
22/45 (49%) 32/44 (73%) n/a n/a 0.03 
Plasma HBV DNA >2000
 
IU/ml 
12/45 (26%) 15/44 (32%) n/a n/a 0.5 
HBeAg positive, (%) 13/46 (28%) 6/46 (13%) n/a n/a 0.12 
*Not all participants were tested due to insufficient specimen. The effect of therapy in the HBV group was also 
evaluated and the results are described in section 2.2.2.1. 
 
Plasma HIV RNA was detected in 10/36 (27.8%) of the co-infected subjects compared to 
6/33 (18%) among those that were HIV mono-infected, p=0.4. The proportion of co-infected 
subjects with HIV viral load greater than 1000 copies/ml was 6/36 (17%) compared to HIV 
3/33 (9%) among the HIV mono-infected, p=0.48. 
There was a higher proportion of HBV mono-infected subjects [32/44 (73%)] with detectable 
HBV DNA compared to those that were co-infected [22/45 (49%)], p=0.03. Results showed 
statistically significant negative correlation between HBV DNA and duration of antiretroviral 
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therapy within the HBV/HIV group with Spearman rho=-0.53, p<0.05. The proportion of 
HBV mono-infected subject with HBV DNA viral load greater than 2000 IU/ml was 15/42 
(32%) compared to 12/45 (26%) among the co-infected subjects, p=0.49. HBeAg, a marker 
of high HBV replication and infectivity, was more frequently detected among the co-infected 
participants with 13/46 (28%) being HBeAg positive compared to 6/46 (13%) among HBV 
mono-infected participants, p=0.12. 
Among the co-infected subjects, 4/29 (13.8%) had detectable HBV DNA with undetectable 
HIV RNA. Also among the HBV/HIV group, 3/29 (10.3%) had detectable HIV viral loads 
with undetectable HBV DNA whilst co-detection of HIV RNA and HBV DNA was seen in 
5/29 (17.2%) of the co-infected participants. 
4.2.2.1 Comparison between treated and untreated HBV subjects 
Since not all HBV mono-infected subjects were on therapy, an analysis to compare the 
treated and untreated individuals was performed. The treatment duration ranged from one 
week to 36 months. Among the untreated HBV mono-infected subjects, 3/34 (9%) were 
positive for HBeAg compared to 3/12 (25%) among the treated HBV mono-infected 
participants, p=0.17. Detectable HBV DNA was observed in 24/32 (75%) of the untreated 
subjects compared to 8/12 (67%) of the treated subjects, p=0.7. Two untreated participants 
could not be tested for HBV DNA because of unavailability of sample. HBV viral loads 
greater than 2000 IU/ml were recorded in 11/32 (34%) of the untreated subjects compared to 
4/12 (33%), p=1.00. 
4.2.3 Prevalence of liver fibrosis using non-invasive markers 
The prevalence of liver fibrosis was assessed using the Fibroscan as well as the APRI and 
FIB-4 scores. Sub-group analysis was also performed among the HBV group to detect any 
differences in non-invasive markers of liver fibrosis between the treated and untreated 
patients. The results of the HBV sub-group analysis are reported in section 4.2.3.6. 
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4.2.3.1 Relationship of Fibroscan and participants’ BMI values 
Of the 148 Fibroscan measurements that were performed, 135 (91%) had success rates ≥60% 
and IQR/median <30%. These were considered as the valid Fibroscan measurements that are 
included in the analysis. The control group had the highest number of participants with valid 
readings, although it also had the lowest number of participants that were eligible for a 
Fibroscan examination based on BMI. There was a weak and inverse relationship between 
success rate of Fibroscan measurements and the BMI with a slope of -0.14 ± 0.035, 
p=0.0001. A representation of the relationship between success rate of Fibroscan 
measurements and BMI is shown in Figure 4.8.  












Figure 4.8 Correlation of Fibroscan success rate against the BMI. The plot shows 95% confidence interval of 
the slope and also the cut-off point (60%) for a success rate that was considered for a valid result on the x axis. 
The recommended BMI cut-off value of 30 on which the Fibroscan may be performed using the medium probe is 
indicated on the y axis. The figure shows that the majority of participants had a success rate of 100%, even 
among some with a BMI greater than 30. 
4.2.3.2 Association of gender and Fibroscan scores 
Differences in Fibroscan scores between males and females were calculated for the entire 
Immune Study cohort. The median of Fibroscan scores among males of 6.3 kPa (IQR: 5.0-
8.7) was significantly higher compared to that in females whose median was 5.2 kPa (IQR: 
4.7 -7.1), p=0.003. When reanalysed according to group; the co-infected and controls showed 
males having significantly higher median stiffness scores, p=0.03 and p=0.049, respectively. 
The HBV mono-infected and HIV mono-infected group showed no significant difference in 
Fibroscan scores according to gender with p=0.1 and p=0.41, respectively. The median and 
IQR of Fibroscan scores according to gender are shown in Table 4.17. 
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Table 4.17 Fibroscan scores and gender showing medians and IQR in parenthesis (kPa) 
 Males Females p 
HBV/HIV 7.4 (5.6-8.7) 5.1 (4.7-7.3) 0.03 
HBV 7.8 (6.0-14.2) 5.9 (4.9-8.1) 0.1 
HIV 4.8 (4.3-6.1) 4.7 (3.8-5.2) 0.4 
Controls 6.2 (5.4-8.1) 5.3 (4.5-6.0) 0.048 
 
4.2.3.3 Distribution of Fibroscan scores 
There was a statistically significant difference in the medians of the liver stiffness 
measurements using the Kruskal Wallis (K-W) test; p=0.0001. The HBV mono-infected 
group had the highest median of 6.9 (5.5 – 8.8), followed by the co-infected group 6.2 kPa 
(4.8 – 8.0); control group that had a median of 5.6 kPa (4.6 -6.8) and finally the HIV mono-
infected group that had the lowest median of 4.7 kPa (3.9 – 5.9). These results are shown in 
Table 1-11. Following statistically significant Kruskal-Wallis tests, the Dunn's Multiple 
Comparison Test was used to detect the groups with the significant differences. There were 
statistically significant differences in rank sums between the co-infected group and the HIV 
mono-infected group and also between the HBV mono-infected compared to the HIV mono-
infected group. The distribution of Fibroscan values is shown in Figure 4.9.  


























Figure 4.9 Box-and-whisker plot of Fibroscan scores grouped according to infection status. The middle 
line represents the median; the box represents the IQR while the whiskers correspond to the non-outlier range. 
The dots beyond the whiskers show outlier and extreme values. The figure shows that HBV mono-infected 
subjects had a statistically significant higher median of Fibroscan values compared to those with HIV alone 
(p=0.00001). Similarly the HBV/HIV co-infected individuals had statistically significant higher Fibroscan scores 
compared to those with HIV alone. 
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4.2.3.4 Distribution of APRI scores 
The median APRI score of the HBV mono-infected group was highest at 0.34 (0.21-0.66), 
followed by the co-infected and HIV mono-infected groups, both with median APRI scores 
of 0.32. The control group had the lowest median of the APRI score at 0.21 (0.13-0.42). The 
differences in APRI scores between the groups were not statistically significant, p=0.08. The 
distribution of the APRI scores for the four groups is shown graphically in Figure 4.10. 




















Figure 4.10 Box-and-whisker plot of APRI scores. The middle lines represent the median values while the 
boxes correspond to the interquartile range. The whiskers show the non-outlier range while the dots show 
extreme and outlier measurements. There were no statistically significant differences in the APRI score between 
any of the groups, p=0.8. 
4.2.3.5 Distribution of FIB-4 scores 
The FIB-4 score showed the co-infected group having the highest median score compared to 
the other groups. The median FIB-4 score for the co-infected group was 0.96 (0.58-1.30); 
0.86 (0.59-1.20) in the HBV mono-infected; 0.77 (0.55-1.30) in the HIV group and 0.63 
(0.41-1.00) in the control group. The difference in medians across the groups were not 
statistically significant, p=0.11. A scatter dot plot of FIB-4 scores is shown in Figure 4.11. 
p=0.08 
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Figure 4.11 Box-and-whisker plot of FIB-4 scores according to group. The middle lines represent the 
median values; boxes correspond to the 25th and 75th percentiles while the whiskers show the non-outlier range. 
The dots beyond the whiskers represent the outliers and extreme values. There were no statistically significant 
differences in the APRI score between any of the groups, p=0.1. 
In order to determine the distribution of fibrosis measurements derived from the three 
different tests, the scores obtained were classified into three strata representing F0-F1, F2-F3 
and F4 stages of the Metavir system for fibrosis grading. The different strata were 
constructed using values that were previously published from elsewhere. The frequency of 
fibrosis stages according to group determined by the three different tests is shown in Table 1-
12. These results are shown in Table 4.18.  
p=0.1 




Table 4.18 Summary and distribution of fibrosis results according to group 
 HBV/HIV  HBV  HIV  Controls  p 
Valid Fibroscan 
readings 
36/40 (90%) 38/41 (93%) 32/37 (86%) 29/30 (97%) 0.5 
Fibroscan (kPa) 
<7.0 









  7 (18) 
n=32 
28 (88) 
  1 (3) 
  3 (9) 
n=29 
23 (79) 
  6 (21) 








  9 (21) 
  3 (7) 
n=35 
25 (71) 
  7 (20) 
  3 (9) 
n=26 
21 (81) 
  4 (15) 
  1 (4) 
n=22 
19 (86) 
  3 (14) 








  9 (21) 
  2 (5) 
n=34 
27 (79) 
  4 (12) 
  3 (9) 
n=26 
19 (73) 
  7 (27) 
  0 
n=22 
20 (91) 
  2 (9) 
  0 
0.32 
ALT, U/L* 34 (24-45) 25 (22-47) 31 (21-44) 24 (19-39) 0.32 
AST, U/L* 31 (25-46) 27 (23-42) 32 (27-45) 21 (18-32) 0.001 
Fibroscan, kPa* 6.2 (4.8 – 8.0) 6.9 (5.5 -8.8) 4.7 (3.9 -5.9) 5.6 (4.6 -6.8) 0.001 
APRI* 0.32 (0.24-0.58) 0.34 (0.21-0.66) 0.32 (0.23-0.46) 0.21 (0.13-0.420 0.08 
FIB-4* 0.96 (0.58-1.30) 0.86 (0.59-1.20) 0.77 (0.55-1.30) 0.63 (0.41-1.00) 0.11 
*Median values and IQRs are shown in parenthesis. 
4.2.3.6 Effect of therapy on non-invasive markers of liver fibrosis in the HBV 
group 
Non-invasive markers of liver fibrosis as well as liver enzyme activities of the treated and 
untreated HBV patients were compared using the Mann-Whitney test. There were no 
statistically significant differences in any of the markers between the two subgroups. The 
summary of results is shown in Table 4.19. 
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Table 4.19 Differences in liver fibrosis markers between treated and untreated HBV mono-infected 
subjects.  
 Untreated HBV Treated HBV p 
AST (U/L) 27 (24-37) 31 (28-60) 0.13 
ALT (U/L) 24 (21-43) 41 (24-87) 0.11 
Fibroscan (kPa) 7.6 (5.7-8.7) 7.2 (5.5-11.8) 1.00 
FIB-4 0.88 (0.61-1.25) 0.76 (0.58-1.88) 0.70 
APRI 0.34 (0.20-0.52) 0.40 (0.28-0.91) 0.27 
Medians and interquartile ranges in parenthesis are shown 
4.2.3.7 Effect of alcohol consumption and herbal medicine use on fibrosis scores 
The results from this study showed no significant effect of alcohol consumption or herbal 
medicine use on fibrosis scores. The median (IQR) of median stiffness among those that 
consumed alcohol was 5.8 kPa (4.7-6.2) compared to 5.9 kPa (4.7-8.0) in non-drinkers, 
p=0.4. Past or current use of herbal medicine did not seem to have an effect on median 
stiffness scores. The median (IQR) of current herbal users was 9.2 kPa (4.5-10.4) compared 
to 5.9 kPa (4.7-7.8) in those that had never used herbal medicine, p=0.6. 
4.2.3.8 Correlation between the Fibroscan, APRI, FIB-4 and liver enzymes 
Using the Spearman rank test, there was statistically significant correlation between the 
Fibroscan, liver enzymes (AST and ALT) and the serum-based APRI and FIB-4 for all 
subjects combined. The Spearman rho value between the Fibroscan and APRI was 0.47 (95% 
CI 0.30 - 0.61) while that between Fibroscan and FIB-4 was 0.4 (95% CI 0.22 - 0.56). 
However, there was a stronger correlation between the APRI and FIB-4 with rho=0.88.  
The correlations were not all maintained when analyses was performed according to infection 
status. In the HBV group, there was no statistically significant correlation between the FIB-4 
versus Fibroscan and also between the FIB-4 against ALT. In the HBV/HIV group, Fibroscan 
scores had no statistically significant correlation with AST or ALT. There was also no 
significant correlation between FIB-4 and ALT. In the HIV group, the Fibroscan had no 
statistically significant correlation with ALT. There was no statistically significant correlation 
between Fibroscan against APRI; FIB-4; AST and ALT in the control group. The correlation 
matrices for all participants and according to group are shown in Table 4.20 A-E  












1.00 0.78 0.27 0.53 0.81
0.78 1.00 0.44 0.76 0.60
0.27 0.44 1.00 0.39 0.21
0.53 0.76 0.39 1.00 0.32
0.81 0.60 0.21 0.32 1.00
HBV group






1.00 0.81 0.43 0.49 0.79
0.81 1.00 0.65 0.75 0.59
0.43 0.65 1.00 0.34 0.43
0.49 0.75 0.34 1.00 0.25
0.79 0.59 0.43 0.25 1.00
 
HBV/HIV Group






1.00 0.77 0.20 0.55 0.72
0.77 1.00 0.40 0.85 0.48
0.20 0.40 1.00 0.36 0.10
0.55 0.85 0.36 1.00 0.20
0.72 0.48 0.10 0.20 1.00
 
HIV Group






1.00 0.76 0.48 0.47 0.89
0.76 1.00 0.47 0.79 0.73
0.48 0.47 1.00 0.51 0.26
0.47 0.79 0.51 1.00 0.42
0.89 0.73 0.26 0.42 1.00
 
Control Group






1.00 0.78 0.03 0.57 0.84
0.78 1.00 0.04 0.57 0.67
0.03 0.04 1.00 0.25 0.05
0.57 0.57 0.25 1.00 0.53







Table 4.20 Table A shows correlation for all study subjects with statistically significant correlation between all 
markers. Table B shows correlations between the different markers within the HBV group. Table C is a 
correlation matrix for the non-invasive markers of liver fibrosis with the HBV/HIV group. Table D and E show the 
HIV and control groups respectively. Statistically significant correlations at p<0.05 are shown in red font 
A 
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4.2.3.9 Association of Fibroscan score and viraemia 
Among the HBV mono-infected subjects, those with detectable HBV DNA had significantly 
higher median Fibroscan scores (median 7.8 kPa: IQR 6.2-10.1) compared to those without 
undetectable HBV DNA (median 5.2 kPa, IQR: 4.3-7.4), p=0.03. Among the co-infected 
subjects, those with detectable HBV DNA had higher (median 6.4 kPa, IQR: 5.1-8.2) but 
non-statistically significant Fibroscan scores compared to those without DNAaemia (median 
5.9 kPa, IQR: 4.8-7.9), p=0.3. 
4.2.4 Microbial translocation markers 
The hypothesis of the study was that microbial translocation is increased in HIV infection and 
drives immune activation that will lead to increased liver fibrosis in HBV infected 
individuals. Microbial translocation was investigated by measuring the serum concentrations 
of sCD14 and LBP which are released upon recognition of microbial products. As such the 
two biomarkers serve as proxies of microbial translocation. 
4.2.4.1 Plasma sCD14 concentration 
The HBV/HIV group had a median of 3.6 µg/ml (IQR: 2.4-6.2) compared to 1.8 µg/ml (IQR: 
1.1-2.4) in the HBV group; 2.4 µg/ml (1.8-4.3) in the HIV group and 1.6 (1.2-2.2) in the 
control group. The plasma sCD14 concentration for the four study groups are also 
summarised in Table 4.21. Levels of sCD14 were significantly higher in the co-infected 
group compared to all other groups, p<0.0001. Following the statistically significant result of 
the Kruskal-Wallis test, post-test was done using the Dunn’s Multiple Comparison test to 
detect the groups that had significant differences. Statistically significant differences were 
detected between: co-infected compared to the HBV mono-infected (p<0.0001); co-infected 
against the controls (p<0.00001), HBV mono-infected versus HIV mono-infected (p=0.02) 
and controls compared to HIV mono-infected (p=0.0007). These results are also shown in the 
box and whisker plot in Figure 4.13.  
Table 4.21 Summary of plasma sCD14 levels in µg/ml  
  HBV/HIV HBV HIV Control 
n 42 38 38 37 
Median (IQR), (µg/ml)  3.6 (2.4-6.2) 1.8 (1.1-2.4); 2.4 (1.8-4.3) 1.6 (1.2-2.2). 
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There was no significant correlation between sCD14 and HBV DNA load for all participants, 
rho=0.14; p=0.3. There was also no significant correlation between plasma sCD14 and HIV 
viral load for all participants, rho= -0.02, p=0.8. Correlation between sCD14 and HIV viral 
load was stronger but not significant in the co-infected group (rho= -0.21, p=0.22) compared 
to the HIV group, (rho=-0.1, p=0.6). The sCD14 results showed a statistically significant 
inverse correlation with HAART duration for the HBV/HIV group but not for the HIV group. 
The Spearman rho calculated for sCD14 and HAART duration was -0.34, p=0.03 (p<0.05) in 
the HBV/HIV group compared to -0.23 with p=0.16 in those with HIV alone.  
























Figure 4.12 Box and whisker plot of CD14 grouped according to infection status. The middle lines show the 
median while the boxes represent the 25th and 75th percentiles. The whiskers show the non-outlier range, asterix 
represent the outliers and the solid black squares indicate the extreme values. The y axis showing the sCD14 
values is drawn using a logarithmic scale. The medians and interquartile ranges in parenthesis were as follows: 
Co-infected 3.6 µg/ml (IQR, 2.4-6.2); HBV mono-infected 1.8 µg/ml (1.1-2.4); HIV mono-infected 2.4 µg/ml (1.8-
4.3) and control 1.6 (1.2-2.2). 
 
The effect of whether HBV treatment impacts microbial translocation was evaluated by 
comparing the sCD14 levels between on-treatment against untreated individuals within the 
HBV group. Levels of sCD14 were higher but not statistically significant in the untreated 
compared to the treated group with medians and interquartile ranges of 2.6 µg/ml (1.7- 3.6) 
and 1.6 µg/ml (1.1- 2.2) respectively; p=0.06. 
4.2.4.2 Plasma levels of LBP 
The results of the quantitative detection of LBP showed a trend toward increased LBP levels 
in the co-infected group relative to the other groups although the difference was not 




 percentiles are shown in Table 
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4.21. Differences in plasma LBP levels between on-treatment and untreated HBV mono-
infected subjects were also investigated. There was no difference in the LBP levels with on-
treatment subjects having median 10.0 (8.4- 12.5) compared to 13.1 (9.0- 14.7) in those that 
were untreated, p=0.14. 
Table 4.22 Summary of plasma LBP levels (µg/ml) 
  Co-infected HBV mono HIV mono Control 
n 42 38 38 37 
Median (IQR) 12.4 (10.2-15.6) 10.8 (8.4-13.4) 9.9 (7.8-16.0) 9.6 (8.2-13.3) 
 
4.2.4.3 Correlation between LBP and sCD14 
Soluble CD14 can only bind to LPS in the presence of LBP. Overall, there was weak but 
statistically significant positive correlation between sCD14 and LBP with Spearman rho 
=0.24 (95% CI, 0.08-0.31) and p=0.003. The scatter plot of the LBP and sCD14 is shown in 
Figure 4.14. There was no correlation between the microbial translocation markers when 
stratified according to the four groups of subjects. The rho values and their 95% confidence 
interval were: co-infected 0.2 (-0.12-0.49), HBV mono-infected 0.27 (-0.06-0.55), HIV 
mono-infected 0.3 (-0.029-0.57) and controls -0.15 (-0.46 - 1.9). 
 
Figure 4.13 Scatter plot of sCD14 against LBP for all subjects. The scatter plot reflects weak but significant 
positive correlation between plasma sCD14 and LBP, with Spearman rho=0.24, p=0.003. Spearman correlation 
was used because of the non-parametric distribution of the sCD14 and LBP plasma concentrations.  
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4.2.5 Cell-associated markers of activation 
CD38 and HLA-DR are markers of immune activation and their increased expression on T 
lymphocytes in HIV infection is associated with a poor prognosis (Levacher et al., 1992). 
Differences in the percentage of CD4+ and CD8+ T lymphocytes expressing CD38 and 
HLA-DR were assessed using 6-colour flow cytometry. Group statistics were expressed used 
medians and interquartile ranges because the results did not follow a normal distribution 
pattern. Comparative analyses were carried out using the Kruskal-Wallis test followed by 
Dunn’s test for multi-group comparison where the p statistic was significant. 
4.2.5.1 Expression of CD38 and HLA-DR on CD8 and CD4 T lymphocytes 
Statistically significant differences were observed for the expression of the following 
activation marker combinations on CD4+ T-lymphocytes: HLA-DR+/CD38- (single 
expression), HLA-DR+/CD38+ (dual expression), CD38+/HLA-DR-, HLA-DR+ (total) and 
CD38+ (total). Statistically significant differences in expression on CD8+ T-lymphocytes 
were observed for CD38+/HLA-DR+, CD38+/HLA-DR- and total HLA-DR. The p values, 
median, first and third quartiles of percentage expression of the different activation marker 
combinations on the respective T-lymphocytes are shown in Table 4.23. Representative plots 
of CD38 and HLA-DR expression by CD8+ T lymphocytes are shown in Figure 4.15. 
 
Figure 4.14 Representative density plots of cell-associated activation markers. Percentage co-expression 
of CD38 and HLA-DR by CD8+ T lymphocytes is shown for an HBV/HIV co-infected participant in A; HIV mono-
infected subject in B, HBV-mono-infected subject in C and a control in D. Figure A shows that 82.4% of CD8+ 
lymphocytes co-expressed CD38 and HLA-DR while there was 70.1% in B; 20.9% in C and 7.5% in D. 
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Table 4.23 Expression of activation markers (CD38 and HLA-DR) on CD4+ and CD8+ T lymphocytes. 
 Co-infected  HBV Mono  HIV Mono Control p 
%CD4/CD38-/HLA-DR+ 24 (16-33) 13 (9.8-22) 16 (13-22) 12 (8.1-18) <0.0001 
%CD4/CD38+/HLA-DR+ 9.9 (6.2-17) 4.7 (3.6-6.3) 7 (4.5-12) 3.5 (2.6-6) <0.0001 
%CD4/HLA-DR+ 37 (28-50) 19 (14-27) 25 (21-31) 17 (12-22) <0.0001 
%CD4/CD38+ 49 (37-65) 42 (34-52) 56 (44-68) 44 932-51) 0.0002 
%CD4/CD38+/HLA-DR- 32 (18-48) 36 (30-46) 41 (35-57) 38 (28-46) 0.0362 
%CD8/CD38-/HLA-DR+ 39 (19-55) 38 (22-46) 37 (25-50) 33 (25-40) 0.794 
%CD8/CD38+/HLA-DR+ 30 (17-53) 17 (14-22) 23 (16-33) 16 (7.7-26) <0.0001 
%CD8/CD38+/HLA-DR
-
 11 (5.5-17) 22 (18-27) 16 (9.8-26) 16 (14-26) 0.0005 
%CD8/CD38+ 46 (33-68) 40 (35-53) 45 (34-64) 38 (31-50) 0.11 
%CD8/HLA-DR+ 79 (66-87) 57 (43-68) 65 (51-78) 55 (43-63) <0.0001 
Median and IQR (in parenthesis) are shown. Values are percentages of either CD4+ or CD8+ T cells expressing 
marker of interest. 
 
Co-infected subjects had significantly higher co-expression of HLA-DR and CD38 on CD4+ 
T lymphocytes compared to HBV mono-infected and controls. There was no statistically 
significant difference between the co-infected and HIV mono-infected participants. HIV 
mono-infected participants had significantly higher co-expression of CD38 and HLA-DR on 
CD4+ cells compared to HBV mono-infected and controls. There was no statistically 
significant difference between the HBV mono-infected and control groups. A graphical 
representation of differences in the co-expression of CD38 and HLA-DR on CD4 T cells is 
shown on Figure 4.16. 
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Figure 4.15 Co-expression of CD38 and HLA-DR on CD4+ T lymphocytes. The middle lines show the 
medians, boxes represent interquartile range while the whiskers show the non-outlier range. The dots are the 
outliers and extreme values. The asterix signs represent the strength of significant differences as calculated by 
Dunn’s post-test. Only the significant differences are indicated. HBV/HIV vs HBV, p=0.00001; HBV vs HIV, 
p=0.01; HIV vs control, p=0.00001, HBV/HIV vs control, p<0.000001. 
The co-expression of CD38 and HLA-DR on CD8+ lymphocytes in co-infected subjects was 
significantly higher than in the HBV mono-infected and control groups. There were no other 
significant differences between the groups. Conversely, the expression pattern CD38+/HLA-
DR- on CD8 lymphocytes was higher on the HBV mono-infected group compared to those 
with co-infection. Controls also had higher expression of CD38 on CD8 lymphocytes in the 
absence of HLA-DR compared to the co-infected group. Figure 4.17 is a box plot of the 
percentage of CD8 T lymphocytes co-expressing CD38+/HLA-DR+. 


























Figure 4.16 Expression of CD38/HLA-DR on CD8+ lymphocytes according to group. The middle lines show 
the medians, boxes represent interquartile range while the whiskers show the non-outlier range. The dots are the 
outliers and extreme values. The asterix signs represent the strength of significant differences as calculated by 
Dunn’s post-test. Only the significant differences are indicated. HBV/HIV vs HBV, p=0.001; HBV/HIV vs controls, 
p=0.0004. 
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The independent expression of CD38 and HLA-DR by CD8+ T lymphocytes was also 
evaluated as shown in Table 4.22. There was no significant difference in the total percentage 
of CD8+ T cells expressing CD38 alone or in combination with HLA-DR across the four 
groups as shown in Table 4.22 and Figure 4.18A. Significant differences were observed in 
the expression of total HLA-DR on CD8+ T lymphocytes (refer to Table 4.22. These results 
are also shown in Figure 4.18B. 
 
Figure 4.17 Total percentage of CD8+ T cells expressing CD38 and HLA-DR. No differences were observed 
for total % of CD8+ T cells expressing CD38 shown in figure A, p=0.1. There were statistically significant 
differences in the % of CD8+ T cells expressing HLA-DR between HBV/HIV compared to controls (p=0.00005); 
HBV/HIV vs HIV (p=0.002) and HBV/HIV compared to HIV (p=0.04) as shown in Figure B. The middle lines show 
the medians, boxes represent interquartile range while the whiskers show the non-outlier range. The dots are the 
outliers. The p values as calculated by the Dunn’s post-test are indicated on top of the arrows. Only the 
significant differences are indicated. 
 
Correlational analysis within the HBV/HIV group of the co-expression of CD38 and HLA-
DR by CD8+ T cells against CD4+ cells count and CD4/CD8 ratio showed a statistically 
significant negative correlation with Spearman rho values of -0.48 and -0.38 respectively 
(p<0.05). No similar statistically significant correlations were observed in the other groups. 
Co-expression of CD38 and HLA-DR by CD8+ T cells within the HBV/HIV group was also 
significantly correlated with HBV viral load (R=0.37, p<0.05) and HIV viral load (R=0.40, 
p<0.05). There was no correlation between viral loads and co-expression of CD38 and HLA-
DR on CD8+ T cells in the HBV- or the HIV- group.  
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4.2.6 Cell associated markers of immune exhaustion 
4.2.6.1 PD-1 and CTLA-4 expression on CD4+ and CD8+ T lymphocytes 
The percentage of CD4+ and CD8+ T lymphocytes with surface expression of CTLA-4 was 
consistently low (<2% of both CD4+ and CD8+ T cells). As a result of low surface 
expression of CTLA-4, its co-expression with PD-1 was also low. Representative density 
plots of CTLA-4 and PD-1 expression are shown in Figure 4.19.  
 
Figure 4.18 Density plot of PD-1 and CTLA-4 expression by CD8+ T cells. Plot A shows 17.1% PD-1 
expression by CD8 T lymphocytes in an HBV subject, B shows 35.9% in an HIV patient, C reveals high 
expression (68.3%) expression in an HBV/HIV subject while D shows the expression of PD-1 in a control 
individual. All graphs consistently show <2% expression of CTLA-4 on the CD8+ T lymphocytes. 
 
The expression of PD-1 on both CD4+ and CD8+ T lymphocytes was highest amongst co-
infected subjects compared to all other groups, p<0.0001 in each instance. The median, first 
and third quartiles of total percentage expression of CTLA-4 on CD4+ and CD8+ 
lymphocytes is shown in Table 4.24.  
Table 4.24 % Expression of CTLA-4 and PD-1 by CD4+ and CD8+ T lymphocytes 
 HBV/HIV HBV HIV Control p 
%CD4+/CTLA4+  1.79 (0.94-3.56) 1.64 (0.65-2.30) 1.81 (1.24-3.33) 1.80 (0.85-2.48) 0.71 
%CD8+/CTLA4+  1.49 (0.99-2.94) 1.65 (0.91-2.42) 1.57 (1.57-2.44) 1.67 (0.69-3.23) 0.99 
%CD4+/PD-1+  24.8 (18.2-33.7) 17.9 (13.2-22.8) 20.9 (15.0-27.2) 12.8 (7.8-21.9) <0.0001  
 %CD8+/PD-1+  21.9 (15.3-33.0) 13.2 (11.2-20.2) 21.7 (14.9-26.3) 15.3 (8.5-21.3) <0.0001  
  
Post-test analysis showed that the expression of PD-1 on CD8+ cells was significantly higher 
on co-infected subjects compared to HBV mono-infected and controls. HIV mono-infected 
subjects also had significantly higher CD8+/PD-1+ expression compared to HBV mono-
infected and controls but not to the same magnitude as the co-infected participants. The 
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percentage expression of PD-1 on CD4+ lymphocytes was significantly higher in the co-
infected group compared to HBV mono-infected and controls but not HIV mono-infected. 
The HIV mono-infected group had higher expression of PD-1 on CD4+ lymphocytes 
compared to the control group. The results for post-test analysis of percentage PD-
1expression on CD8+ lymphocytes are shown graphically on Figure 4.20. 


















Figure 4.19 Percentage expression of PD-1 on CD8+ lymphocytes. The middle lines show the medians, 
boxes represent interquartile range while the whiskers show the non-outlier range. The dots are the outliers and 
extreme values. The * signs represent the strength of significant differences as calculated by Dunn’s post-test. 
Only the significant differences are indicated. HBV/HIV vs HBV, p=0.0008; HBV/HIV vs control, p=0.0008; HIV vs 
HBV, p=0.03: HIV vs controls, p=0.02. 
 
4.2.7 Correlation of cell-associated immune markers, microbial translocation makers 
and non-invasive liver fibrosis markers 
The HBV group showed significant positive correlation between CD38 and HLA-DR co-
expression and PD-1 expression by CD8+ T lymphocytes with Spearman rho=0.34, p<0.05. 
In addition, there was also significant correlation between CD8/CD38+/HLA-DR+ and 
CD8/CD38+ (total) with rho=0.45 and between CD8/CD38+/HLA-DR+ and CD8/HLA-DR+ 
(total) with R=0.51 (p<0.05 in both instances). In the HBV/HIV group, only CD8/HLA-DR+ 
(total) had a significant positive correlation with PD-1 expression by CD8+ T lymphocytes, 
R=0.31, p<0.05. There was a statistically significant inverse correlation between CD38 and 
PD-1 expression by CD8+ cells in the HIV group with rho=-0.38, p<0.05. No statistically 
significant correlations between PD-1 expression and either CD38 or HLA-DR on CD8 cells 
were observed in the control group. There was significant positive correlation observed 
between the percentage of CD8+ T cells co-expressing CD38 and HLA-DR as well as HLA-
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DR alone and LBP in the HIV group. The other groups did not show similar correlation 
between cell-associated biomarkers and microbial translocation proxies.  
Correlation was also performed for all participants without stratification of groups. The 
results showed that sCD14 positively correlated with the % of CD8+ T cells co-expressing 
the activation markers CD38 and HLA-DR and also %CD8+/PD-1+ expression (p<0.05 in 
each instance). In addition, sCD14 showed significant negative correlation to CD4+ T cell 
count (rho=-0.35) and CD4/CD8 ratio (rho=-0.47). Similar, although weaker, significant 
inverse correlation were observed between LBP and CD4+ T cell count (rho=-0.18) and also 
LBP against CD4/CD8 ratio (-0.21). Correlation matrices for the cell-based immune markers, 
microbial translocation products and non-invasive markers of liver fibrosis for all ungrouped 
participants are shown in Figure 4.21. The correlation markers according to group are shown 
in Appendices 9-12. 
 





Figure 4.20 Correlation matrix of cell-associated immune markers, microbial translocation biomarkers and liver fibrosis markers for all participants ungrouped. 
Analysis was performed using Spearman rank correlation test. Significant correlation at p<0.05 are indicated in red font. Median stiffness, but not APRI or FIB-4, was positively 
correlated with %CD8+ T cells expressing CD38. Median stiffness also positively correlated with both HBV DNA and HIV viral load. 
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4.2.8 Detection of soluble immune markers 
As the study investigated the association between expression of immune markers and non-
invasive markers of liver fibrosis, the presence and concentration of soluble/plasma immune 
markers (cytokines and chemokines) was measured using Luminex technology. 
4.2.8.1 Detection rates of cytokines 
The majority of cytokines were detected in all samples except for some whose detection rates 
were variable between groups. The reason for non-detection of certain cytokines was due to 
plasma levels that were below the limit of detection for that particular assay. Detection rates 
were particularly low for IL-5 and IL-15 on which none of the groups had more than 50% 
detection. Rates of detection of IL-5 were especially low among the HIV mono-infected 
where only 7% of the plasma samples had detectable cytokine. The detection of IL-15 was 
poor across the groups with only the HBV mono-infected group having 20% of samples with 
concentrations above the lower limit of detection. The other groups all had less than 10% of 
subjects with detectable IL-15, with the control group not having any participant with 
detectable IL-15. The non-detection of these soluble cytokines may hold clinico-pathological 
significance. IL-15 was excluded from further statistical analysis because of the low number 
of samples with detectable amounts (all, except the HBV group, had less than 10% of 
samples with detectable plasma IL-15). All samples with a concentration of cytokine below 
the lower limit of quantitation were assigned a value of zero in order to standardize the data 
for statistical analysis. The list of cytokines with detection rates less than 90% is shown in 
Table 4.25.  
Table 4.25 List of plasma cytokines with detection rates of less than 90% of samples in any group 
 
HBV/HIV, n=45 HBV, n=44 HIV, n=39 Controls, n=19 
IL-2 15 (33%) 34 (77%) 16 (41%) 8 (42%) 
IL-5 22 (49%) 21 (48%) 3 (7%) 8 (42%) 
IL-6 35 (78%) 42 (95%) 31 (79%) 16 (84%) 
IL-7 31 (69%) 34 (77%) 20 (51%) 16 (84%) 
IL-15 2 (4%) 9 (20%) 3 (8%) 0 (0%) 
GM-CSF 15 (33%) 31 (70%) 17 (44%) 10 (53%) 
MCP-1 27 (60%) 33 (75%) 20 (51%) 12 (63%) 
MIP-1a 36 (80%) 42 (95%) 36 (92%) 18 (95%) 
The table shows cytokines that were detected in less than 90% of all samples within any group. Low levels across all groups 
were particularly seen for IL-15.  
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4.2.8.2 Plasma cytokine concentrations across groups 
The HBV group was heterogeneous because not all the subjects were on therapy. In order to 
determine the effect of anti-HBV therapy on the expression of cytokines, data of treated and 
untreated HBV mono-infected subjects was analysed using the Mann-Whitney test. There 
were no statistically significant differences in expression of the majority of cytokines 
between the treated and untreated individuals and as a result the HBV mono-infected 
participants were subsequently analysed as a single homogenous group. The only cytokine 
that showed statistically significant differences between the on-treatment and non-treated 
HBV mono-infected subjects was platelet derived growth factor (PDGF) which was higher in 
the treated with median 3843 pg/ml (IQR: 3275-4777) compared to the untreated with mean 
2699 pg/ml (IQR: 1807-3570), p=0.04. The results of the comparison between the on-
treatment and untreated HBV mono-infected patients are shown on Table 4.26.  
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Table 4.26 Comparison between on-treatment and treatment-naïve HBV mono-infected subjects. 
Variable Units On treatment HBV  Non-treated HBV  p 
IL-1b pg/ml 2.1 (1.6- 3.0) 2.3 (1.5- 5.2) 0.71 
IL-1ra pg/ml 112.5 (95.3- 407.9) 106.3 (80.5- 184.3) 0.65 
IL-2 pg/ml 8.7 (3.9- 20.0) 5.9 (0- 15.2) 0.57 
IL-4 pg/ml 2.9 (2.1- 3.7) 2.8 (2.2- 5.4) 0.95 
IL-5* pg/ml 0 (0- 14.1) 7.0 (0- 19.2) 0.45 
IL-6 pg/ml 12.0 (8.0- 26.2) 11.0 (6.9- 32.4) 0.67 
IL-7 pg/ml 6.9 (2.5- 12.9) 10.4 (3.7- 22.9) 0.42 
IL-8 pg/ml 53.0 (24.7- 119.4) 51.9 (28.3- 192.8) 0.78 
IL-9 pg/ml 74.4 (51.6- 127.1) 70.2 (62.1- 112.9) 0.85 
IL-10 pg/ml 15.9 (11.9- 30.6) 15.0 (12.3- 26.2) 0.90 
IL-12 pg/ml 43.6 (25.5- 73.2) 70.5 (39.1- 98.7) 0.11 
IL-13 pg/ml 13.4 (7.5- 29.1) 17.5 (11.4- 48.0) 0.38 
IL-15* pg/ml 0 (0- 0) 0 (0.0- 0.0) 0.58 
IL-17 pg/ml 87.1 (54.0- 133.2) 81.7 (74.2- 133.2) 0.45 
EOTAXIN pg/ml 129.3 (68.0- 164.8) 140.1 (89.4- 213.8) 0.50 
Basic FGF pg/ml 65.7 (45.4- 91.5) 71.1 (48.1- 93.0) 0.80 
G-CSF pg/ml 59.1 (44.2- 97) 63.8 (34.0- 132.2) 0.97 
GM-CSF pg/ml 35.2 (7.2- 89.6) 4.0 (0.0- 85.5) 0.51 
IFN-γ pg/ml 130.2 (88.7- 168.0) 84.1 (75.7- 253.4) 0.27 
IP-10 ng/ml 0.89 (0.70- 1.2) 1.2 (0.9- 1.5) 0.46 
MCP-1 pg/ml 21.2 (0- 47.0) 33.9 (18.6- 73.3) 0.15 
MIP-1a pg/ml 7.2 (4.8- 11.5) 8.2 (3.9- 10.0) 0.97 
PDGF ng/ml 2.97 (1.81- 3.57) 3.8 (3.3- 4.8) 0.04 
MIP-1b pg/ml 129.4 (93.7- 204.7) 154.7 (138.0- 182.2) 0.29 
RANTES ng/ml 19.0 (13.6- 22.5) 19.0 (14.4- 23.7) 0.68 
TNF-α pg/ml 21.8 (18.5- 47.2) 40.6 (22.9- 57.4) 0.36 
VEGF pg/ml 111.2 (50.1- 187.7) 141.8 (117.3- 239.2) 0.08 
TGF-β1 ng/ml 44.4 (38.3- 56.8) 46.4 (41.6- 54.2) 0.71 
TGF-β2 ng/ml 2.2 (1.8- 2.4) 1.9 (1.8- 2.5) 0.99 
TGF-β3 ng/ml 1.9 (1.3- 2.2) 1.5 (1.5- 2.1) 0.93 
CD8/CD38+/HLADR+ % 19.37 (15.1- 26.32) 18.0 (13.8- 31.7) 1.00 
CD8/PD1+ % 13.62 (11.52- 17.98) 13.1 (11.2- 25.8) 0.92 
*IL-5 and IL-15 had very low detection rates across all groups of participants. 
Statistical differences in serum concentration were observed for 21/28 (75%) of the analysed 
cytokines. The majority of cytokines had highest concentrations in the HBV mono-infected 
group compared to the other groups which also had the highest CD4+ T cell counts. The 
summary statistics different plasma cytokine concentrations according to infection status are 
shown in Table 4.27 using the medians and inter-quartile ranges. Because of the low 
concentration of IL-5 and IL-15, the medians and 25
th
 percentiles had values of zero across 
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all groups. The difference in plasma levels are best indicated using means and one standard 
deviation for each group. For IL-5, the mean ± standard deviation in ng/ml for each group 
was - HBV 18.0±48.2; HBV/HIV 28.7±166.8; HIV 1.1±3.9 and controls – 2.4±3.9. For IL-
15, the means and standard deviations for the each group were: HBV- 31.8 pg/ml ±101.8; 
HBV/HIV -8.0 pg/ml ±52.8 and HIV- 1.2 pg/ml ± 4.5. There was no specimen with 
detectable IL-15 within the control group. 
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Table 4.27 Median plasma cytokine concentrations.  
 
Units LDL HBV/HIV, n=45 HBV, n=44  HIV, n=39  Control, n=19 p 
IL-1β pg/ml 0.465 1.3 (0.9- 2.8) 2 (1.5- 3.1) 1.2 (0.9- 1.9) 1.7 (1.2- 2.8) 0.001 
IL-1ra pg/ml 5.33 59 (40.4- 100.8) 110.8 (85.1- 376.7) 62.2 (40.4- 85.8) 69.8 (53.7- 106.3) <0.00001 
IL-2 pg/ml 1.52 0 (0- 5.4) 8 (0.5- 18.4) 0 (0- 7.3) 0 (0- 4.7) 0.0002 
IL-4 pg/ml 0.24 2.2 (1.6- 3) 2.8 (2.1- 4.1) 2.2 (1.6- 3.2) 2.3 (2- 2.9) 0.03 
IL-5* pg/ml 1.00 0 (0- 7) 0 (0- 15.5) 0 (0- 0) 0 (0- 4) 0.0005 
IL-6 pg/ml 1.68 10 (0.8- 18.3) 11.3 (7.2- 29.3) 4.3 (0.5- 10.3) 6.3 (1.5- 12.5) 0.002 
IL-7 pg/ml 0.84 9 (3.7- 14.6) 7.4 (2.5- 14.8) 1.2 (0- 7.9) 5.9 (1.2- 9) 0.002 
IL-8 pg/ml 2.44 26.8 (19.5- 53.3) 51.9 (22.8- 121.8) 21.7 (13.9- 43.6) 120.1 (35.2- 437.2) <0.00001 
IL-9 pg/ml 1.19 54.7 (44.5- 73.8) 73.1 (55.6- 118.5) 59.5 (45.5- 83.7) 78.2 (57.6- 97.1) 0.01 
IL-10 pg/ml 2.21 10.2 (5.8- 18.8) 15.9 (11.3- 29.2) 9.5 (5.6- 14.5) 9.7 (7.7- 15.9) 0.001 
IL-12 pg/ml 2.25 50.8 (31.9- 63.6) 47.4 (27.1- 87.9) 35.2 (19.4- 59.9) 44.5 (31.7- 65.4) 0.3 
IL-13 pg/ml 0.40 12 (6.2- 24.8) 13.8 (8- 29.6) 9.5 (5.2- 13.7) 6.5 (4.8- 10.4) 0.004 
IL-15* pg/ml 5.73 0 (0- 0) 0 (0- 0) 0 (0- 0) 0 (0- 0) 0.02 
IL-17 pg/ml 5.81 44.5 (27.7- 84.3) 81.7 (61.6- 133.2) 67.7 (54.1- 111.9) 78.5 (64.1- 110.4) 0.004 
EOTAXIN pg/ml 1.75 107.9 (81.2- 172.8) 129.3 (72.1- 171.3) 115.8 (73.9- 160.1) 142.5 (93.1- 261.1) 0.4 
Basic-FGF pg/ml 3.91 43.1 (21.8- 66.9) 65.7 (46.2- 92.3) 44.8 (24.2- 61.3) 50.4 (34.2- 65.7) 0.0006 
G-CSF pg/ml 3.06 51.1 (32.1- 66.1) 59.7 (44.1- 98.6) 41.9 (30.3- 58.1) 37.6 (32.1- 66.1) 0.006 
GM-CSF pg/ml 2.94 0 (0- 22.2) 25.5 (0- 87.6) 0 (0- 35.7) 0.6 (0- 15.3) 0.006 
IFN-γ pg/ml 42.93 88.7 (57.5- 145.3) 121.2 (80.1- 182.0) 66.7 (48- 125.7) 97.2 (51.1- 116.7) 0.004 
IP-10 ng/ml 4.94 1.5 (1.0- 2.8) 0.9 (0.7- 1.5) 1.1 (0.8- 1.5) 1 (0.8- 1.2) 0.0001 
MCP-1 pg/ml 1.24 4.7 (0- 27.2) 21.3 (0- 54.4) 0.4 (0- 20.5) 17.3 (0- 78.8) 0.03 
MIP-1a pg/ml 0.15 4.4 (1.3- 7.7) 7.3 (4.6- 11.4) 4.7 (2.5- 6.3) 8.2 (5.3- 10.3) 0.001 
PDGF ng/ml 1.00 2.4 (1.7- 3.3) 3.2 (1.8- 3.9) 2.9 (1.9- 3.8) 3.3 (2.3- 4.5) 0.09 
MIP-1b pg/ml 0.46 140.9 (95.5- 218.8( 147.3 (102.7- 199.1) 128.8 (103.8- 227.4) 217 (155.5- 264.7) 0.06 
RANTES ng/ml 3.72 19.9 (16.7- 26.7) 19.0 (13.8- 23.1) 19.1 (16.7- 22.6) 22.1 (17.8- 24.7) 0.23 
TNF-a pg/ml 3.77 19.5 (15.1- 27.4) 23.5 (18.5- 54.5) 19.5 (15- 24) 18.5 (15.1- 26.2) 0.01 
VEGF pg/ml 2.30 88.9 (52.2- 147.7) 117.7 (60- 211.5) 77.8 (45.2- 138) 89.6 (51.5- 160.5) 0.22 
TGF-β1 ng/ml  41.7 (34.1- 53.6) 46.4 (38.3- 56.8) 49.7 (42.1- 55.7) 48.2 (42.5- 55) 0.10 
TGF-β2 ng/ml  1.8 (1.7- 1.9) 2.1 (1.8- 2.4) 2.3 (1.8- 2.5) 2 (1.7- 2.4) <0.00001 
TGF-β3 ng/ml  1.3(1.2- 1.5) 1.9 (1.4- 2.2) 2.2 (1.5- 2.3) 1.8 (1.4- 2.2) <0.00001 
*Plasma levels of IL-5 and IL-15 were below detection limit in most samples across the groups hence the statistics (refer to Table 4.25). 
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4.2.8.3 Multi-group comparison of cytokines with significantly different 
concentrations 
Multiple comparison analyses were performed on cytokines with significant p values on the 
Kruskal-Wallis test to determine the groups that had statistically significant cytokine 
concentrations. The majority of cytokines with significant differences in concentration had 
the highest quantities in the HBV mono-infected group and the lowest concentration among 
the HIV mono-infected. IL-Ira was significantly higher in HBV compared to HBV/HIV 
(p<0.0001); HIV (p<0.0001) and controls (p=0.03). Exceptions of cytokines without highest 
concentration in HBV were observed for IL-8 where the controls had the highest plasma 
concentration compared to all other groups and also for IP-10 which had the highest 
concentration in the co-infected subjects compared to HIV mono-infected, HBV mono-
infected and controls. Multi-group comparison statistics for soluble markers with statistically 
significant p values as calculated using the Kruskal Wallis test are shown in Figure 4.22. 
Cytokine expression within the control group might suggest that the control subjects were not 
altogether healthy as was expected or that the HBV and/or HIV infected patient groups had 
lower levels than the “normal” controls. Analysis of differences in cytokine expression was 
rerun excluding the control group. The results still showed that the 9/27 (33%) of cytokines 
were significantly more highly expressed in the HBV group compared to both the HBV/HIV 
and the HIV group. The 9 cytokines were IL-1b, IL-1ra, IL-2, IL-4, IL-10, basic FGF, GM-
CSF, MIP-1α and TNF-α. The HIV group showed significantly lower IL-5 and IL-7 
expression compared to both HBV and HBV/HIV groups whilst the HBV/HIV had 
significantly lower TGF-β2 and -β3 isoforms compared to HBV and HIV. Results of multiple 
comparison analyses excluding the control group are shown on Figure 4.23  
 




Figure 4.21 Multiple group comparison statistics for cytokines with significantly different plasma concentration including control group. Statistically significant 
results are shown in red font. The p statistic calculated using the Kruskal-Wallis (K-W) test is also indicated on the top row of each analyte.IL-1ra shows that the HBV group 
had statistically significant higher levels compared to all other groups while IP-10 shows that the HBV/HIV subjects had higher expression relative to others subject groups. 
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Figure 4.22 Multi-group comparison of soluble markers excluding controls. The figure shows statistically significant differences shown in red font. The Kruskal Wallis p 
statistic values are also indicated for each marker. The expression of IL-10 was statistically significant higher in the HBV group compared to the HBV/HIV and the HIV groups. 
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4.2.9 Multiple correlation analysis  
Correlational analysis was performed using the Spearman Rank test on biomarkers that 
showed statistically significant differences between groups as determined by the Kruskal-
Wallis test. Correlation was also performed for all study participants as a single group as well 
according to their infection status using all continuous variables measured in the study. There 
was significant positive correlation between IP-10 and sCD14 (rho=0.32) and IP-10 against 
LBP (rho=0.19). IL-2 and IL-1ra both had significant negative correlation with sCD14 with 
correlation coefficients of -0.18 in both instances. Median stiffness had significant negative 
correlation with the three TGF-β isoforms and IL-5. Not all correlations that were observed in 
the ungrouped analysis were replicated in the grouped analysis. 
No statistically significant correlation between median stiffness and any of the soluble or 
cell-associated immune markers was observed within the HBV group. Median stiffness in 
this group had significant positive correlation with co-expression of CD38 and HLA-DR 
expression on CD8 cells (rho=0.43) and negative correlation with TGF-β2 (rho=-0.44). 
Within the HIV group, median stiffness had statistically significant negative correlation with 
IL-2 (rho=-0.34); IL-4 (-0.46) and GM-CSF (-0.38). There were correlations between 
cytokines that were observed across all patient groups. There was positive correlation 
between IL-1b with- IL-1ra; IL-2; IL-4; IL-6; IL-10; MIP-α; GM-CSF and TNF-α. These 
correlation matrices are shown graphically in the collage of tables shown in Figure 4.24. 
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Figure 4.23 Multiple correlation matrices of markers with statistical significance across groups. Table A shows the correlation for all participants combined. Table B 
shows correlations within the HBV group, C shows correlation within the HBV/HIV group whilst D has reveals correlations within the HIV group. All significant correlations at 
p<0.05 are marked with red font. 
. 
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4.2.10 Molecular characterisation of HBV among Immune Study subjects 
4.2.10.1 HBV genotyping 
Genotyping of HBV using the overlapping polymerase/surface antigen was successfully 
performed on 42 samples, 13 (31%) of whom were co-infected and 29 (69%) that were HBV 
mono-infected.  
4.2.10.1.1 Distribution of genotypes according to HBV and HIV infection status 
Among the thirteen co-infected participants with detectable HBV DNA that was successfully 
sequenced, eight (62%) were infected with HBV genotype A, three (23%) with D and two 
had HBV genotype E (15%). In comparison, the distribution of genotypes among the HBV 
mono-infected group was- 16/29 (55%) A, 11/29 (38%) D and 2/29 (7%) E. The distribution 

























Figure 4.24 Frequency of HBV genotypes according to HBV and HIV infection status. The red columns 
represent HBV genotype A, green is for genotype D and the blue corresponds to genotype E. Genotyping was 
frequently more successful in the HBV mono-infected group compared to the co-infected group.  
The overall distribution of sub-genotypes among the 24 genotype A samples was 23 
subgenotype A1 and a single A2. The distribution of the 14 genotype D sequences according 
to subgenotype was D3 (9), D4 (4) and D2 (1). Genotype A1 sequences derived from the 
Immune Study subjects closely clustered with other African-derived sequences deposited 
onto GenBank, particularly those from South Africa. The subgenotype D4 sequences 
clustered together with a D4 isolate from Martinique. A phylogenetic tree of study sequences 
and other representative sequences is shown in Figure 4.26.  




Figure 4.25 Evolutionary relationships of Immune Study HBV sequences. The evolutionary history was 
inferred using the Neighbor-Joining method (Saitou and Nei, 1987). The optimal tree with the sum of branch 
length = 0.53668300 is shown. The percentage of replicate trees in which the associated taxa clustered together 
in the bootstrap test (500 replicates) are shown next to the branches (Felsenstein, 1985). The tree is drawn to 
scale, with branch lengths in the same units as those of the evolutionary distances used to infer the phylogenetic 
tree. The evolutionary distances were computed using the p-distance method and are in the units of the number 
of base differences per site. The analysis involved 79 nucleotide sequences. Sequences of co-infected subjects 
are annotated with a red square and those of HBV mono-infected with a black square. Codon positions included 
were 1st+2nd+3rd+Noncoding. All ambiguous positions were removed for each sequence pair. There were a 
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4.2.10.1.2 Association between liver stiffness and HBV genotypes 
The median of the Fibroscan score for the different genotypes were- 7.9kPa (5.8-12.1) for 
genotype A; 6.3kPa (5.8-7.6) for genotype D and 7.0kPa (5.3-7.9) for genotype E. Even 
though there seemed to be a trend towards more advanced fibrosis in genotype A, there was 
no statistically significant difference in the distribution of fibrosis scores according to the 
genotype of HBV, p=0.43; Fisher’s exact test for proportions. There was no association 
between HBV genotypes and fibrosis scores (using the Fibroscan) when results were 
stratified according to whether participants had HBV mono-infection (p=0.47) or co-infection 
(p=0.73). The distribution of fibrosis frequency according to genotype is shown in Table 
4.28.  
Table 4.28 Proportions of fibrosis scores according to the HBV genotype 
 <7.0 kPa 7-13 kPa >13 kPa 
Genotype A, n=21 7 (33%) 9 (43%) 5 (24%) 
Genotype D, n=11 7 (64%) 3 (27%) 1 (9%) 
Genotype E, n=4 2 (50%) 2 (50%) 0 
 
4.2.10.2 Analysis of mutations 
Analysis of mutation patterns was performed for selected regions of the polymerase region 
(to detect drug-resistance associated mutations), surface antigen (to detect vaccine escape 
mutants), precore region to detect mutations associated with the stop codon that abrogates 
synthesis of HBeAg and on the X region to detect the double core promoter mutation that is 
associated with increased risk of HCC development. 
4.2.10.2.1 Polymerase gene mutations 
Mutations were more commonly observed in the HBV mono-infected group of participants 
compared to the HBV/HIV co-infected group. No classic mutations associated with resistance 
to nucleot(s)ide reverse transcriptase were observed in either group. An I169L mutation was 
observed in one co-infected participant. The effect of the I169L mutation on resistance is 
unknown but occurred on a rated position that is associated is associated with resistance to 
entecavir.  
Another mutation that was also observed was A181S in an untreated HBV mono-infected 
participant. Amino acid 181 of the polymerase gene is rated and the occurrence of valine (V) 
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or threonine (T) at this position predicts resistance to lamivudine, adefovir and telbivudine. 
The distribution of mutations across the polymerase region is shown in a column chart on 
Figure 4.27. 
 
Figure 4.26 Mutations in the HBV polymerase mutations region according to HIV status. The figure shows 
more frequent occurrence of mutations in the polymerase region of HBV mono-infected participants compared to 
the co-infected subjects. The horizontal axis corresponds to the amino acid positions of the polymerase region. 
Mutations detected from samples of HBV mono-infected subjects are shown in blue bars while those from co-
infected subjects are shown in red. 
 
4.2.10.2.2 Surface antigen mutations 
Mutations in the surface antigen region are associated with the emergence of vaccine escape 
mutants and also variants that may be missed by diagnostic tests. Using the list of mutations 
that have been associated with vaccine and detection failure as described on the geno2pheno 
web-based tool, the number of participants infected with mutant viruses was similar in the co-
infected and HBV-mono-infected groups. Three sequences in each group had mutations that 
are associated with vaccine or detection escape. The escape mutations that were observed are 
shown in Table 4.29. Other accompanying surface antigen mutations and whether subject was 
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HBsAg mutations Escape  
mutations 
LF003 yes K122KR, T143M, K160N, Y161S, S207N 122K 
LF029 yes M133I, E164G, L173P, A194V, S207N 133I 
LF045 no Y100C, K122R, Y161F, A194V, S207N 100C 
LF052 no T127P, Q129HQ 129H 
CTRL18 no T45NT, Q101HQ, T118A 101H 
LF096 yes L109LM, T127P, S143L, D144E, T189I, V190A, V194A 143L, 144E 
 
Similar to observations of the polymerase region, sequences from HBV mono-infected 
subjects had more mutations across the surface antigen region compared to the co-infected 
group although the significance of some of these mutations is unknown. One co-infected 
subject had a variant with a stop codon at W182*. The sample revealed a mixed virus 
population as there was both wild type and mutated surface antigen. Another co-infected 
participant had a sequence with truncated surface antigen at codon L216*.  
4.2.10.2.3 HBV Precore region mutations 
The W28* codon mutation was observed in 5/31 (16%) samples that were successfully 
sequenced in the precore region. All the five subjects were infected with genotype D. All 
except one of the participants with the precore stop codon mutation were HBV mono-
infected. In two of the five cases, the W28* mutation occurred with the G29D mutation 
representing a mixed virus population.  
4.2.10.2.4 HBV BCP and X mutations 
The triple mutation T1753C, A1762T and G1764A was observed in 3/25 (12%) subjects. 
Two of the three subjects were co-infected. The double A1762T and G1764A mutation was 
seen in 4/25 (13%), all of whom were HBV mono-infected. The G1764A only mutation 
pattern was seen in 2/25 (8%) subjects. There was no subject with the A1762T mutation 
alone. 
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As a result of mutations in the BCP region, the I127T, K130M and V131I triple mutation of 
the X protein was seen in 3/35 (12%). The double change K130M and V131I on its own was 
detected in four cases. The V131I was seen on two subjects in whom it occurred together 
with the F132Y in keeping with the T1768A mutation in the overlapping BCP region. An 
image of the amino acid alignment of the X protein is shown in Figure 4.28. The presence of 
BCP mutants did not seem to have a statistically significant effect on the Fibroscan scores 
although the mean of median stiffness in those with BCP mutants was 11.3 kPa (±8.8) 
compared to 8.1 kPa (±4.5) in those without, Mann Whitney test p=0.2.  
 
 
Figure 4.27 Alignment of the HBV X protein region. Conserved sites are toggled off and appear as dots while 
the variable sites reveal the amino acid arising from the nucleotide change. Variability was particularly observed 
around codons 101, 116 and 127-131. 
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4.3 Differences in HBV mutation patterns between HCC cases and HBV-infected 
subjects with no known diagnosis of HCC 
Sequence variation of HBV may be responsible for disease outcomes in chronic HBV 
infection. Comparison of HBV variability between the HCC Epidemiology Study cases and 
the HBV-infected Liver Fibrosis and Immune Markers Study participants was performed in 
order to determine if the distribution of genotypes and occurrence of mutations differs within 
the BCP, precore and surface antigen regions. 
4.3.1 Differences in the distribution of HBV genotypes 
HBV genotype A is the most prevalent genotype within South Africa. There was an over-
representation of HBV genotype A among the HCC cases compared to the non-HCC subjects 
from the Liver Fibrosis study with prevalence of 34/43 (79%) and 24/42 (58%) respectively. 
HBV genotypes D and E were less prevalent among the HCC cases compared to those 
without a diagnosis of HCC, p=0.07. The prevalence of HBV genotypes grouped according to 
























Figure 4.28 Distribution of HBV genotypes according to diagnosis of HCC. There was a high occurrence of 
HBV genotype A among the HCC cases compared to any other genotypes. The occurrence of genotype A was 
also highest among the non-HCC cases reflecting its existing background prevalence within the general 
population infected with hepatitis B. No other genotypes except for A, D and E were detected amongst the 
patients in the two studies. 
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4.3.2 BCP region 
The results revealed that there was a higher prevalence of the double 1762T/1764A mutation 
in the HBV genome of the HCC cases compared to the Immune Study subjects that did not 
have a diagnosis of liver malignancy. There were 21/33 (64%) of HCC cases with the double 
BCP mutation compared to only 7/25 (28%) among the Immune Study participants that were 
successfully sequenced, p=0.009. The relative risk of HCC cases having the double BCP 
mutation pattern compared to chronically infected subjects without a known diagnosis of 
HCC was 2.3 (95% CI: 1.1-4.5). 
4.3.3 Precore region 
The sequencing results also showed that there was a more frequent occurrence of stop codon 
mutations in the HBV precore region of HCC cases relative to subjects with chronic HBV but 
with no diagnosis of HCC. There were 10/33 (30%) of HCC cases with precore stop codon 
mutations compared to only 5/31 (16%) among the Immune Study subjects, p=0.24. The 
relative risk of HCC cases having the precore stop codon was 1.9 (95% CI: 0.7-4.9) compared 
to the Immune Study subjects. In addition, Immune Study subjects only had the W28* 
mutation pattern compared to HCC cases that had W28* (80%) and also a unique Q2* (20%) 
precore stop codon mutations. 
4.3.4 Surface antigen region 
While the P120T mutation was observed in 6/14 (43%) of HCC cases with at least one escape 
mutation, it was not seen among any of the Liver Fibrosis and Immune Markers Study 
samples. The occurrence of the L216* mutation was more frequent among HCC cases with 
three patients having the variant compared to only one among those without a diagnosis of 
HCC. The occurrence of the W182* stop codon was rare in both studies.  
4.3.5 Phylogeny of HBV sequences from the HCC and Immune Study 
Phylogenetic analysis using the polymerase/surface region of sequences from the two studies 
was performed to detect any distinct clustering patterns. The results showed no monophyletic 
clustering of HBV sequences according to whether the subject had a diagnosis of HCC or not. 
Figure 4.30 is a Neighbour-Joining phylogenetic tree showing the clustering of HBV 
sequences derived from HCC - (prefixed by HCC) and Immune- Study subjects. 




Figure 4.29 Evolutionary relationships of HCC- and Immune Study-derived HBV sequences. The 
evolutionary history was inferred using the Neighbor-Joining method (Saitou and Nei, 1987). The optimal tree with 
the sum of branch length = 0.74823423 is shown. The percentage of replicate trees in which the associated taxa 
clustered together in the bootstrap test (1000 replicates) are shown next to the branches (Felsenstein, 1985). The 
tree is drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to infer 
the phylogenetic tree. The evolutionary distances were computed using the p-distance method and are in the 
units of the number of base differences per site. The analysis involved 118 nucleotide sequences. HIV co-infected 
HCC cases are annotated with a red square while HIV-negative HCC cases with a black square. Non-HCC co-
infected sequences are shown with a red triangle while the HBV mono-infected non-HCC cases are shown with a 
blue triangle. All ambiguous positions were removed for each sequence pair. There were a total of 546 positions 
in the final dataset. Evolutionary analyses were conducted in MEGA5 (Tamura et al., 2011). The tree shows no 
monophyletic clustering according to whether patients had HCC or not. There was also no apparent clustering 









5. Discussion  
This discussion chapter is presented in three parts. The first part (section 5.1) discusses the 
results arising of the HCC Study while the second part (section 5.2) covers the results of the 
Immune Study. Section 5.3 is a discussion of the strategies to mitigate against HBV-driven 
liver diseases. 
5.1. HCC Study 
The HCC Study, a multicentre, prospective longitudinal study aimed at describing the 
occurrence of HIV and/or HBV infection in patients presenting with HCC at selected 
teaching hospitals in South Africa. The study sought to determine the prevalence of hepatitis 
B in HIV-infected and HIV-uninfected patients with HCC and also to characterise HBV, in 
terms of genotypes and mutations, in cases of HBV-related HCC. 
5.1.1. Age at presentation of HCC  
According to GLOBOCAN 2012 data, liver cancer is the leading cause of cancer mortality 
among males and the third leading cause of cancer death among females in Africa (Ferlay et 
al., 2015). A total of 107 subjects diagnosed with HCC were prospectively recruited between 
December 2012 and October 2015. The mean age at presentation with malignancy was 46 
years (95% CI: 43-49) with 75% of cases presenting with malignancy by 56 years of age. 
HCC cases were most frequently diagnosed between the ages of 30-40 years. The age at 
presentation tended to be younger in HBV-associated HCC patients in comparison to those 
that did not have HBV infection, although the difference was not statistically significant. 
However, patients with HCV-associated HCC were statistically significantly older compared 
to those that had HBV-associated malignancy. This is consistent with literature which 
describes that HCV-associated HCC tends to peak in the sixth decade of life compared to 
HBV-associated where the peak is in the fourth decade (Kew et al., 1997, Yang et al., 2015). 
The reasons for the differences in age at presentation are probably related to the age at which 
infection with the respective virus is acquired and also the different pathogenic mechanisms 
of the two infections. Hepatitis B is usually acquired early in childhood mainly through 
vertical or horizontal transmission while hepatitis C is acquired later in adulthood through 
horizontal transmission that includes among others injecting drug-use and sexual activity. 
HCV-related HCC usually presents on a background of cirrhosis and severe fibrosis while 
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HBV-associated may arise with no underlying cirrhosis (Zemel et al., 2011). Also, HBV is 
directly carcinogenic being able to directly integrate into the host genome while HCV does 
not and this may also impact on the rate of hepatocarcinogenesis. 
5.1.2. Effect of place of birth 
The place of birth (rural vs urban) did not have an effect on the mean age at presentation of 
HCC in this study, contrary to previous data. The urban born cases had a mean age of 43.3 
years (95% CI: 38.3-48.3) and that was four years younger than that of patients that had been 
born and lived in a rural setting for at least 10 years (mean 47.3 years, 95% CI: 43.3-51.3), 
p=0.8. Kew et al. have previously described that people born in rural areas who later move to 
urban areas present with HCC at a younger mean age relative to those who are born and grow 
up in urban areas (Kew, 1981, Kew et al., 1986). A possible reason for rural-born HCC cases 
presenting younger than their urban-born counterparts is the likely greater exposure to co-
carcinogens such as aflatoxin and dietary iron overload (Kew et al., 1986). The results from 
the present study may suggest that the risk factors that were previously associated with rural 
birth have been diminishing over the years but this needs to be verified with further studies. 
One of the most prevalent risk factors that is known to have a synergistic effect on 
hepatocarcinogenesis in HBV-driven HCC in rural-born patients is exposure to aflatoxin 
(Qian et al., 1994, Wang et al., 1996, Kew, 2003). The effect of declining aflatoxin exposure 
on mortality due to HCC has been demonstrated in Asian countries where the number of 
people dying from liver cancer has decreased with reduced detection of aflatoxin adducts in 
urine from 219 μg/ml in 1991/1992 to 0.017 μg/ml in 2004 (Chen et al., 2013). Aflatoxin 
exposure is likewise decreasing in some African countries as better agricultural and food 
storage practices are adopted (Grace et al., 2015). Indeed, African countries now have a 
partnership, the Partnership for Aflatoxin Control in Africa (PACA), whose responsibilities 
include ensuring effective aflatoxin control so that people, animals and crops are protected 
from the harmful effects of the toxins. More data using archived and prospectively collected 
samples are needed to evaluate the level of aflatoxin exposure among HCC patients in sub-
Saharan Africa. 
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5.1.3. Effect of race 
Black Africans account the highest proportion (55%) of the HCC cases compared 35% of 
Mixed Ancestry, 5% of Caucasians and 4% whose racial origin was not provided. The 2011 
General Census data of the general population of the Western Cape estimates that 48.8% of 
the province’s population is of Mixed Race descent while Black Africans make up 32.9% 
(StatsSA, 2012). The difference in proportion of race between the general population and the 
HCC cases may be reflective of Black Africans being at higher risk of HCC due to greater 
exposure to factors predisposing to HCC such dietary iron overload and HBV infection 
(Mandishona et al., 1998, Kew, 2008). Alternatively, the discrepancy may be indicative of 
selection bias in that Black Africans are more likely to seek healthcare from public/state-
owned rather than private healthcare institutions and also migration from provinces with 
poorer healthcare facilities compared to other races (StatsSA, 2012). An accurate National 
Cancer Registry would be beneficial to ascertain the effect of race on HCC epidemiology in 
South Africa. There was a non-significant trend towards older age at presentation with HCC 
among Caucasians compared to Black Africans and those of Mixed Descent. This finding is 
consistent with literature describing older mean age at HCC presentation in low-risk 
populations that have a low prevalence of risk factors such as hepatitis B and aflatoxin 
exposure (Kew et al., 1986, Kew, 2010, Kew, 2013). It has been suggested that Black 
Africans tend to present with HCC at younger age compared to Caucasians but this current 
study did not observe a significant difference between the two races, p=0.1. The reason for no 
significant difference may be related to the small number of Caucasian cases (n=6) that were 
recruited compared to Black Africans (n=59). 
5.1.4. HBsAg prevalence 
The prevalence of HBsAg in the cohort was 64.1% and is higher than previously described 
data from South Africa but consistent with the estimated contribution of hepatitis B to the 
development of HCC (Kew et al., 1997, Parkin, 2006). Due to the study design, it was not 
possible to determine whether carriage of HBsAg was chronic (more than 6 months) but it is 
likely that infections were chronic due to the known routes of transmission of hepatitis B in 
South Africa. More male HCC were HBsAg positive than women that were HBsAg positive, 
p=0.3. This is a well-recognized phenomenon possibly explained by the contribution of 
hormonal differences between genders in the incidence of HBsAg (Beasley, 1988). The 
HBsAg positive cases were younger (mean 44.1±13.9 years) compared to those that were 
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HBsAg negative (48.5±17.1 years), although this was not statistically significant. The 
difference between the HBsAg-positive and -negative males was larger (about 6 years) than it 
was between HBsAg-positive and -negative females with a similar mean. It has been 
described previously among South African HCC patients that HBsAg positive patients on 
average present at least 10 years younger than those that are HBsAg negative (Kew et al., 
1997). This study did not see such a large difference, perhaps because of a smaller sample 
size or because of other unidentified effects. The prevalence of HBeAg was much higher 
among females (45%) than males (28%). The reason for this result may be due to the higher 
proportion of HBsAg positive females that were HIV-infected (36%) compared to males 
(18%). HIV infection has been demonstrated to delay the seroconversion of HBeAg to anti-
HBe resulting in higher carriage of HBeAg among co-infected individuals (Oshitani et al., 
1996, Thio, 2009, Andersson et al., 2012, Andersson et al., 2013). A particular cause for 
concern is the age at which HBV-related cases presented. Almost 50% of the cases occurred 
by the age of 40 years and 75% by 50 years of age, that is in age groups as most 
economically productive. These findings support the recommendations that African-born 
persons at risk for HCC should be placed under surveillance from the age of 20 years (Bruix 
et al., 2011).  
5.1.5. Prevalence of HIV among HCC cases 
There was an HIV prevalence rate of 22% among HCC cases overall, which is higher than 
any previously reported from Africa which ranged between 3-20% (Stein et al., 2008, Kew et 
al., 2010, Ocama et al., 2011, Tanon et al., 2012a). The prevalence of HIV was higher among 
the female HCC cases with 8/22 (36%) being HIV positive compared to 14/78 (18%) of 
males, p=0.08. The high prevalence may be a reflection of the underlying higher prevalence 
of HIV among females compared to males in much of sub-Saharan Africa where the 
UNAIDS statistics show that more than 50% of the 25.8 million individuals living with HIV 
are females (UNAIDS, 2015). Results of the 2012 South African National HIV Prevalence, 
Incidence and Behaviour Survey Report showed that 14.4% of females were HIV-infected 
compared to 9.9% of males (Zuma et al., 2016). The prevalence of HIV among HCC cases 
will probably increase over time as more individuals get access to HAART that would allow 
them to live long enough for the cancer to develop (Silverberg et al., 2015). The 
administration of HAART is thought to be one of the reasons for earlier studies reporting a 
lower HIV prevalence among HCC cases in the pre-HAART era (Thio et al., 2002, Giordano 
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et al., 2004). In the pre-HAART era HIV-infected patients died from AIDS before HCC 
could develop. Increased longevity of HIV-infected persons in the context of HAART has 
resulted in an increase in age-related conditions like cardiovascular disease and non-AIDS 
defining malignancies such as prostate cancer (Palella et al., 2006, Deeks and Phillips, 2009). 
5.1.6. Effect of HIV on age at presentation 
HIV infection seems to have an effect on age at presentation of HCC especially among HBV-
infected females. HIV/HBV co-infected females presented with malignancy about 10 years 
younger with mean 36.8 years (95% CI: 32.2-41.5) compared to HBV mono-infected women 
whose median age was 50.5 years (95% CI: 30.2-70.8), p=0.09. The data is consistent with 
the few studies from Africa that have investigated the effect of HIV on the epidemiology of 
HCC. A study from Western Africa reported that HIV-infected liver cancer patients were 
seen at an age that was 10 years younger compared to those that were HIV-uninfected and 
that the difference was significant (Tanon et al., 2012a). However the study from West Africa 
included only 60 cases overall of whom only seven were HIV-positive. 
In contrast, the effect of HIV on age of presentation with HCC among males is not as clear 
amongst males as HBV/HIV co-infected males were only slightly younger than the HBV 
mono-infected males with mean age of 41.3 years (95% CI: 35.1-47.4) and 45.5 years (95% 
CI: 40.5-50.5), respectively, p=0.7. The fact that HIV-infected cases presented at a younger 
age could be argued that this is because of lead-time bias as patients with HIV are likely to 
have more frequent presentation at healthcare institutions. However, this is not supported by 
data from this cohort in which HIV-infected cases presented with a similar stage of advanced 
malignancy similar to those without HIV infection. This is likely to reflect the lack of 
strategic screening protocol for HCC in South Africa. 
5.1.7. Effect of gender 
There were three and a half times more males than females in this HCC cohort. This is in 
keeping with literature where male gender has been described as a risk factor of developing 
HCC (Kew, 2000, El-Serag, 2012). A Taiwanese study reported a male to female ratio of 
4.5:1 among a cohort of HCC patients (Lee et al., 1999). The reason for males being more 
prone to developing HCC than females has been ascribed to higher levels of androgens in 
men (Wu et al., 2010a). HBV transgenic mouse models where genes coding for the androgen 
receptor within the liver were knocked-out showed that the lack of androgen receptors 
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reduces HBV replication and is protective against development of HCC when the mice were 
exposed to carcinogenic nitrosamines (Wu et al., 2010a). Males historically have a higher 
prevalence of hepatitis B that would also explain the greater proportion of males than females 
that were diagnosed with HCC over the recruitment period (El-Serag, 2012). Other possible 
factors previously invoked to explain the male preponderance of HCC include an increased 
exposure to hepatocarcinogenic aflatoxins due to higher food intake and iron overload arising 
from consumption of traditional alcoholic beverages brewed in iron pots (Kew, 2013). 
However, no objective data in this cohort exists to support the assertion that males have 
higher aflatoxin exposure compared to females because of greater food intake. Comparing 
gender differences in the concentration of urinary metabolites of aflatoxin or other plasma 
biomarkers such as serum aflatoxin B1 (AFB1) -albumin adducts may confirm or disprove if 
males have greater exposure to the fungal toxin and hence greater risk. 
5.1.8. Lifestyle risk factors 
5.1.8.1. Alcohol consumption 
There was a low prevalence of self-reported alcohol dependence of only 22% (95% CI: 14-
30) among the HCC cases from this study. Surprisingly, cases reporting alcohol dependence 
had a significantly higher mean age (52.7 years, 95% CI: 46.3-59.2) compared to those 
without alcohol dependence (44.0 years, 95% CI: 40.4-57.5) despite the fact that some of the 
cases also had HBV infection and one would expect a synergistic interaction that might result 
in earlier development of malignancy in cases exposed to both risk factors. This may be a 
result of under-reporting of alcohol misuse which is a well-recognised phenomenon. South 
Africa is rated as the country with highest alcohol consumption (>12.5 litres/capita/year) 
amongst all African countries (Ferreira-Borges et al., 2016) and alcohol misuse is a known 
risk factor for HCC development. Alcohol dependence was seen in 35% of cases that did not 
have any evidence of exposure to HBV or HCV in this study. 
5.1.8.2. Aflatoxin exposure 
This HCC study did not directly measure aflatoxin exposure but instead investigated peanut 
consumption as a proxy of aflatoxin exposure especially among cases that consumed home-
grown peanuts which are more likely to be improperly stored. There was a prevalence of 22% 
for consumption of home-grown peanuts. The prevalence of aflatoxin contamination of food 
has previously been described to range from about 2.0% to 25% in the Eastern Cape province 
Stellenbosch University  https://scholar.sun.ac.za
144 
 
of South Africa (Van Rensburg et al., 1985). The questionnaire to collect aflatoxin exposure 
data was probably not optimal; it should have captured maize meal consumption which also 
carries the risk of mycotoxin contamination. Maize meal is a staple of many Black Africans 
who prepare it as pap. Despite the limitation of asking about peanut consumption only, 
previous data from South Africa show that peanuts carry the highest risk of contamination 
with more than 70% (Van Rensburg et al., 1975). 
5.1.8.3. Iron overload 
The consumption of large quantities of traditionally brewed beer that would be associated 
with iron overload was 26% of the entire cohort. However, none of the HCC cases in this 
study had a clinical history of hepatic siderosis. With increased modernisation, it can be 
expected that the role of dietary iron overload, associated with traditional beer consumption, 
in the development of HCC will diminish. Dietary iron overload is a risk factor that is 
common in rural Africa where people consume traditional beer that is brewed in iron pots or 
drums resulting in iron leaching into the brew (Walker and Arvidsson, 1953). Apart from 
dietary iron overload, hereditary hemochromatosis may also lead to the development of HCC 
(Kew, 2009). 
5.1.9. Familial history of HCC 
A low proportion of only 15% of the HCC cases reported a family history of liver disease 
with an even lower 5% reporting a family history of HCC. Having a family history of liver 
disease did not impact on the mean age at HCC presentation. A family history of liver disease 
is a recognised risk factor for the development of HCC, explained by familial clusters of 
HBV infection as well as shared exposure to environmental carcinogens coupled with a 
genetic disposition to cancer development (Yu et al., 2000). A study from Italy reported that a 
family history of HCC and the presence of HBV infection increased the risk of developing 
HCC 72 times relative to those without a family history of liver disease and with no HBV 
infection (Turati et al., 2012). Family history of liver disease has also been independently 
associated with increased risk of developing HCC and this probably points to the contribution 
of host genetics apart from the presence of other risk factors (Yu et al., 2000). However, the 
accuracy of family history data may be compromised by recall bias especially in patients with 
malignancy as they link unconnected events to the development of HCC. There is also the 
possibility of the data being inaccurate due to break-up of families and loss of the traditional 
family structure. 
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5.1.10. Clinical presentation 
Of 107 HCC cases, 72 (67%) presented with an abdominal mass which is consistent with the 
previous studies of HCC among African patients (Kew, 1981, Umoh et al., 2011). An 
abdominal mass in HCC is a sign of late presentation and is indicative of a tumour that has 
grown big. This in turn may be an indicator of the lack of screening for HCC in at-risk 
patients. Ascites which reflects decreased synthetic capacity of the liver was seen in 33% of 
cases. There was a low prevalence of concomitant liver cirrhosis among the HCC cases with 
only 23% of patients at the time of HCC presentation. This rate is lower than previously 
reported cirrhosis rates in South Africa and indeed in much of sub-Saharan Africa. Cirrhosis 
prevalence in HBV-associated HCC among African patients has previously been reported to 
be in the range between 44-63% (Paterson et al., 1985, Kew, 1989, Yoshida et al., 1994).  
The low prevalence of cirrhosis in this cohort may in part due to under-reporting, lack of 
contact with gastroenterologists prior to diagnosis of malignancy and also due to the low 
utilization of histologic examinations for the diagnosis of HCC. The lack of histologic 
diagnosis of HCC is itself an indicator of cancers that are diagnosed when they are far 
progressed such that clinical diagnosis is often sufficient without needing to subject patients 
to a procedure that has a risk of post-procedure bleeding complication, especially in those 
that have liver-disease related coagulopathies (Terjung et al., 2003). The under-diagnosis and 
under-reporting of cirrhosis is not unique to sub-Saharan Africa as studies from the USA 
have also shown that there is 24-30% rate of not recognizing prior cirrhosis among HCC 
patients (Singal et al., 2012, Walker et al., 2016). The inability to detect underlying cirrhosis 
might be reflective of poor HCC surveillance because most algorithms are based on the 
monitoring of cirrhotic patients in order to have early diagnosis of HCC yet most cases with 
undiagnosed cirrhosis will present with more advanced cancer (Walker et al., 2016). 
Moreover, in places where HCC is common, more than 50% of the patients will present with 
asymptomatic cirrhosis (Ahmet et al., 2013). Therefore any screening modality that is 
targeted at cirrhotic patients would also exclude more than 50% of patients at high-risk of 
HCC. 
The results showed that a significant proportion (70%) of the HCC cases presented with 
elevated concentrations of serum AFP greater than 400 µg/L. Serum AFP concentration >400 
µg/L is considered diagnostic for HCC with specificity of 99.4% (Stefaniuk et al., 2010). 
However, the European Association for the Study of the Liver (EASL) and the American 
Stellenbosch University  https://scholar.sun.ac.za
146 
 
Association for the Study of Liver Diseases (AASLD) no longer recommend the 
measurement of serum AFP for the diagnosis and/or prognosis of HCC because it is deemed 
to be not sensitive or specific enough as it can be elevated in HBV infection without the 
presence of malignancy and may also remain within normal levels in some patients that have 
well-differentiated small HCC lesions (Bruix et al., 2011, EASL-EORTC, 2012). However, 
the position of EASL and AASLD regarding use of serum AFP in HCC surveillance and 
diagnosis has been challenged with others suggesting that AFP is still important in 
diagnosing HCC especially when the serum concentration is extremely elevated (El-Serag 
and Davila, 2011, Marrero and El-Serag, 2011). 
ALT is a liver specific enzyme, the serum concentration of which may increase following 
liver injury (Giannini et al., 2005). Only 30% of HCC cases had overt evidence of liver injury 
as evidenced by serum ALT levels >80 U/L. The utility of ALT in HCC screening and 
prediction is inconclusive with some research groups concluding that use of ALT is 
inadequate as a predictor of HCC risk (Hann et al., 2012). However, a Taiwanese study 
described ALT as being “best able to predict HCC risk even among subjects with unknown or 
HBV- or HCV-negative infection status” (Wen et al., 2012). An algorithm was developed for 
predicting HCC in cirrhotic HCV-infected patients which combine ALT together with AFP, 
platelets and the patient’s age (El-Serag et al., 2014). In addition, the risk estimation for 
hepatocellular carcinoma in chronic hepatitis B (REACH-B) model was developed to predict 
the risk of developing HCC among Asian patients with CHB and it incorporates ALT 
together with gender, age, serum ALT concentration, HBeAg status, and serum HBV DNA 
load (Yang et al., 2011). It therefore appears that the ALT is useful when combined with 
other markers to predict HCC. 
Early diagnosis of HCC is associated with better survival (5-year survival rates near 70% 
with resection or liver transplantation) whilst median survival is usually <1 year for those that 
present with advanced malignancy (Patel et al., 2015, Singal and El-Serag, 2015). More than 
60% of all cases in this study presented with advanced malignancy as shown by the stage of 
presentation. These results suggest that there is room for improvement: Currently, there is 
limited recognition of at-risk patients, poor surveillance for HCC of patients with known 
HBV infection and/or inadequate guidelines for screening in sub-Saharan Africa (Singal and 
El-Serag, 2015). Data from elsewhere suggests that early diagnosis of HCC in HBV-infected 
patients has better outcomes than in hepatitis C because of better liver reserve and reduced 
hepatic inflammation (Njei et al., 2015). However, the challenge of late diagnosis of HCC is 
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not limited to Africa only as 46.2% of HCC cases in the USA are diagnosed at an early and 
localized stage and most of the patients will not receive curative therapy (Njei et al., 2015, 
Singal and El-Serag, 2015). The situation becomes bleak if one considers the fact that the 
diagnosis rate of patients with hepatitis B in America is less than 40% and that an even 
smaller percentage (<10%) of those that are eligible for hepatitis B therapy are on treatment 
(Cohen et al., 2011). Clearly, awareness of HBV and ultimately HCC needs to be raised 
amongst the healthcare providers as well as the general public, especially those that are at risk 
of infection.  
5.1.11. Molecular characteristics of HBV 
5.1.11.1. Effect of HBV genotypes on HCC presentation 
HBV genotype A has been described as having four times the hepatocarcinogenic potential of 
the non-A genotypes within the South African setting (Kew et al., 2005, Kew, 2008). 
Genotype A made up 79% of the sequenced isolates in the HCC study. Other genotypes 
observed were genotype D in 16% and genotype E in 5%. Genotype E was detected among 
two HCC cases of West African origin where it predominates. With increased migration 
within Africa, the distribution of genotypes may shift. New genotypes may be introduced 
from other regions reflecting the interaction between individuals from different geographical 
regions. Some European and North American countries have already seen introduction of 
foreign genotypes among immigrant populations (Palumbo et al., 2008, Pourkarim et al., 
2014, Martinez et al., 2015). In addition, there is a possibility of the formation of 
recombinants as a result of re-infection, especially in highly endemic settings (Pourkarim et 
al., 2014). The study results showed an effect of HBV genotypes on age of onset of HCC 
with the median age of those infected with genotype A being lower than that of genotype D 
cases by about 17 years. The finding that cases infected with genotype A were significantly 
younger than those infected with non-A genotypes is consistent with the results by Kew et al. 
who described a mean age difference of almost 7 years (Kew et al., 2005). It is not clear as to 
why there exists such a difference between genotype A and D in terms of age at presentation 
of HCC but perhaps the absence of HBeAg and the basal core promoter mutations in 
genotype D may provide an explanation. HBeAg, which is a marker of high HBV replication, 
is a known risk factor for HCC development (Yang et al., 2002c). Prospective studies have 
shown that patients who are positive for HBeAg have an increased risk of developing HCC 
compared to those who are HBsAg but HBeAg negative (Yang et al., 2002b, You et al., 
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2004). However, the data is not clear as to whether there is also rapid progression to HCC 
due to HBeAg positivity. 
5.1.11.2. Precore mutations 
The G1896A mutation which translates to a W28* change in the precore region frequently 
occurs in genotype D abrogating the synthesis of HBeAg that acts as a tolerogen to the 
immune system and is thought to hold a lower hepatocarcinogenic potential as the mutation is 
not detected in all HCC tissues (Manzin et al., 1992). The W28* mutation was observed in all 
the genotype D sequences and in a single genotype E in this study. This data is consistent 
with occurrence of W28* mutation among genotype D sequences and not among genotype A 
(Kramvis et al., 1998). However, the results also showed that some patients were infected 
with mixed virus populations as their plasma still had HBeAg despite the presence of the 
precore stop codon mutation. Two sequences showed a rarely described Q2* stop codon 
mutation whose significance in hepatocarcinogenesis is not well understood (Laras et al., 
1998). The Q2* stop codon is characteristic of HBV genotype G (Stuyver et al., 2000, Kato et 
al., 2002). One of the cases with the Q2* mutation had serum ALT concentration >40 IU/ml. 
Whether the detection of this Q2* mutation may actually suggest infection with two viruses 
of different genotypes would need to be confirmed by clonal sequencing which has not been 
done in this study.  
5.1.11.3. BCP mutations 
The basal core promoter (BCP) region of HBV guides the transcription of precore  and core 
RNA which code for HBeAg and the HBV core antigen, respectively (Buckwold et al., 
1997). The double 1762T/1762A BCP mutation causes a reduction of HBeAg synthesis 
through suppressing transcription of precore mRNA (Alexopoulou, 2009). There was a high 
occurrence of the double 1762T/1764A BCP mutation which was detected in 64% of the 
cases. The 1762T/1764A double BCP mutation frequently occurred with the 1753C mutation 
in 12 cases. This mutation was more frequently detected in the HIV-uninfected than in HIV-
infected cases. The double 1762T/1764A BCP mutation has been associated with an 
increased risk of developing HCC (Zhang and Cao, 2011). Although the mutation is detected 
in HBV-infected patients without HCC its prevalence is greater in those with HCC 
suggesting that it may play a role in hepatocarcinogenesis (Zhang and Cao, 2011). Previous 
studies in South Africa have detected the mutation in 11-35% of CHB patients without HCC 
(Baptista et al., 1999, Selabe et al., 2007, Andersson et al., 2013, Makondo et al., 2013). A 
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study from Taiwan previously reported that the likelihood of the BCP mutations parallels the 
development of liver disease with its prevalence increasing from 3% among inactive carriers 
up to 65% in those with HCC (Kao et al., 2003). Interestingly, the occurrence of the triple 
mutation BCP mutation pattern T1753C, A1762T and A1764G was associated with an older 
median age at presentation. HCC cases with the T1753C, A1762T and G1764A mutation 
pattern presented at median age 53 years (IQR: 50-60) compared to 37 years (IQR: 29-45) 
among those without any BCP mutation. A study among Korean patients with HCC has 
previously described that older HCC patients were more likely to have the A1762T, G1764A 
double mutations than younger HCC patients (Lee et al., 2011). This probably suggests that a 
longer time with infection may be needed for the mutation patterns to develop. Indeed, it has 
been described that the frequency of BCP mutations increases as the infections progressed 
from asymptomatic HBV carriage to chronic disease and then to HCC (Zheng et al., 2011, 
Yang et al., 2016). The change across these phases of HBV infection is a function of time and 
this probably explains the higher median age of HCC cases with the triple mutation pattern 
compared to those without the triple mutation pattern.  
The HBV precore region partially overlaps with the X region and mutations in the former 
also result in changes in the latter. The T1753C, A1762T and A1764G mutations in the BCP 
result in amino acid changes K127T, K130M and V131I in the X region (Zhang and Ding, 
2015). HBx protein is a known non-specific transactivator of cellular and viral genes that has 
been described to play a role in hepatocarcinogenesis. Some of the cellular genes that are 
affected by HBx are involved in signalling processes, cell cycle checkpoints, apoptosis and 
protein degradation (Murakami, 2001, Tang et al., 2006). The K127T, K130M, V131I and 
F132Y mutations were detected among the HCC cases. The occurrence of the K127T and 
F132Y mutants is consistent with literature describing that these changes usually occur with 
progression of HBV infection from CHB to cirrhosis and HCC (Guo et al., 2008, Liu et al., 
2009, Yan et al., 2015). A combination of the K127T, K130M, V131I and F132Y mutations 
has been shown to reduce expression of p53 tumour suppressor gene in hepatoma cell lines 
(Yan et al., 2015). The K127T (1753C) mutation has been described among HCC cases only 
and not in asymptomatic HBV carriers in South Africa (Baptista et al., 1999).  
5.1.11.4. Drug resistance mutations 
Despite a number of HIV/HBV co-infected HCC cases being on HAART that comprised 
lamivudine as the only anti-HBV drug, the frequency of drug-resistance mutations was low 
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with only 3/43 (7%) having changes that are associated with drug resistance. Curiously, the 
most common mutation in the reverse transcriptase region was the L80I/V mutation that has 
been described as a compensatory mutation associated with resistance to lamivudine and 
telbivudine (Ogata et al., 1999, Warner et al., 2007). The mutation commonly develops after 
the M204V/I mutation restoring replication fitness by as much as 150% (Warner et al., 2007). 
The L80V occurred together with the M204V + L180M in an HIV-infected case while the 
L80I was in conjunction with the M204I + L180M in another HIV-infected patient. The 
development of these mutations is associated with HAART and indeed data showed that one 
of the HIV-infected patients was on lamivudine while drug therapy data for the other case 
was not available. The infrequency of resistance associated mutations in the HBV mono-
infected patients is probably a reflection of the low proportion that are diagnosed in time to 
be placed on therapy. It may be expected that had more HBV-mono-infected HCC cases been 
diagnosed earlier, they would most likely have been on therapy with lamivudine and more 
resistance mutations would have been observed. Resistance to lamivudine has been described 
to reach as much 80% after 5 years on therapy among patients infected with HBV 
(Bartholomeusz and Locarnini, 2006, Ghany and Doo, 2009, Kamili et al., 2009). 
5.1.11.5. Detection and vaccine escape mutations 
Escape mutations in the surface antigen region of HBV, as annotated by the Max Planck 
Institute for Informatics, were detected in 14/43 (33%) of HCC samples. The most frequent 
of these mutations, P120T, has been associated with vaccine, therapy (immunoglobulin) and 
detection escape. The P120T sits in the major hydrophilic region 2 of the surface antigen 
covering amino acids 120-123 and mutations in this region may cause impaired detection in 
immunoassays (Tian et al., 2007). The P120 mutation was previously shown to markedly 
reduce the binding of antibodies mapped to amino acids l39-147 as well as to amino acid 122 
(Wallace et al., 1994). The mutation is thought to arise due to immune pressure (Wallace et 
al., 1994, Sheldon and Soriano, 2008). More importantly in terms of pathogenesis, the P120T 
mutations is thought to cause impaired secretion of HBsAg from hepatocytes despite normal 
transcription levels (Amini-Bavil-Olyaee et al., 2010). It has been postulated that failure to 
secrete HBsAg leads to retention within hepatocytes leading to cellular stress which could be 
a trigger for carcinogenesis but this would have to be confirmed by further functional studies 
(Pollicino et al., 2014, Li et al., 2016b). Stop codon mutations other than the escape 
mutations were also detected in the surface antigen region and the results showed that these 
were part of mixed populations of viruses. The W182* mutation is associated with the V191I 
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change in the overlapping reverse transcriptase region and leads to decreased viral replication 
(Yang et al., 2002a, Sheldon and Soriano, 2008). The V191I mutation has been described to 
occur in patients receiving therapy using any one of the drugs- adefovir, famciclovir, 
lamivudine and tenofovir (Seigneres et al., 2000, Wakil et al., 2002, Yang et al., 2002a, 
Sheldon et al., 2005, Sheldon and Soriano, 2008, Margeridon-Thermet et al., 2009). The 
L216* has also been described in samples from naïve and nucleotide reverse-transcriptase 
inhibitor (NRTI)-experienced patients and is associated with silent mutations within the 
reverse transcriptase region (Margeridon-Thermet et al., 2009). The significance of these 
mutations in pathogenesis of hepatitis B is not well understood and there is a need for further 
functional studies. 
5.1.12. Occurrence of HCV infection on presentation of HCC 
Exposure to HCV infection as evidenced by the presence of antibodies to HCV was 9.9% 
(95% CI: 4.1-15.7) in this study. The rate of active infection with HCV among HCC cases 
was lower with only 63% of the anti-HCV positive subjects having detectable HCV RNA 
translating to about 5% of the entire HCC cohort. The mean age ± standard deviation at 
presentation with HCC among those with HCV antibodies was older relative to those that 
were HCV negative being 57.5±16.4 years compared to 44.6±14.7 years respectively, p=0.01. 
The data is consistent with the known pathogenesis of HCV among African patients where 
cases present with HCV presented 20 years later compared to those that were not infected 
with HCV and were likely to be HBV-infected (Kew et al., 1997, de Martel et al., 2015, 
M'Bengue et al., 2015). The difference in age at presentation perhaps reflects the effect of the 
age at which one becomes infected with either HBV or HCV and also different rates of 
progression and pathogenesis of the infections (Kew et al., 1997, MacDonald et al., 2008). 
While hepatitis B in sub-Saharan Africa is traditionally spread from child to child through 
horizontal transmission, hepatitis C tends to be acquired later in life through iatrogenic 
transmission in resource-limited countries and through injecting drug in resource-rich 
countries (MacDonald et al., 2008). HCC in HCV-infected patients will only develop where 
there is underlying cirrhosis while this is not necessary for HBV-driven hepatocarcinogenesis 
(MacDonald et al., 2008). In addition, HBV integrates into the host genome causing genomic 
instability whereas HCV does not, underscoring the different pathogenic mechanisms in these 
two infections (MacDonald et al., 2008). The results showed a tendency towards greater 
exposure to HCV among males as only one female had evidence of HCV exposure which is 
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in agreement with previous findings from other African countries (Andoulo et al., 2014). The 
results also show evidence of co-infection of HCV and HBV although the sample number 
was too low to draw meaningful conclusions.  
South Africa is described as predominantly having HCV genotype 5a in circulation with 
prevalence ranging from 54% up to as much as 72% (Prabdial-Sing et al., 2008, Gededzha et 
al., 2012, Musyoki et al., 2015). This study detected genotype 1a and 1b in addition to 5a. 
However, the number of sequenced HCV isolates in this study is too low to make meaningful 
conclusions about the effect of these genotypes among South African HCC cases. 
5.1.13. Limitations of the HCC Study 
This current study only recruited HCC cases who were seen at the participating recruitment 
sites that are tertiary referral centres. As a result, many HCC cases would have been missed 
because of not getting to these referral centres thereby introducing recruitment bias into the 
study. Patients presenting with advanced HCC at primary health facilities may fail to live 
long enough to be seen at a referral centre. It is also plausible that a number of potential HCC 
cases could also have been missed through misdiagnosis and under-diagnosis at the primary 
health centres thus potentially excluding them from enrolment into the study. Sequencing of 
HBV was done in separate segments and it is thus impossible to determine whether the 
mutations affected virus fitness or not and if they were on the same virus particle. In addition, 
mutations were tested in viral DNA isolated from plasma and this may not necessarily reflect 
the diversity of HBV within the malignant hepatocytes. Collection of biopsy samples when 
diagnosing HCC and where it can be safely performed would enable sequencing of virus in 
malignant tissue and comparisons to be made as to whether the virus sequence is the same as 
that which is isolated in peripheral blood. More cases could also have been recruited from the 
participating sites in Gauteng if there were study nurses stationed at the recruiting units. 
5.1.14. Implications of the HCC Study results 
The first and best step approach to tackling HCC would be to increase awareness of hepatitis 
B among primary health care providers and to adopt a public health approach in the testing 
and diagnosing of viral hepatitis infections, similar to the approach toward HIV. It is 
currently not easy to get HBV mono-infected patients onto antiviral therapy in the state sector 
yet the same is readily available for HBV/HIV co-infected patients. There is therefore a need 
to recognize HBV infection as an important and independent disease entity with a significant 
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effect on public health. Only then will it also become possible to allocate the necessary 
resources for screening, treatment and care of people with CHB. Importantly, accurate and 
complete data on the rate of diagnosis of hepatitis B is not widely available for African 
countries and this perpetuates the cycle of mostly diagnosing hepatitis B only after a 
diagnosis of HCC has been made. The HCC results also bring into question the suitability of 
current hepatitis B treatment and HCC screening and surveillance guidelines for the South 
African setting. Many of the guidelines work well in places where access to sophisticated 
equipment and testing are readily available but the results show that a sizeable number of 
HBV-infected patients develop HCC with no underlying cirrhosis. Therefore, using 
significant fibrosis or cirrhosis as checkpoints to begin therapy or start screening for HCC 
have been shown to be unsuitable for the South African setting. There is a need to identify 
patients with high HBV viral loads and those who are HBeAg positive as they are highly 
infectious and likely to be the source of ongoing infection within the communities. 
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5.2. Liver Fibrosis and Immune Markers Study 
Liver fibrosis refers to the excessive deposition of extracellular proteins including collagen, 
usually in the setting of a chronic liver disease (Bataller and Brenner, 2005). Chronic viral 
hepatitis due to HBV may cause liver fibrosis which may lead to cirrhosis and ultimately in 
the development of HCC (Pellicoro et al., 2012). Clearance of HBV and disease pathogenesis 
are mediated by the adaptive immune response (Guidotti and Chisari, 2006). Patients who are 
able to clear hepatitis B infection have a vigorous, polyclonal T-cell response to multiple 
antigenic epitopes (Chisari et al., 2010). Meanwhile, patients who develop chronic infection 
with HBV have a weak adaptive immune response that causes continuing hepatocyte injury, 
regeneration, non-resolving inflammation, DNA damage and dysregulation of cell growth 
genes that may lead to liver cirrhosis and HCC (Chisari et al., 2010). Liver fibrosis is 
reversible but may progress to cirrhosis and eventually to HCC if the underlying stimuli are 
not eliminated (Crane et al., 2012). The development of CHB is linked to acquisition of 
infection in early life thus implicating an immature immune system in enabling establishment 
of chronicity. Early life is characterized by an immune tolerant immune status and early 
infections prior to the switch to pro-inflammatory status gives viruses an advantage. 
However, the change to the immune clearance phase of HBV is associated with immune 
mediated liver damage that can be seen histologically on liver biopsy as necroinflammation 
with varying degrees of fibrosis and elevated liver transaminases (Chang, 2007). 
5.2.1. Immunologic and virologic markers 
It is well-known that HIV co-infection has an adverse impact on the natural progression of 
HBV infections. There is little data describing the effect of HBV infection on the progression 
of HIV. This Immune Study had a cross-sectional design where only HIV and HBV/HIV co-
infected patients who were on HAART for at least three months were examined. HAART 
duration of at least three months was considered in order to eliminate extreme data variability 
due to uncontrolled HIV replication. HIV viraemia is known to decrease to <25 copies/ml 
following 8 weeks of treatment with combination therapy in adherent patients (Perelson et al., 
1997). Clinic matched controls that were not infected with HIV or HBV were also recruited 
in order to establish baseline expression of immune markers. 
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5.2.1.1. CD4 cell counts 
The results showed that while on HAART administration, HBV/HIV co-infected patients had 
lower CD4 cell counts compared to those infected with HIV alone. This finding is consistent 
with results from elsewhere (De Luca et al., 2002, Idoko et al., 2009, Wandeler et al., 2013). 
The Swiss HIV Cohort Study reported that despite 3 years of HAART, HBV/HIV co-infected 
individuals had impaired CD4 cell count recovery relative to those with resolved HBV 
infection and HBV-uninfected patients (Wandeler et al., 2013). A study from Nigeria also 
showed lower CD4 cell counts in co-infected individuals compared to those with HIV mono-
infection prior to and 48 weeks after HAART (Idoko et al., 2009). However, other studies 
have not detected a significant difference in CD4 cell counts between HIV-mono-infected 
and co-infected patients (Konopnicki et al., 2005, Hoffmann et al., 2008). It should be noted 
that this current study (Immune Study) had a small sample size compared to previous studies. 
Some of the reasons that have been postulated for the decreased immune recovery include 
upregulation of apoptotic pathways in co-infection also sequestration of lymphocytes within 
the spleen following HBV-driven liver fibrosis (Nebbia et al., 2012, Wandeler et al., 2013). 
Also, a lower initial CD4 count (<350 cells/µL) at initiation of therapy is indicative of greater 
T cell depletion and the restoration is incomplete compared to those patients that are stared 
on therapy earlier with a CD4 cell count above 350 cells/µL (Robbins et al., 2009). The CD4 
cell count at HAART initiation was unknown but could also be a factor. 
5.2.1.2. HIV RNA detection 
Despite similar HIV treatment duration, the HBV/HIV group had a higher but non-significant 
proportion of individuals with persistent HIV RNAemia compared to the HIV group with 
prevalence rates of 27.8% and 18.1%, respectively. HIV viral loads above 1000 copies/ml 
were detected in 6/33 (18.1%) of co-infected and 3/33 (9.1%) of HIV mono-infected 
participants. This data is similar to results of a Chinese study that reported higher but non-
significant detectable HIV RNA among co-infected patients compared to HIV-mono-infected 
after 37 months of HAART (Yang et al., 2014). The World Health Organization and the 
South African Department of Health defines HIV virological treatment failure as “a 
persistently detectable viral load exceeding 1000 copies/ml (that is, two consecutive viral 
load measurements within a 2-month interval, with adherence support between 
measurements) after at least six months of using antiretroviral drugs” (WHO, 2013). The 
study cannot determine whether the patients that had detectable HIV RNA were failing 
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therapy or if this was due to non-adherence. The detection of HIV viremia among the 
participants in this study is a cause for concern. It has been reported that the effect of HBV 
co-infection in HIV participants on HAART becomes more apparent with longer duration of 
therapy causing more frequent detection of HIV RNA and accentuating the delayed recovery 
of CD4 cells (Yang et al., 2014). A decreased CD4/CD8 ratio despite effective HAART is 
associated with continuous immune dysregulation, immune senescence and is predictive of 
non-AIDS morbidity and mortality (Lu et al., 2015). The results showed that co-infected 
patients had significantly lower median CD4/CD8 ratio compared to those infected with HIV 
alone. This is explained by the fact that normalisation of CD4/CD8 ratio is solely based on 
the recovery of the CD4 cells (Lu et al., 2015). 
5.2.1.3. HBV DNA detection 
This study showed that HBV mono-infected subjects more frequently had detectable HBV 
DNA compared to the co-infected patients; 49% vs 73%, p=0.03. However, the carriage of 
HBeAg, although not statistically significant, was higher in the co-infected (28%) compared 
to the HBV-mono-infected patients (13%). HIV infection negatively impacts the natural 
progression of hepatitis B by increasing rates of HBV replication and reactivation of previous 
infection (Hoffmann and Thio, 2007). In addition co-infection decreases the chances of 
spontaneous clearance of HBsAg, causes higher occurrence of occult HBV, increases the rate 
of progression to cirrhosis and HCC and pushes up liver-related morbidity and mortality 
(Hoffmann and Thio, 2007, Puoti et al., 2008, Thio, 2009). HBV/HIV co-infection has also 
been shown to decrease response to treatment compared to persons with HBV mono-infection 
(Wandeler et al., 2013). Although the occurrence of HBV DNA in the HBV mono-infected 
subjects was not unexpected because not all the HBV-mono-infected subjects were on anti-
HBV therapy, its presence among the co-infected patients who were on therapy with two 
drugs (tenofovir and emtricitabine) that are effective against HBV is a cause of concern. 
Questions may be justifiably raised as to whether patients are adherent to therapy especially 
in light of the non-detection of drug-resistance mutations which might have explained the 
detection of HBV viraemia. Also, the fact that almost 18% of co-infected individuals had 
detectable and quantifiable HBV DNA and HIV RNA is probably indicative of non-
adherence to therapy. The low rate of drug-resistance mutations may be explained by the fact 
that all co-infected patients were on tenofovir and emtricitabine and also that Sanger 
sequencing was used for mutation detection as compared to deep sequencing that has higher 
Stellenbosch University  https://scholar.sun.ac.za
157 
 
sensitivity to detect minor variants when present. Therefore, low level drug-resistance cannot 
be entirely ruled out. Drug-resistance mutations in HBV infection have been detected by 
deep-sequencing where they were missed by Sanger sequencing (Margeridon-Thermet et al., 
2009, Margeridon-Thermet et al., 2013, Aoudjane et al., 2014). Tenofovir has a higher 
genetic barrier to resistance compared to lamivudine or adefovir because it acts at three 
different sites of HBV replication (Marcellin et al., 2008).  
This study is not the first to report detectable HBV DNA in co-infected patients on therapy. 
Di Bisceglie et al. reported that after 6 months of HAART, only 7/18 (38.8%) of patients had 
suppressed HBV replication to undetectable levels, although it must be noted that the 
participants of that study were receiving lamivudine as the only drug effective against HBV 
(Di Bisceglie et al., 2010). A multinational study comparing HBV-active HAART regimens 
in co-infected patients reported that 63% of subjects receiving tenofovir with emtricitabine 
achieved HBV DNA levels <200 IU/ml after 24 weeks of therapy although it might be 
expected that the proportion of patients with detectable HBV DNA would be even higher if 
more sensitive assays were used (Thio et al., 2015). A study of Zambian and South African 
patients reported that only 15/21 (71%) of co-infected subjects achieved HBV suppression 
after 12 months using tenofovir plus lamivudine or emtricitabine (Hamers et al., 2013). It is 
recognized that not all HBV-infected patients on therapy will achieve virologic suppression 
especially those with high levels of replication such as in HIV co-infection and in those that 
are HBeAg positive who have been shown to have delayed viral suppression (Marcellin et al., 
2008, Huang and Nunez, 2015, Thio et al., 2015).  
5.2.1.4. HBeAg prevalence 
The higher prevalence of HBeAg among co-infected subjects compared to HBV mono-
infected subjects is a well-recognised effect of HIV infection (Oshitani et al., 1996, 
Hoffmann and Thio, 2007, Di Bisceglie et al., 2010, Andersson et al., 2013). Even with 
administration of an effective regimen such as tenofovir plus emtricitabine, not all patients 
will achieve HBeAg seroconversion. Kosi et al reported that after 5 years of continuous 
therapy HBeAg seroconversion was achieved by only 57% of HIV/HBV co-infected patients 
(Kosi et al., 2012). The higher prevalence of HBeAg among treated HBV mono-infected 
patients compared to those that were untreated in this study is probably a reflection of the 
reason why such patients had to be placed on therapy because they had active disease. It was 
beyond the scope of this study to determine the rate of HBeAg loss because of its cross-
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sectional nature. A longitudinal study starting from the time of therapy initiation would be 
able to determine the rate of HBeAg seroconversion to anti-HBe.  
5.2.2. Non-invasive markers of liver fibrosis 
Liver fibrosis was assessed using the Fibroscan 402 with a medium probe. In addition, APRI 
and FIB-4 scores were calculated using relevant laboratory tests and patients’ ages. 
5.2.2.1. Fibroscan 
The results of transient elastometry (TE) showed that the HBV mono-infected group had the 
highest proportion of patients with significant or advanced fibrosis compared to all other 
groups. In addition, the median of TE values of the HBV mono-infected patients was higher 
than of the other groups. It was significantly higher than that of the HIV mono-infected group 
which was also significantly lower than that of the co-infected group. The results showing a 
higher proportion of patients with significant fibrosis among those with HBV/HIV 
coinfection compared to HIV mono-infected patients are consistent with findings from other 
groups where coinfection was associated with higher TE values (Castellares et al., 2008, 
Stabinski et al., 2011, Hawkins et al., 2013). HIV mono-infection has been described to 
independently increase liver fibrosis (Vlahakis et al., 2003, Tuyama et al., 2010). However, 
the finding of a higher proportion of HBV mono-infected individuals with advanced fibrosis 
compared to HIV mono-infected is not unexpected because of the fact that HBV is a 
hepatotrophic virus that drives liver pathogenesis. Furthermore, the majority of HBV mono-
infected patients in this cohort were not on treatment allowing viraemia that drives fibrosis. 
Treatment of HBV infection has been shown to improve fibrosis and this probably explains 
the reason for lower TE values in the co-infected patients compared to those with HBV 
mono-infection (Marcellin et al., 2013). The study did not show a significant correlation 
between the TE scores and HBV viral loads in the HBV mono-infected group. However, the 
ungrouped analysis showed significant positive correlation between the median stiffness and 
both HBV and HIV viral loads. The fact that the same correlation was not observed in the 
grouped analyses is probably due to the effect of a larger sample size in the ungrouped 
analysis. 
The results also showed that males had higher TE scores compared to females. This is an 
effect of gender that has been previously observed and a variety of reasons have been 
postulated (Corpechot et al., 2006, Roulot et al., 2008). It is thought that higher TE scores in 
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males compared to females may be due to physiologic differences in the liver ECM (Wang et 
al., 1998). Mice models have shown that oestrogen inhibits HSCs from producing fibrotic 
collagen in dimethylnitrosamine-induced liver fibrosis (Yasuda et al., 1999). These 
differences may warrant an investigation of whether or not different cut-off values for the 
various fibrosis strata are needed according to gender.  
5.2.2.2. APRI and FIB-4 
Although the APRI and FIB-4 tests also showed the HBV mono-infected group with highest 
proportion of patients with moderate to advanced fibrosis, the differences between study 
groups were not statistically significant. All three non-invasive tests showed some degree of 
positive correlation, albeit poor. A study on Burkinabe patients evaluating these tests against 
the gold standard of liver biopsy reported that the APRI and FIB-4 performed poorly 
compared to the Fibroscan for the diagnosis of significant fibrosis (Bonnard et al., 2010). A 
separate study conducted in Senegal reported the superiority of the Fibroscan compared to the 
Fibrotest and Fibrosure among patients with CHB and normal ALT values (Mbaye et al., 
2011). Other researchers have advised against the use of APRI for diagnosing advanced 
fibrosis in patients with HBV/HIV co-infection because of a poor positive predictive value 
despite the WHO recommending the use of APRI in resource-limited settings (Stockdale et 
al., 2016). 
5.2.3. Microbial translocation markers 
Primary HIV infection is known to cause damage of the defensive barriers of the gut-
associated lymphoid tissue (GALT) leading to massive depletion of CD4+ T cells (Brenchley 
et al., 2006). Destruction of the GALT causes increased microbial translocation into the 
systemic circulation leading to systemic activation which is a hallmark of HIV infection 
(Brenchley et al., 2004, Brenchley et al., 2006, Brenchley and Douek, 2012). Microbial 
translocation has previously been measured using various biomarkers that include LPS, 
sCD14, LBP, or bacterial 16S ribosomal DNA (16S rDNA) (Abad-Fernandez et al., 2013).  
CD14 plays a role in immunity and exists as membrane bound (mCD14) or soluble (sCD14) 
(Li et al., 2015). Soluble CD14 is a marker of monocyte/macrophage activation that is 
normally induced by exposure to LPS. The results from this study showed that co-infected 
patients had the highest plasma sCD14 levels compared to those infected with either HBV or 
HIV alone and also controls. The pattern of plasma sCD14 results suggest that HIV plays a 
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more prominent role in shedding of sCD14 following activation by LPS as evidenced by HIV 
mono-infected patients having higher sCD14 quantities relative to those with HBV mono-
infection. A study on patients from Thailand reported that co-infected patients that had not 
started HAART had higher plasma sCD14 than those with HBV mono-infection (Crane et al., 
2014). Research in paediatric and older patients infected with HIV has shown that despite 
HAART, there is persistently higher immune activation punctuated by elevated levels of 
sCD14 and that this is not related to HIV viraemia (Wallet et al., 2010, Wallet et al., 2015). 
The results from this current study also support these findings because plasma sCD14 did not 
correlate with either plasma HBV DNA or HIV RNA in individual groups or total 
participants thus supporting the idea that gut microbial translocation is independent of current 
(on treatment) viral load. This also probably explains the reason for not detecting any 
differences in microbial translocation markers between HBV mono-infected patients that 
were on therapy and those that were not. A potential mechanism for continued monocyte 
activation may be due to blunted recovery of CD4 T cells during HAART (Dunham et al., 
2014). However, this study cannot determine the rate of CD4 T cell recovery of the HIV-
infected patients that were recruited because of its cross-sectional design. 
Surprisingly, there was no difference between the controls and the HBV-mono-infected with 
regard to sCD14. This marker was expected to be significantly increased among the HBV-
mono-infected patients compared to the controls. A role for sCD14 in pathogenesis of both 
acute and chronic hepatitis B has previously been described (Oesterreicher et al., 1995, 
Sandler et al., 2011, Li et al., 2015). The lack of a difference between the HBV mono-
infected and controls is probably because hospital controls from the Gastroenterology Clinic 
were used and some of them may have had yet-undiagnosed inflammatory conditions 
associated with increased sCD14, such as inflammatory bowel disease (Pastor Rojo et al., 
2007). It has been previously reported that patients with chronic viral hepatitis have 
significantly higher serum sCD14 levels compared to healthy controls (Oesterreicher et al., 
1995, Steyaert et al., 2003). Interestingly, there was no correlation between Fibroscan values 
and sCD14 value for the entire cohort. No association of liver disease and sCD14 was 
reported previously (Crane et al., 2014). The significance of increased sCD14 in CHB has 
been questioned with suggestions that elevated levels of the marker (sCD14) may actually 
serve to protect liver function by downregulating the inflammatory cascade (Kitchens et al., 
2001, Marchetti et al., 2012). 
Stellenbosch University  https://scholar.sun.ac.za
161 
 
LBP binds to LPS via the lipid A part of the endotoxin and transfers it to phagocytic cells 
through mCD14 or sCD14 (Park and Lee, 2013). The results from this study showed a trend 
towards increased plasma concentration of LBP in co-infected patients compared to those with 
mono-infection and controls. It has previously been reported that there was no significant 
difference in plasma LBP between patients with CHB and healthy controls (Steyaert et al., 
2003). It is possible that the concentration of LBP may have been attenuated by HAART in the 
co-infected and HIV-mono-infected patients. In theory, HAART does not restore gut integrity 
and therefore continued elevations of LBP and sCD14 are expected in HIV-infected 
individuals despite HAART (Chen et al., 2014, Wada et al., 2015). A study in HCV/HIV co-
infection reported that while sCD14 levels did not change with treatment duration, LBP was 
lowered by the administration of HAART and anti-HCV medication (Nystrom et al., 2015). 
The overall results from this study showed non-significant weak positive correlation between 
LBP and sCD14. This is consistent with other studies that have shown some degree of 
statistically significant and non-significant positive correlation between the two biomarkers in 
different disease entities (Redd et al., 2009, Abad-Fernandez et al., 2013, Gonzalez-Quintela et 
al., 2013). LBP and sCD14 were used in this current study rather than LPS because LPS has a 
short half-life in circulation and its measurement using the widely-utilized Limulus assay is 
subject to interference from other molecules in the blood where it may be bound to serum 
binding proteins (Ruiz et al., 2007). Measurement of sCD14 and LBP is considered as better 
than LPS because the two former biomarkers are more stable, long-lived and are markers of 
the body’s physiologic response to the latter (Ruiz et al., 2007). The overall finding from the 
microbial translocation markers and liver fibrosis markers would seem to suggest that gut 
translocation is not associated with liver stiffness in this treated cohort. Instead, viral 
replication is probably the driver of liver fibrosis according to the results of the ungrouped 
analysis. 
5.2.4. Effect of HBV genotypes on liver fibrosis 
Effect of HBV genotype on liver inflammatory activity and fibrosis has previously been 
shown for genotypes B and C where the latter was associated with worse liver disease and the 
former with development of HCC at a younger age (Kao et al., 2000). This study showed no 
significant association between liver fibrosis and HBV genotypes A, D and E using TE. 
There is little data from Africa reporting the effect of HBV genotypes on liver fibrosis apart 
from the association studies between genotype and replication as well as HCC development 
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(Kew et al., 2005, Kramvis and Kew, 2005). Genotype D was previously described to be 
associated with more severe liver disease compared to genotype A among Indian patients but 
another study from the same country suggested that genotype D did not influence the 
progression of liver disease in CHB patients (Thakur et al., 2002, Gandhe et al., 2003). No 
clear association between HBV genotypes and liver diseases severity (determined using 
histologic examination of liver biopsy) was also observed from a French study (Halfon et al., 
2006). 
5.2.5. Cell-based immune activation markers 
T lymphocytes are responsible for the pathogenesis as well as the clearance and resolution of 
CHB infections (Guidotti and Chisari, 2006, Chisari et al., 2010). However, very little is 
understood concerning the change of expression of activation markers by CD4+ T cells in 
either HIV infection or HBV/HIV co-infection. On the other hand, the percentage of CD8+ 
lymphocytes expressing CD38 and HLA-DR is well characterised, hence the discussion of 
activation markers is focussed on these cells (CD8+ T cells). CD8+ T lymphocytes mediate 
clearance of HBV infections from infected hepatocytes through cytolytic and cytokine-
mediated non-cytolytic mechanisms (Thimme et al., 2003, Phillips et al., 2010). The results 
of the current showed that co-infected patients had highest percentage of CD4+ and CD8+ T 
lymphocytes expressing the immune activation markers HLA-DR and CD38. Furthermore, 
the results suggest that HIV infection is the driver of immune activation because HIV-mono-
infected patients also had higher, although non-significant, percentage of cells expressing 
HLA-DR and CD38 on both CD4+ and CD8+ T lymphocytes compared to HBV-mono-
infected patients. Interestingly, there was no correlation between the expression of immune 
markers of activation and liver stiffness as measured by any of the fibrosis markers. This may 
be due to the fact that the study measured immune activation in peripheral blood which may 
not be reflective of the hepatic environment. Research on the hepatic environment in 
HBV/HIV co-infected patients found no evidence of increased inflammation but rather 
apoptosis as the driver of liver disease (Iser et al., 2011). There is little data comparing the 
expression of the immune activation markers between co-infected and HBV mono-infected 
patients and where this was attempted, the researchers used subjects that were untreated for 
HIV. Significantly increased HLA-DR and CD38 among CHB patients compared to healthy 
controls has previously been described among Chinese patients (Cao et al., 2011).  
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5.2.6. Cell-based immune exhaustion markers 
It is known that chronic viral infections such as HIV, HCV and HBV cause a state of immune 
exhaustion in both CD8+ and CD4+ T lymphocytes as a way to protect from the effects of a 
continuous immune viraemia-associated activation leading to poor effector function (Zajac et 
al., 1998, Urbani et al., 2002, Day et al., 2006, Blackburn et al., 2009). Some of the markers 
that are upregulated in this state of immune exhaustion include CTLA-4, PD-1, Tim-3 and 
LAG-3 (Zajac et al., 1998, Urbani et al., 2002, Day et al., 2006, Blackburn et al., 2009). CD4 
and CD8 T lymphocytes from co-infected and HIV mono-infected patients exhibited higher 
levels of immune exhaustion as shown by the percentage of cells staining positive for PD-1 
compared to HBV mono-infected and control individuals. HBV co-infection seems to have a 
negligible effect on PD-1 expression in patients with HIV infection because there was no 
difference between the co-infected and HIV mono-infected subjects. However, there was a 
significant difference in expression of PD-1 on T lymphocytes of HIV mono-infected patients 
compared to controls. Surprisingly, expression of PD-1 on the CD8 T lymphocytes of 
controls was higher than that of the HBV mono-infected patients. This result may be 
reflective of underlying chronic inflammatory conditions among the hospital-based controls. 
Use of healthy controls might reflect a different result. There was a very low surface 
expression of the exhaustion marker CTLA-4 on T lymphocytes in this study. This is 
consistent with CTLA-4 being predominantly located in the intracellular compartments and 
barely detectable at the cell surface (Linsley et al., 1992, Leung et al., 1995, Valk et al., 
2008). Detection of CTLA-4 might have been better investigated through intracellular 
staining or quantification of its mRNA transcripts (Valk et al., 2008). 
5.2.7. Soluble immune markers  
There were significantly higher systemic levels of a broad range of cytokines in the HBV 
mono-infected patients compared to the other groups. The effect of therapy within the HBV 
group was not apparent. This is most likely due to the fact that there was a wide range of 
treatment duration within the HBV group with individuals receiving tenofovir from between 
one week up to more than two years. Also, the sample size to compare individuals on therapy 
to those that were not on therapy was low. However, the finding that the HBV mono-infected 
group tended to have the highest serum concentration for the majority of cytokines is 
probably due to the fact that this group also had the highest (normal) CD4+ T cell counts and 
also the highest number of infected patients that were not on therapy. CD4+ T cells are the 
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primary cytokine producers. Also, the HBV mono-infected group tended to have lower PD-1 
expression on CD8 and CD4 T lymphocytes meaning that they had fewer cells with an 
exhausted phenotype. However, the levels of cytokines in HBV may be more indicative of 
“normal” rather than elevated and that the HIV-infected (mono-infected/co-infected) groups 
were suppressed. 
The IL-1 family of cytokines (IL-1β and IL-1ra) were significantly increased in the plasma of 
HBV mono-infected patients compared to the HIV mono-infected and co-infected patients. 
The concentrations of IL-1β and IL-1ra had strong positive correlation with levels of IL-10, 
IL-12 and TNF-α. The concentrations of TNF-α, IL-4, IL-6, IL-10, IL-13, IL-17, Basic-FGF, 
G-CSF and IFN-γ were also highest in the HBV mono-infected group compared to all others. 
IL-1β is a mediator of inflammation that is produced by innate immune cells. It is important 
for host immunity in response to pathogens but its secretion in chronic disease such as CHB 
may worsen injury and also causes tissue damage in acute disease (Lopez-Castejon and 
Brough, 2011). IL-6 is an acute phase protein and a mediator of inflammation (Lan et al., 
2015). IL-1ra is produced by a range of cells and is a natural inhibitor of the pro-
inflammatory effects of IL-1β and IL-1α (Arend et al., 1998). The balance in tissues between 
IL-1b and IL-1ra is known to determine the outcome inflammatory disease. An excess of IL-
1b relative to the antagonistic IL-1ra leads to structural damage (Arend et al., 1998). It was 
shown that an increased IL-1β/IL-1ra ratio in HCV infection was associated with increased 
liver fibrosis (Gramantieri et al., 1999). The role of IL-6 is HBV-driven liver disease is 
extensively described and its secretion follows after IL-1β and TNF-α induction (Lan et al., 
2015, Schmidt-Arras and Rose-John, 2016). Levels of IL-6 have been shown to positively 
correlate with severity of hepatitis B with patients that have severe acute infection having 
higher concentrations compared to those with chronic active disease (Tan et al., 2010, Zhang 
et al., 2011a). 
IL-4 is produced by T cells and its functions include the differentiation of naïve cells into Th2 
cells, the regulation of humoral immunity and the activation of macrophages. In HBV 
infection, IL-4 has been associated with persistent replication of HBV and induction of 
tolerance through downregulation of IFN-γ production from Th1 cells (Li et al., 2016a). 
Higher serum levels of TNF-α, IL-4, IFN-γ and IL-2 have previously been described in CHB 
patients compared to controls (Jiang et al., 2010). Jiang et al also showed the manner in 
which cytokine secretion pattern switches from Th2 to Th1 following long term treatment 
with adefovir (Jiang et al., 2010). However, the effect of IL-4 is not as clear when one 
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considers that treatment with adefovir was associated with increasing plasma concentration of 
the cytokine (Jiang et al., 2010) while another group treating CHB using pegylated IFN-α2a 
reported that the levels decreased in patients that exhibited virological response (Park et al., 
2012). Using proteomic analysis, it was reported that IL-4 inhibited the expression of HBsAg 
and HBeAg in a “HBV stably transfected HCC cell line (HepG2.2.15)” (Yao et al., 2011). It 
has been hypothesized that IL-4 negatively regulates the immune system as a protective 
mechanism to reduce inflammation (Yao et al., 2011). Another Th2 cytokine is IL-13, which 
was significantly higher in the HBV mono-infected group compared to the HIV-mono-
infected and controls. IL-13 shares the similar functional activities with IL-4 and the two 
cytokines engage with a common receptor α chain/signal transducer and activator of 
transcription protein 6 (STAT6) (Weng et al., 2009). Hepatic concentrations of IL-13 have 
been shown to positively correlate with amount of liver fibrosis in CHB and serum levels 
were also elevated in patients with hepatitis C compared to controls (Weng et al., 2009). The 
rate of detection of IL-13 was also reported to be higher in CHB patients (40%) compared to 
patients with occult HBV infection (8%) (Martin et al., 2009). This study had high detection 
rates for IL-13 compared to the report by Martin et al. The difference in detection rates of IL-
13 and other cytokines is probably reflective of the variety of tests (Luminex vs ELISA vs 
qPCR) and matrices (hepatic vs serum) that different investigators have used. 
The TNF family of cytokines is produced from T lymphocytes as well as macrophages. The 
cytokine is part of the acute phase proteins and has been associated with hepatic 
inflammation and fibrosis in CHB (Li et al., 2016a). Median plasma TNF-α concentration 
was significantly higher in the HBV mono-infected patients compared to those with HIV 
mono-infection. The levels of TNF-α were higher in the HBV mono-infected, but not 
significantly so when compared to the co-infected and control groups. Higher plasma levels 
of TNF-α and IFN-γ have been described in CHB patients compared to healthy controls 
(Zhang et al., 2011b). There was no significant difference between the HBV mono-infected 
and controls in this study because hospital controls were used who may not have been 
completely healthy although they did not have liver disease or symptoms of any infection. 
TNF-α is involved in the immunopathogenesis, inactivation and immune clearance of 
hepatitis B (Daniels et al., 1990, Suri et al., 2001, Phillips et al., 2010, Zhang et al., 2011b). 
TNF-α and IFN-γ were previously shown to be responsible for non-cytolytic control of HBV 
replication using various in-vitro models (Guidotti et al., 1996, Suri et al., 2001, Phillips et 
al., 2010). However, TNF-α and IFN-γ may also potentiate hepatic damage as demonstrated 
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by the maintained secretion of the two cytokines in CHB patients with high HBV DNA and 
liver inflammation (Das et al., 2008). 
IL-17 is the principle effector molecule produced from Th17 lymphocytes (Li et al., 2016a). 
The concentration of IL-17 was significantly higher in the HBV mono-infected group 
compared to the co-infected group only. Previous studies have described IL-17 being 
upregulated in CHB and has been linked with pathogenesis of liver cirrhosis and 
hepatocarcinogenesis (Wu et al., 2010b, Du et al., 2013). In light of these previous studies, 
the results of IL-17 in this study are puzzling because the HBV mono-infected and co-
infected groups had higher proportions of patients with moderate to advanced liver fibrosis as 
determined by Fibroscan and levels of the cytokine would have been expected to be also high 
in the latter group. The effect of HAART on the expression of IL-17 in co-infected patients 
may provide clues and a longitudinal study tracking IL-17 levels in patients starting therapy 
may be useful in providing clarity. 
Plasma levels IL-10 of the HBV-mono-infected group were significantly higher than that of 
the HIV mono-infected group but not of controls or the co-infected subjects. IL-10 is 
produced by Th2 lymphocytes and also macrophages. It has anti-inflammatory properties 
inhibiting the production of pro-inflammatory cytokines in hepatitis B hence its former name 
“cytokine synthesis inhibitory factor (Sabat et al., 2010, Li et al., 2016a). IL-10 is responsible 
for continual HBV replication and orchestrates liver fibrosis by inhibiting the secretion of 
IFN-γ (Li et al., 2016a). Increased serum IL-10 has been described in patients that were 
seropositive for HBeAg and HBV DNA with persistently elevated ALT compared to controls 
(Bozkaya et al., 2000, Das et al., 2012). No differences between controls and HBV mono-
infected subjects were detected in this study probably due to the heterogeneity of the patients 
with HBV infection in terms of antiviral therapy and duration thereof. 
Basic fibroblast growth factor (FGF) also referred to as FGF2 induces growth of fibroblasts 
and plays a role in angiogenesis during cancer development (Ribatti et al., 2007). The 
biomarker was significantly elevated in the plasma of HBV mono-infected patients compared 
to those with co-infection and HIV mono-infection. However, the levels in HBV-mono-
infected patients were not significantly higher than in controls. Basic-FGF levels have been 
described to correlate with progression of HBV-driven liver disease and have highest 
expression in patients with HCC (Hsu et al., 1997, Jin-no et al., 1997). 
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IP-10 is the only cytokine that had significant elevated expression in the co-infected group 
compared to all other groups. There was no significant difference in IP-10 expression 
between the mono-infected groups and the controls (refer to Figure 2-21). IP-10 is known to 
be associated with liver fibrosis progression in HCV infection (Diago et al., 2006, You et al., 
2011). It appears that the increased concentration of IP-10 in this study was mainly due to 
HIV infection. IP-10 levels positively correlated with both HBV and HIV viral load in the co-
infected group. IP-10 also had positive correlation with both LBP and sCD14 in the 
ungrouped analysis. There was significant positive correlation of IP-10 and expression of 
CD38 by CD8 lymphocytes in HIV-infected patients. HIV infection is known to be a potent 
inducer of IP-10 secretion from dendritic cells and monocytes and in turn IP-10 promotes 
HIV replication in macrophages and lymphocytes (Lane et al., 2003, Simmons et al., 2013). 
Increased IP-10 levels could thus be an indicator or biomarker of continued immune 
activation from viral replication and gut translocation in HBV/HIV co-infection. 
Unexpectedly, TGF-β2 and TGF-β3 were detected at higher concentrations in the HIV-mono-
infected group relative to the co-infected group. In addition, plasma levels of TGF-β2 in the 
HBV-mono-infected group were also higher than in the co-infected group. There was no 
significant difference in the plasma concentration of TGF-β1 across the four groups of 
subjects. These were unexpected findings as it was postulated that co-infected patients would 
have higher plasma TGF-β1 values compared to those with mono-infection and controls. 
TGF-β1 is known as a highly pro-fibrogenic cytokine that also has immunosuppressive 
properties (Cerwenka and Swain, 1999, Sacchi et al., 2015). However, the levels of TGF- β in 
this current study did not seem to correspond with the amount of liver fibrosis. The result 
may be due to HAART but the effect should also have been similar in the HIV-mono-
infected group. In addition, other researchers have reported an inverse relationship between 
liver fibrosis and TGF-β1 levels in HCV-mono-infected and HCV/HIV co-infected patients 
giving rise to conclusions that high levels of the cytokine may actually be protective against 
liver fibrosis in HCV infections (Rallon et al., 2011, Sacchi et al., 2015). It would seem that 
the levels and effects of TGF-β1 in HBV infection is different from that in HCV infection 
because it has been reported that the cytokine occurs in greater amounts in patients infected 
with chronic HCV compared to those with CHB (Kirmaz et al., 2004). Furthermore, the 
results from this study suggest that TGF-β2 and TGF-β3 probably play a more 
immunosuppressive role in HIV infection than in HBV infection. Of the three TGF-β 
isoforms, the least is known about TGF-β2 and TGF-β3 with most literature having 
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investigated the expression of TGF-β1. However, the concentrations at which TGF-β1 is 
detected are about 20-fold higher compared to those of TGF-β2 and –β3. 
The chemokine macrophage inflammatory protein-1α (MIP-1α) was detected at significantly 
higher levels in the controls and HBV mono-infected compared to the HIV-mono-infected 
subjects. MIP-1α is one of the two isoforms of MIPs, the other being MIP-1β that also had a 
trend towards a higher concentration in controls and HBV-mono-infected subjects relative to 
those with HIV mono-infection. MIP-1α and MIP-1β have been described as CC chemokines 
that supress HIV replication and are produced by CD8 T cells (Cocchi et al., 1995, Vicenzi et 
al., 2000). MIP-1α has previously been demonstrated to be higher in HIV-infected patients 
compared to controls but decreasing with HAART administration (Ye et al., 2004). It would 
appear that MIP-1α levels in HIV-infected patients in this study were low because of 
normalization by the administration of HAART. 
Some cytokines had poor detection rates across all groups. IL-15 was poorly expressed 
although the HBV-mono-infected group had the highest proportion of patients with 
detectable plasma concentration of the cytokine. Increased concentrations of IL-15 have 
previously been found in the liver environment of patients with active hepatitis attributed to 
infection to HCV infection (Kakumu et al., 1997, Golden-Mason et al., 2004). The cytokine 
is linked to the cytolytic activity of NK cells and the development of liver fibrosis and HCC 
(Kakumu et al., 1997, Zhang et al., 2011c). 
The original hypothesis of the Liver Fibrosis and Immune Markers Study was that in patients 
infected with both HIV and HBV, HIV infection facilitates the development of liver fibrosis 
via immune activation in response to the leakage of gut microbial products into the systemic 
circulation. Instead, the study found that although there was increased microbial translocation 
(shown by increased sCD14) and elevated immune dysregulation (increased % 
CD8/CD38/HLA-DR and % CD8/PD-1) in HBV/HIV co-infected patients, the proportion of 
patients with moderate/advanced liver fibrosis (measured by Fibroscan) was higher in the 
HBV mono-infected group compared to those with co-infection. Also, the finding that there 
was no correlation between microbial translocation markers and liver fibrosis scores would 
seem to imply that microbial products are not the driver of fibrosis but rather viral replication. 
This is because median stiffness had significant positive correlation with both HIV and HBV 
viral loads in the ungrouped analysis. The relationship of active viral replication with fibrosis 
implicates active antigen-specific anti-viral responses as being important to pathogenesis of 
Stellenbosch University  https://scholar.sun.ac.za
169 
 
liver fibrosis. This would be probably be due to CTL destruction of hepatocytes, recruitment 
of macrophages promoting “healing” and stimulation of HSC-derived myofibroblasts to 
produce collagen. 
5.2.8. Limitations of the study 
The inability to obtain liver biopsies from the study participants makes it difficult to ascertain 
the accuracy of the results of the non-invasive tests for fibrosis although these have been 
suggested for use by the WHO. Fibroscan examinations could not be obtained on all subjects 
mainly due to visceral obesity. An effect of other undiagnosed infections such as 
cytomegalovirus on the expression of markers of immune activation cannot be ruled out 
although care was taken to exclude any patients with overt symptoms of infectious disease. 
The cross-sectional nature of the study makes it impossible to have a view of the temporal 
changes in the expression of immune markers and to determine how these are altered by 
duration on therapy. Another limitation is that the assessment of immune markers was not 
virus-specific. Use of viral antigen stimulation to assess T cell-specific responses of HBV- 
and HIV-specific cells may help in elucidation of the role of the specific viral infections. 
Immune activity in peripheral blood (cells and plasma) may not give a clear indication of 
events in the liver. Nevertheless, the data arising from this study is important in developing 
prospective studies to monitor prognosis of HBV infection, especially among the HBV-
mono-infected patients. Most HBV-mono-infected patients were not on therapy because of 
being in the low replication phase of hepatitis B. However, there is still immune activity 
within the low replication phase that can lead to moderate fibrosis which may be a concern in 
the context of hepatocarcinogenesis. There is therefore a need for longitudinal African studies 
that will determine the clinical outcomes of patients that stay in the low replication phase for 
a long time vis-à-vis the finding that viraemia is the driver of fibrosis. 
5.2.9. Implications of the Liver Fibrosis and Immune Markers Study 
The results from the Immune Study highlight the under-recognition of hepatitis B as an 
independent disease that needs to be given more attention. The findings suggest that HBV-
mono-infected patients seem to have worse clinical status than co-infected patients, with 
regards to liver fibrosis as measured using non-invasive tests, and this may be treatment 
related. HBV/HIV co-infected patients have easier access to effective treatment and 
monitoring than HBV-mono-infected patients. Such a situation leaves HBV-mono-infected 
patients at risk of disease progression such that they will only be seen at the clinic upon 
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presentation with advanced disease such as liver cirrhosis and HCC. However, raising 
awareness may improve the diagnosis and care of patients infected with HBV who are 
usually asymptomatic until the infection has progressed substantially, hopefully allowing 
initiation of meaningful and life-saving therapy in time.  
5.3. Options for the control of HBV-driven liver disease in Africa 
It has been proposed that lessons learnt in responding to the HIV pandemic and also in also 
setting up initiatives such as the Global Alliance for Vaccines and Immunization could be put 
to use in advocating for lowering of prices of the diagnostic tests and medication for viral 
hepatitis infections (Lemoine et al., 2013). Another strategy that has been proposed is to 
merge HBV control programs with those for other infections (Mihigo et al., 2013). In the case 
of sub-Saharan Africa, the huge pool of HIV infected patients and the facilities and programs 
availed in response to the HIV pandemic offer an ideal opportunity for implementing HBV 
and HCC control programs alongside. Reports suggest that liver disease and HCC incidence 
have been rising among HIV-infected patients since the roll-out of HAART compared to the 
pre-HAART era (Brau et al., 2007, Rosenthal et al., 2009, Kew et al., 2010). HIV infected 
HCC cases are presenting at a younger age compared to those that are not infected with HIV 
(Puoti et al., 2004, Brau et al., 2007). The mechanism by which liver disease arises especially 
in HBV-infected patients in the context of HIV is still under-investigated. Most published 
research has focussed on HCV/HIV co-infected patients in developed nations while other 
research has focussed on the toxicity of antiretroviral medication on liver function and 
pathology. However, HCV is not as prevalent as HBV in sub-Saharan Africa and the 
pathogenesis of HCV is not similar to HBV (Mohd Hanafiah et al., 2013). It is therefore 
important to try and understand the pathogenesis of HBV-driven HCC in patients that are also 
infected with HIV. 
5.3.1. Changing the epidemiology of HBV-driven HCC in sub-Saharan Africa 
The motto “prevention is better than cure” is true and relevant for efforts to combat HCC. 
Although HBV is undoubtedly hepatocarcinogenic, infection with the pathogen is 
preventable by use of a vaccine which was first reported in 1976 and is recognized as the first 
cancer-preventing vaccine (Buynak et al., 1976, Beasley, 2009). It is estimated that achieving 
90% HBV vaccination coverage with the first dose being given at birth would result in 84% 
decrease in mortality arising from HBV-related liver disease, which includes HCC, 
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worldwide (Goldstein et al., 2005). In countries where HBV vaccine was first introduced 
such Taiwan, Thailand and The Gambia, a decrease in the incidence of HCC has already been 
observed (Beasley, 2009). In Taiwan, a 50% decrease in the incidence of HCC among 
children of the ages 6-14 years was seen after a period of just after 10 years following the 
introduction of infant vaccination (Chang et al., 1997). It is therefore of paramount 
importance to ensure good routine vaccination coverage for HBV within sub-Saharan Africa 
in order to prevent new HBV infections which may progress to HCC. Despite the WHO’s 
recommendations for a birth dose, most African countries do not follow this because vertical 
transmission from mother to infant is thought to play a minor role in HBV transmission in the 
African setting. Early age of acquisition of HBV is the main risk factor for developing CHB, 
which poses the greatest risk for development of HCC with sub-Saharan Africa (Kiire, 1996). 
The majority of chronic HBV carriers in sub-Saharan Africa acquire the infection before the 
age of five years through horizontal transmission which may involve household contacts, 
playmates, cultural scarification rituals and unsafe medical procedures (Kiire, 1996, WHO, 
2008). It is established that most HBV infections acquired in childhood progress to chronic 
infection due to the immaturity of the immune systems of children who fail to clear the virus 
thereby allowing chronicity to be established with a high risk of developing into cirrhosis and 
HCC (Pungpapong et al., 2007). In contrast, 95% of HBV infections acquired in adulthood 
resolve and do not establish chronicity (Tran, 2009). The fact that most chronic HBV 
infections found in adults within sub-Saharan Africa arise from horizontal transmission in 
childhood explains the reason why immunisation protocols in Africa are not designed to 
prevent vertical transmission (Burnett et al., 2005). However, there is evidence of decreased 
HBsAg carriage among vaccinated children which should eventually translate into decreased 
HCC incidence in adults over time (Tsebe et al., 2001, Viviani et al., 2008).  
Despite relatively reasonable vaccine coverage rates of around 75% among infants within 
most of sub-Saharan Africa (rates according to 2014 WHO data on HepB3 immunisation 
coverage) , there remains a risk for vertical transmission from highly viraemic pregnant 
mothers as shown by data from Ghana and more recently South Africa (Candotti et al., 2007, 
Andersson et al., 2012, Andersson et al., 2013, Hoffmann et al., 2014). Data from South 
Africa suggests that more than 15% of HBsAg positive and HBeAg positive pregnant women 
regardless of their HIV status are at risk of transmitting infection to their infants (Andersson 
et al., 2012, Andersson et al., 2013). This risk will only be eliminated once a policy to 
actively screen all pregnant women for HBV infection is implemented. Until pregnant 
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women that are infected with HBV are identified and treated with antivirals to reduce 
infectivity as well as having their babies vaccinated at birth and given prophylaxis, a pool of 
vertically-acquired infections will continue to exist which will become a source of horizontal 
transmission and later through sexual contact in adulthood to susceptible partners. 
Unfortunately, public health antenatal facilities in most African countries do not provide for 
HBsAg screening in pregnant women. It has been suggested that with the availability of a 
vaccine for HBV, maternal transmission has taken over as the “major source of HBV 
infection in the post-immunization era” (Chen et al., 2012). Breakthrough maternally-
acquired infections are thought to result in chronic liver disease that has a higher risk of 
progressing to HCC compared to vertically-acquired HBV infections in non-vaccinated 
children (Chang et al., 2005).  
CHB causes persistent inflammation which may progress to significant fibrosis but this can 
be stopped and even reversed by treating patients with CHB using drugs such as tenofovir 
and lamivudine (Dienstag et al., 2003, Hadziyannis et al., 2006, Mallet et al., 2007). 
However, the success of treatment hinges on being able to first diagnose people infected with 
HBV. It is not currently known what percentage of African patients with HBV are actually 
diagnosed but the findings from this study seem to suggest that most HBV infections in HCC 
cases are diagnosed too late, that is around the time that patients present with cancer showing 
that enough is not being done to ensure timely diagnosis and treatment of CHB. Treatment of 
HBV infection has been shown to improve prognosis of the infection and also to reduce the 
incidence of HCC.(Liaw et al., 2004, Yuen et al., 2007, Wu et al., 2014). Data on the efficacy 
of nucleos(t)ide treatment in preventing HCC among African patients is still lacking but 
would be extremely useful particularly taking into account the existence of other 
environmental and dietary carcinogens such as aflatoxin exposure and iron overload. 
5.3.2.  Improving diagnosis and prognosis of hepatitis B and liver disease in 
Africa 
Early diagnosis and treatment of CHB and liver disease is a very important factor in 
determining outcome and in also changing the epidemiology of HBV. Identification of 
persons infected with CHB not only helps in getting them into care thereby preventing or at 
least delaying the onset of hepatic disease. Safe and effective options for treating CHB are 
available with antivirals such as tenofovir, entecavir and lamivudine that are effective in the 
treatment of HBV and can be used in the context of HBV/HIV co-infection. Early diagnosis 
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of infections is also useful for breaking transmission clusters as susceptible contacts within 
households and also susceptible sexual partners can be vaccinated (Weinbaum et al., 2009). 
Current international guidelines suggest that all Africans with CHB above the age of 20 years 
should be screened for HCC at regular intervals to enable early diagnosis (Bruix and 
Sherman, 2005). A randomized trial performed in China showed that surveillance leads to 
detection of cancers at early stages thereby allowing for curative options such as surgical 
resection and also reduces mortality (Zhang et al., 2004). Despite the availability of these 
guidelines and the benefits that are expected, implementation remains a challenge because a 
huge proportion of patients infected with CHB are not diagnosed in time to be placed under 
HCC screening programmes. The reason why many people do not get diagnosed is because 
chronic viral hepatitis usually causes subclinical disease so that infected individuals will not 
have a reason to seek medical care until signs and symptoms of chronic viral hepatitis and its 
sequelae are seen later on in life (Weinbaum et al., 2008). This is particularly relevant in 
HBV-driven HCC occurring in Africa where as many as 55% of patients may develop HCC 
without any underlying cirrhosis (Paterson et al., 1985, Kew, 1989, Yoshida et al., 1994). 
This current study also shows a low proportion of only 23% of HCC cases presenting with 
concomitant cirrhosis. As a result of HCC arising in the absence of cirrhosis, opportunities 
for surveillance and early diagnosis are lost. It was recently reported that screening of 
HIV/HBV co-infected patients leads to HCC being diagnosed at an earlier stage and is 
associated with improved survival compared to unscreened patients that present with 
symptoms of the malignancy (Aytaman et al., 2014). This again reiterates the need to have 
pro-active screening programs for HCC diagnosis and also raising awareness on CHB. WHO 
guidelines suggest that HBV serology should be performed at diagnosis of HIV infection and 
before the administration of HAART but this is rarely followed in routine clinical practice.  
5.3.3. Control of other risk factors for HCC 
Suffice to say, it is not only the control of HBV that will change the epidemiology of HCC in 
sub-Saharan Africa. HCV is clearly a significant risk factor in some countries within sub-
Saharan Africa as was shown in this study. It is therefore important to ensure that people 
already infected with HCV get diagnosed and be provided with optimal treatment to curb 
progression of chronic infection into HCC. Also it will be imperative that awareness be raised 
on how new infections may be avoided. Other steps that should also be considered include 
ensuring that donated blood products and tissue are safe. Furthermore, practices such as reuse 
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of syringes in health care facilities should be outlawed while traditional healers should be 
educated on safe hygienic procedures when performing cultural scarification rituals including 
circumcisions. With regards to aflatoxin exposure, small-scale farmers mostly within the 
rural areas will need to be educated on better methods of grain harvesting and storage to 
discourage growth of the Aspergillus fungi.  
Alcohol misuse is a significant risk factor for the development of alcoholic liver disease 
which can result in the development of cirrhosis and ultimately HCC (World Health 
Organization, 2011). Besides being highly endemic for HBV, many sub-Saharan Africa 
countries within the WHO Africa region have the highest rates for heavy episodic alcohol 
drinking/capita/year (World Health Organization, 2011). The Global Burden of Disease for 
2010 results rank as alcohol as being responsible for the third highest cause of liver cirrhosis 
in Southern sub-Saharan Africa after HBV and HCV (IHME, 2013). Excessive alcohol 
consumption by individuals with HBV/HIV co-infection serves to only worsen the prognosis 
as data from the Multicenter AIDS Cohort Study showed that in addition to a low CD4 cell 
nadir, increased weekly alcohol consumption of ≥210g was significantly associated with 
liver-related mortality in HBV/HIV co-infected men-who-have-sex-with-men (Thio et al., 
2002). Education and advocacy against excessive alcohol consumption therefore also need to 
be considered when designing prevention, diagnosis and treatment efforts for liver disease 
among HIV-infected patients in order to curb the incidence and improve the prognosis of 
HCC. Similarly, other diseases such as non-alcoholic steatohepatitis, obesity and diabetes 
will also need to be controlled in order to have a holistic approach to HCC control. In order to 
curb the HCC epidemic in Africa, implementing the WHO proposed action plan will be vital. 
The action plan comprises of some of the following processes: a) a consistent and feasible 
HBV vaccination strategy for children throughout Africa; b) a reduction in dietary exposure 
to aflatoxin; c) knowledge of the epidemiology of HCV in Africa and its relation with 
HIV/AIDS and; d) early diagnosis of malignancies and their complete registration as a means 
of formulating the appropriate clinical interventions (Hainaut and Boyle, 2008). 
 




6. Conclusions and future work 
The HCC Study component of this study has shown that active hepatitis B continues to be the 
most prevalent cause of HCC among patients in South Africa as 64% (95% CI: 59-77) of 
cases were positive for HBsAg. In addition, rates of exposure to HBV among HCC patients 
are very high as 83% (95% CI: 76-90) of subjects were anti-HBc seropositive. In addition, 
this study has shown that despite HCC being non-AIDS defining, there is a high prevalence of 
HIV and HBV co-infection among HCC patients in South Africa. HIV infection seems to 
have an effect on early presentation of malignancy. There is a trend towards younger age at 
diagnosis of HCC among HIV-positive women compared to those who are HIV-negative. The 
results suggest that this early presentation may be linked to modification of the carcinogenic 
process and not due to early detection because cases presented late with malignancy 
regardless of their HIV infection status. The fact that HIV-infected HCC cases presented with 
equally advanced malignancy as the HIV-uninfected HCC cases might suggest HIV infection 
having an influence on the carcinogenesis process in addition to increased longevity 
associated with HAART allowing for the development and presentation of HCC. The effect of 
HIV infection on the age at presentation among male HCC cases was not so apparent. The 
fact that the modal age occurred between 30-40 years supports the calls for HCC screening of 
HBV-infected Africans to be started at 20 years of age (Bruix and Sherman, 2005). Larger 
multi-centred studies are needed to more accurately evaluate the impact of HIV infection on 
the epidemiology of HCC among sub-Saharan populations. To this end, collaborative 
multinational studies may also be necessary to fully understand the epidemiology of HCC in 
the context of HIV infection. Another area of research is to evaluate the implementation of 
recommended guidelines for diagnosing and monitoring of patients with hepatitis B. Hepatitis 
B treatment and HCC screening guidelines will not serve any purpose if they are not put into 
practice because patients will continue to present late with advanced malignancy due to 
untreated underlying HBV infections, thereby resulting in poor survival rates.  
Experimental studies are also needed to determine whether HIV and HBV proteins have a 
synergistic effect on the expression of key cell growth and signalling molecules that are 
involved in the development of HCC. Such a synergistic effect might explain the rapid 
development of HCC in HBV/HIV co-infected patients. Based upon the differences in the age 
at presentation of HCC among cases infected with HBV genotypes A and D, an experimental 
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approach to the effect of genotypes on carcinogenesis may also be appropriate. This could be 
achieved using transgenic animal models of the different HBV genotypes and observing the 
time to cancer development. Alternatively, cell culture models could also be used to 
determine effect of genotypes on cell-signalling and repair pathways. 
The Immune Study component of this study shows that despite receiving HAART, HBV/HIV 
co-infected patients have persistent T-lymphocyte dysregulation and exhibit delayed immune 
recovery. In addition, co-infected patients also have increased gut microbial translocation as 
compared to mono-infected patients. However, immune dysregulation and gut translocation 
do not appear to be associated with severity of liver fibrosis in this cohort. The fact that HIV-
infected individuals continue to have detectable HIV and HBV viraemia also strengthens the 
call to ensure complete adherence to therapy in order to achieve viral suppression in order to 
prevent development of drug-resistance variants of HIV and HBV. The results show that a 
greater proportion of HBV mono-infected patients have moderate/advanced liver fibrosis 
compared to HAART-experienced HBV/HIV co-infected patients. The finding is contrary to 
the original study hypothesis that increased microbial translocation in HBV/HIV co-infection 
is the driver of liver fibrosis. Instead, viral replication seems to be the driver of liver fibrosis 
with a significant association observed between HBV and HIV viral loads and liver stiffness. 
Uncontrolled replication supports the finding of a higher proportion of advanced liver fibrosis 
among the HBV mono-infected patients who were frequently not on therapy. These results are 
indicative of inadequate access to screening and treatment of HBV within much of South 
Africa where a majority of HBV mono-infected patients are also undiagnosed. It is these 
undiagnosed patients that are unlikely to be treated or placed under HCC surveillance 
programs and will only likely present late with advanced malignancy when options for 
therapy are limited.  
Based on the finding that viral (HBV and HIV) replication appears to be the key factor in liver 
fibrosis, future work will need to examine the association between antigen-specific responses 
and hepatocyte damage/death due to the effect of CTLs. Another aspect to be considered is 
change in liver fibrosis scores with duration of therapy. As the period of therapy gets longer, 
it may be expected that rates of viral suppression will improve and confirming the findings 
from this current study, an improvement in fibrosis scores should be seen. It is also necessary 
to continue evaluating and monitoring adherence to anti-retroviral therapy from a public 
health point of view especially when considering the number of subjects that do not achieve 
viral suppression. If viral detection is due to non-adherence and not resistance to antivirals 
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then patients can be appropriately counselled and the unnecessary switching to second-line 
HAART avoided. 
Overall, the results strengthen the call to address the problem of HBV infection within sub-
Saharan Africa countries. Childhood-acquired HBV infections frequently become chronic and 
are the greatest risk factor for developing HCC within the sub-Saharan Africa. HBV birth 
dose vaccination is the cornerstone of the HBV prevention strategy and should be available to 
all, in particular to infants born in high prevalence countries. Meanwhile, better strategies for 
diagnosis and treatment of hepatitis B are needed. In addition, screening and management 
strategies for HCC need to be developed for sub-Saharan African populations who present 
with HCC early in life. 
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Appendix 1 HCC consent form 




TITLE OF THE RESEARCH PROJECT: HIV-associated hepatocellular carcinoma 





PRINCIPAL INVESTIGATOR: Dr Monique Andersson 
 
ADDRESS:  
Division of Medical Virology, Dept of Pathology 
Stellenbosch University, Faculty of Health Sciences 
Francie van Zijl Ave, 8th Floor, Room 8078 
PO Box 19063, Tygerberg Campus, 7505 




CONTACT NUMBER: 082 709 6152 
 
 
You are being invited to take part in a research project.  Please take some time to 
read the information presented here, which will explain the details of this project.  
Please ask the study staff or doctor any questions about any part of this project that 
you do not fully understand.  It is very important that you are fully satisfied that you 
clearly understand what this research entails and how you could be involved.  Also, 
your participation is entirely voluntary and you are free to decline to participate.  If 
you say no, this will not affect you negatively in any way whatsoever.  You are also 
free to withdraw from the study at any point, even if you do agree to take part. 
 
This study has been approved by the Health Research Ethics Committee at 
Stellenbosch University and will be conducted according to the ethical guidelines 
and principles of the international Declaration of Helsinki, South African Guidelines 
for Good Clinical Practice and the Medical Research Council (MRC) Ethical 
Guidelines for Research. 
 
 
What is this research study all about? 
 This study will be conducted in a number of hospitals in South Africa and one 
hospital in Malawi in the departments of Oncology and/or Gastroenterology. 
We will be recruiting a total of about 300 people with liver cancer.  
 We want to know who is getting liver cancer and hope to better understand 
why liver cancer is developing 
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 We will be asking you some questions about risk factors, perform a routine 
medical examination to look for signs of liver disease, we will take a blood 
sample and a urine test 
 The blood tests will tell us about any changes in the blood that may be 
associated with developing liver cancer and any risk factors for liver disease 
eg cirrhosis 
 
Why have you been invited to participate? 
 You have been invited to participate in this study because you have been 
diagnosed with liver cancer. 
 
 
What will your responsibilities be? 
 We would like you to consent to taking part on the study which will involve 
answering some questions, allowing a doctor to examine you, donate a blood 
(two 5ml tubes) sample and some urine. 
 If you have cancer we will keep in touch with you and your family to follow you 
up. A nurse from the department where you have been seen will contact you 
or your family by telephone. 
 
 
Will you benefit from taking part in this research? 
 There will be no benefit to you, but this study will help us be able to help 
others in the future. 
 
 
Are there in risks involved in your taking part in this research? 
 There is some pain associated with taking blood. We will try to take this 
sample when you are having blood taken anyway. 
 
 
If you do not agree to take part, what alternatives do you have? 
 This will not affect your care in any way. 
 
 
Who will have access to your medical records? 




What will happen in the unlikely event of some form injury occurring as a direct 
result of your taking part in this research study? 
 It is unlikely that you experience any major injury as a result of taking part in 
the study. As a result of having blood taken you may experience some pain 
or bruising, which will be minor in nature. 
  
Will you be paid to take part in this study and are there any costs involved? 
 
 No you will not be paid to take part in the study, but we will cover the costs of 
your transport to the clinic if you need a follow up appointment for the study 





Is there anything else that you should know or do? 
 You can contact Dr Andersson at tel 082 709 6152 if you have any further 
queries or encounter any problems. 
 You can contact the Health Research Ethics Committee at 021-938 9207 if 
you have any concerns or complaints that have not been adequately 
addressed by your study doctor. 




Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a 
research study entitled HIV-associated hepatocellular carcinoma – prevalence, 
presentation, survival and risks 
 
I declare that: 
 
 I have read or had read to me this information and consent form and it is 
written in a language with which I am fluent and comfortable. 
 I have had a chance to ask questions and all my questions have been 
adequately answered. 
 I understand that taking part in this study is voluntary and I have not been 
pressurised to take part. 
 I may choose to leave the study at any time and will not be penalised or 
prejudiced in any way. 
 I may be asked to leave the study before it has finished, if the study doctor 
or researcher feels it is in my best interests, or if I do not follow the study 
plan, as agreed to. 
 
Signed at (place) ......................…........…………... on (date) …………....……2012. 
 
 
 ..............................................................   ............................................................ 
Signature of participant Signature of witness 
 
 
Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
 I explained the information in this document to 
………………………………….. 
 I encouraged him/her to ask questions and took adequate time to answer 
them. 
Stellenbosch University  https://scholar.sun.ac.za
203 
 
 I am satisfied that he/she adequately understands all aspects of the 
research, as discussed above 
 I did/did not use an interpreter.  (If an interpreter is used then the 
interpreter must sign the declaration below. 
 
 




 ..............................................................   ............................................................ 
Signature of investigator Signature of witness 
 
 
Declaration by interpreter 
 
I (name) ……………………………………………..……… declare that: 
 
 I assisted the investigator (name) ………………………………………. to 
explain the information in this document to (name of participant) 
……………..…………………………….. using the language medium of 
Afrikaans/Xhosa. 
 We encouraged him/her to ask questions and took adequate time to 
answer them. 
 I conveyed a factually correct version of what was related to me. 
 I am satisfied that the participant fully understands the content of this 









 ..............................................................   ............................................................ 
Signature of interpreter Signature of witness 
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Appendix 2 HCC Case record form 
 
                HEPATOCELLULAR CARCINOMA STUDY  
Patient has diagnosis of HCC? Yes                     Diagnosis:   AFP    Imaging    Clinical   Histology 
Informed consent completed?  Yes                      If no, please complete before proceeding 
Site:                                     Hospital/Clinic Name (PLACE STICKER HERE) 
Hospital number    PLEASE CIRCLE AS APPROPRIATE 
DOB      Sex    M                     F 
Nationality                                                             Race     B   W     I    C    other _____________ 
Monthly Income     ZAR _________                    Education:   Primary         Secondary           Tertiary 
Country of birth                                                     Area Born:  Urban                   Rural   
Other areas for lived >12months 
Dates Area/City/Town Urban/Rural 
   
   
   
Family History of liver disease            YES               NO               Give Details____________________ 
Family History of HCC                        YES                NO              Give Details____________________ 
HIV status                 POS                   NEG                UNKNOWN 
Date HIV diagnosed ________________ 
If HIV positive, CD4 current  __________________           Nadir CD4 _____________________ 
On HAART            YES                     NO 
Length of time on HAART ____________ 
Current HAART (please ring)  tenofovir   lamivudine  efavirenz   nevirapine  AZT  stavudine DdI 
lopinavir/ritonovir  atazanavir other____________________ 
Previous HAART(please ring)  tenofovir   lamivudine  efavirenz   nevirapine  AZT  stavudine DdI 
lopinavir/ritonovir  atazanavir other____________________ 
Cirrhosis    NO                         YES                               Date diagnosed 
Cause of cirrhosis  KNOWN            (detail)  ______________________________ UNK 
Liver biopsy NO                    YES                     Date                   Please attach copy of report 
Ever alcohol dependence/misuse (loss job, breakdown relationships)  YES                         NO 
Consumed (please ring): >28 Units per week for ______years     OR     Average between 10 and 28 
Units  OR     Less than 10 units     (0.5l beer=2.5U, 750ml wine = 9U) 
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Type of alcohol consumed (please ring) Beer  Spirits    Wine   Other please detail_______________ 
 
History of eating peanuts?                   YES                               NO 
Source of peanuts?  Pre-packed      Grows own              Buys from market            Other(detail) ______ 
Dietary Iron exposure – home brewed beer from iron pots ‘Umqombothi’    YES               NO 
Duration of dietary iron exposure____________ years 
Oral contraception           NO                          YES          name______________  duration _____yrs   
Smoker           NO                                YES                                       Pack years_____________ 
CLINICAL PRESENTATION 
Ascites                                      YES                                  NO 
Ankle Oedema                          YES                                  NO 
Abdominal mass                      YES                                  NO 
Liver decompensation (ever)     YES                                 NO 
Childs-Pugh classification   A         B          C 
Weight __________________kg                            Height _____________________________cm 
Evidence of chronic liver disease – please ring positives 
clubbing, leukonychia, spider naevi, gynaecomastia, caput medusa, bruising, jaundice, splenomegaly, 
ascites, liver flap, Dupuytren’s contracture, testicular atrophy, parotid enlargement, hepatomegaly, 
hepatic arterial liver bruit 
 
USS  OR MRI OR CTscan (please tick) – please attach copy of report and please ring positives 
shrunken liver, enlarged liver, splenomegaly, ascites, multiple liver lesions, single liver lesion, 
evidence of hypervascularity 
date of scan:   ______/______/201__ 
 
Planned therapy 
Surgical                                         Liver transplant   Y     N 
Medical         
Palliative 
Name  
Sign                                                                     Date  
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HEPATOCELLULAR CARCINOMA STUDY – RESULTS SHEET 
PLEASE TICK UNKNOWN IF THE TEST HAS NOT BEEN PERFORMED 
 
Site:                                     Hospital/Clinic Name (PLACE STICKER HERE) 
Hospital number 
DOB      Sex 
 
HBV status                HBsAg      POS                           NEG                              UNKNOWN 
                                 antiHBc      POS                           NEG                             UNKNOWN 
                                  eAg            POS                          NEG                            UNKNOWN 
                                   anti-e        POS                           NEG                            UNKNOWN 
 
HBV viral load (if >1 give peak level) ___________________copies/ml  OR IU/ml 
HCV antibody      POS                                    NEG                             UNKNOWN 
HCV PCR            POS                                    NEG                             UNKNOWN 
AFP _________________ 
FBC  Hb                                  MCV 
         Platelets 
eGFR                                                                                                HbA1c 






INR                                                                                                                                                . 
NAME  
Signed                                                          Date  
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Appendix 3 Stellenbosch University HCC Study HREC approval 
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Appendix 4 University of Cape Town HCC Study HREC approval 
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Appendix 6 University of Pretoria HCC Study HREC approval 
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Appendix 7 Immune Study HREC approval 
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Appendix 8 Immune Study Case record form 
LIVER FIBROSIS STUDY CASE RECORD FORM   
Please do not proceed without participant’s consent. 
Informed consent forms signed?  Yes                       
DEMOGRAPHIC DATA 
Race (please circle): B    W     C    I   Other ________________                          
Gender:                Male               Female  
Age: _____ 
Weight (in kilos)   Height (in metres)              
RISK FACTORS             
1. Current alcohol consumption YES NO 
2. How many UNITS of alcohol do you drink on a typical day when you are drinking?      
Pint of regular beer/lager/cider = 2 units                                     _______UNITS 
Can of lager = 1.5 units                                                               _______UNITS 
Glass of wine (175ml) = 2 units                                                   _______UNITS 
Single measure of spirits = 1 unit                                                _______UNITS 
Bottle of wine = 9 units                                                                _______UNITS 
3. Family history of liver disease 
If yes to family history of liver disease, please provide details 
 
YES NO 
4. Smoking history (please tick appropriate response)                                 Current     Past      Never 
5. If yes to smoking, please indicate number of pack years*                           ____pack years 
 
*Number of pack years = (packs smoked per day) × (years as a smoker) 
 
6. Use of herbal medicine (please circle appropriate response)                    Current    Past      Never 
 
If yes to herbal drugs, please provide details 
7. Known diagnosis of diabetes YES NO 
8. Known current diagnosis of TB disease or medication for TB. 
YES NO 
9. History of liver biopsy  
If yes, please provide details 
YES NO 
10. Known diagnosis of any known cancer 
YES NO 
11. HIV status (please tick appropriate response) 
If response is negative skip to 20 
POS NEG 
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12. If positive, state date diagnosed  
13. Current CD4  
14. Nadir CD4 
15. HIV viral load 
16. HAART (please tick appropriate response)                              
If response is no, please skip to 20 
POS NEG 
17. Period of time on HAART 
18. If on HAART, please tick applicable below   









Other (please state) 
19. If on previous HAART, please tick applicable below     









Other (please state) 
20. If HIV negative, treatment for HBV YES NO 
21. If receiving HBV treatment, please state regimen 
Please thank participant and collect blood in 1 SST tubes (yellow top) and 1 EDTA tube (purple top) 
and 1 Heparin tube (green top). 
Interviewer name: 
Signature:                                                    Date:  
Blood collected by: 
Signature: 
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Appendix 9 Correlation matrix (controls) 
Correlation matrix for controls calculated using Spearman test. Values in red font represent statistically significant correlation. 
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Appendix 10 Correlation matrix for HIV mono-infected subjects 
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Appendix 11 Correlation matrix for HBV mono-infected subjects 
Correlation matrix for HBV mono-infected subjects. Significant correlations marked in red font. 
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Appendix 12 Correlation matrix for HBV/HIV co-infected subjects 
Correlation matrix for HBV/HIV co-infected subjects. Significant correlations marked in red font. 
 
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
